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SUMMARY 
 
In order to identify and characterize novel inhibitors of bacterial RNA polymerase, an in vitro 
test system was developed. Therefore, Escherichia coli was used as model organism. The 
inhibitors should prohibit the protein-protein interaction of the βʹ subunit of the core enzyme 
of RNA polymerase and the dissociable σ70 factor, and inhibit thereby transcription. This 
inhibition mechanism shall prevent cross-resistances with clinically used Rifamycins and 
fidaxomicin. 
The test system consists of various binding and functional assays, of which most are based on 
the biophysical surface plasmon resonance technology. The variable assays allow on the one 
hand the determination of affinity and activity of the inhibitors, and on the other hand the 
determination of the mode of action. The binding mode was investigated by competition 
experiments with the σ70 factor and comparative binding studies to wild-type and point-
mutated, truncated βʹ proteins. 
Within the scope of this work, three inhibitor classes of small molecules and one peptide were 
identified that effectively inhibited the σ70 – core RNA polymerase interaction. By the 
generation of structure-activity relationships as well as elucidation of the binding mode, the 
developed test system contributed to the optimization of the compounds. 
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ZUSAMMENFASSUNG 
 
Zur Identifizierung und Charakterisierung neuer Hemmstoffe der bakteriellen RNA 
Polymerase als potentielle antibiotisch wirksame Arzneistoffe wurde ein in vitro Testsystem 
aufgebaut. Dabei wurde Escherichia coli als Modellorganismus verwendet. Die Hemmstoffe 
sollen die Protein-Protein Interaktion zwischen der βʹ Untereinheit des Core-Enzyms der 
RNA Polymerase und dem dissoziierbaren σ70 Faktor unterbinden und so die Transkription 
verhindern. Dadurch sollen Kreuzresistenzen mit den in der Klinik eingesetzten Rifamycinen 
und Fidaxomicin vermieden werden. 
Das Testsystem besteht aus zahlreichen Bindungs- und funktionalen Assays, die größtenteils 
auf der biophysikalischen Oberflächenplasmonresonanz-Technologie basieren. Die 
unterschiedlichen Tests erlauben zum einen die Bestimmung von Affinität und Aktivität, zum 
anderen die Bestimmung des Bindungsmodus. Der Bindungsmodus wird mit Hilfe von 
Kompetitionsversuchen mit dem σ70 Faktor und vergleichenden Bindungsstudien an Wildtyp 
und punktmutierten, verkürzten βʹ Proteinen untersucht. 
Im Rahmen dieser Arbeit konnten drei Wirkstoffklassen kleiner Moleküle und ein Peptid 
identifiziert werden, welche die σ70 – Core RNA Polymerase Interaktion effektiv hemmen. 
Durch die Generierung von Struktur-Wirkungsbeziehungen konnte das entwickelte 
Testsystem zur Optimierung der Verbindungen und zur Aufklärung von deren Bindungsmodi 
beitragen. 
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1  Introduction 
1.1  Biomolecular interaction analysis by surface plasmon resonance 
spectroscopy 
Surface plasmon resonance (SPR) spectroscopy is a biophysical method to analyze 
biomolecular interactions in real-time. Biomolecular interactions or adsorption are 
fundamental life processes as they are involved for example in intra-/extracellular trafficking 
[Johnson 2005, Mellmann and Warren 2000], cell signaling [Neiditch et al. 2006, Jones et al. 
2005], DNA transcription and RNA translation [McGhee and von Hippel 1974], and many 
more. Therefore the study of biomolecular interactions is important in the development of 
new drugs. In the next sections, the SPR principle, the steps of an assay and the use of SPR in 
the drug discovery process are described. 
 
1.1.1 Surface plasmon resonance principle 
Surface plasmon resonance occurs when parallel or p-polarized light shines through a prism 
on a sensor chip, coated with a thin metal film on top, and the light is reflected. This 
phenomenon is called total internal reflection. By changing the angle of incidence, the 
intensity of the reflected light passes through a minimum, the SPR dip. When the light strikes 
the sensor chip, the photons interact with the free electrons of the metal layer, usually gold, 
and induce an evanescent wave which is the oscillation of the electrons. Thereby the intensity 
of the reflected light is reduced. The angle at which the maximum loss of reflected light is 
detected is called SPR angle [Schasfoort and Tudos 2008]. This angle depends on the 
refractive indices of the media on both sides of the gold film. When proteins or small 
molecules adsorb or the medium changes (e.g. buffer composition, concentration) on the chip 
surface, the refractive index on that side of the metal changes whereas the refractive index on 
the prism side remains constant. The change in refractive index then in turn shifts the SPR 
dip. SPR can measure this shift in time, converting the angle shift into a sensorgram (Figure 
1). This response signal is usually expressed as resonance units (RU). If this shift is due to a 
biomolecular interaction, the kinetics of the interaction can be studied in real-time. 
2  
 
 
Figure 1. Schematic set-up of an SPR experiment (Kretschmann configuration; left side), 
modified from Löfås (2004). A laser creates p-polarized light that shines through a prism on a 
sensor chip coated with a gold film. At a certain angle of incidence the reflected light reaches 
a minimum (SPR dip; I in the upper right panel). In dependence of the mass on the chip the 
refractive index on the side of the flow channel changes. In turn the SPR dip shifts (II in the 
upper right panel). When this shift is monitored over time, the result is a sensorgram (lower 
right panel), from which the kinetic parameters of the biomolecular interaction can be derived. 
 
The correlation of mass adsorption and response signal has been determined experimentally 
[Stenberg et al. 1991] to: 
1 RU = 1 pg/mm² 
However, the penetration depth of the evanescent field on the sensor surface is limited to 
approximately 200 nm and fades with increasing distance [Schasfoort and Tudos 2008]. Thus, 
one of the interaction partners, e.i. the ligand, needs to be fixed relatively close to the surface. 
This process is called immobilization and will be described in the following section. 
 
1.1.2 SPR-based assays 
During an SPR experiment the first step is always to immobilize a target biomolecule, the so-
called ligand, to the sensor surface. Next, the ligand has to be evaluated regarding its integrity, 
since only properly folded proteins bind analytes specifically. Then the biosensor is ready for 
various applications such as detection of binding, binding selectivity, binding affinity, binding 
kinetics, determination of active concentration, and thermodynamics [Biacore.com April 
2014, Myszka and Rich 2000] providing a much greater information depth than traditional 
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end-point assays, which can give only limited ranges of affinity and only one binding 
characteristic per experiment [Löfås 2004]. 
 
Immobilization 
The term immobilization of the protein ligand is often misunderstood as immobile fixation 
onto a surface. However, the ligand is more tethered than immobilized, since it is usually 
bound at only one point to the inert immobilization hydrogel. This 3D matrix improves the 
ligand’s accessibility and can also protect it against denaturation [Schasfoort and Tudos 
2008]. Therefore, the composition and choice of the biosensor chip is of importance for the 
assay set up. A sensor chip contains glass as a carrier which is covered with a thin gold film, 
enabling surface plasmons to be excited. On top of the metal is an adhesion linking layer, 
connecting the gold with the immobilization matrix. The matrix is the most critical element of 
the sensor chip, since it is in contact with both, the ligand and the analyte. The most common 
matrix polymers are polysaccharides, such as carboxymethyldextran (CMD). It can be used 
directly for amine coupling or can be modified with streptavidin in order to capture 
biotinylated ligands. A schematic representation of a biosensor chip with the above described 
coupling techniques is shown in Figure 2. 
Figure 2. Biosensor chip composition. Protein-ligands (green) are directly covalently coupled 
to the CMD matrix (left side) or – in case of biotin-tagged ligands – captured by one of the 
four biotin-binding sites of streptavidin-modified (red) immobilization matrices (right side). 
 
Amine coupling. The first choice coupling procedure is covalent amine coupling, since it 
usually gives high yields and stable bonds. Disadvantageous are the random orientation of the 
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protein ligands on the chip and the low pH used for coupling that may result in the 
inactivation of the protein, leaving a heterogeneous surface. In order to couple a protein to the 
biosensor by its surface exposed lysine residues, first the carboxylic acid functions of the 
CMD matrix have to be activated by N-ethyl-N’-(dimethylaminopropyl)carbodiimide (EDC). 
At pHs between 4.5-6.5 the O-acylisourea intermediate is formed before being replaced with 
the N-hydroxysuccinimide (NHS), which gives a more stable active ester intermediate. Upon 
injection of the ligand, aminolysis takes place, releasing the NHS and leaving the protein 
coupled to the CMD by an amide bond [Johnsson et al. 1991] (Figure 3). 
 
Figure 3. Amine coupling reaction, modified from Schasfoort and Tudos (2008) and 
piercenet.com (NHS and Sulfo-NHS, 05/05/2014). 
 
Biotin coupling. An indirect immobilization technique can be achieved by capturing 
biotinylated ligands on streptavidin-coated sensor chips. This directed coupling method is 
milder than amine coupling and therefore usually better retains the ligand’s integrity. 
Although this is a non-covalent attachment of the ligand, “chip bleeding” (loss of target 
protein from the biosensor over time) is minimal due to the strong complex formation (KD ~ 
10
-15
 M) [Schasfoort and Tudos 2008] which is stable over a wide pH and temperature range. 
 
Biomolecular interactions 
Once the ligand is tethered to the biosensor surface, the first step in an experiment is to 
condition it with a suitable buffer solution. A stable baseline is very important for high quality 
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interaction data, as drifts may alter the sensorgram shape. When injecting the analyte, which 
is captured by the target, the mass on the surface increases, allowing adsorption kinetics to be 
determined in real-time. This adsorption can also be non-specific to either the ligand or the 
linker layer, hence, a suitable reference flow cell is needed. The SPR response expresses the 
mass accumulated on the sensor surface. By a constant flow of running buffer dissociation is 
induced, flushing off non-specifically-bound compounds first and then also all other 
reversible bound analytes. In case of very tight interactions, where buffer flow alone is not 
sufficient to get back to baseline-level, a regeneration solution is injected, breaking the 
interactions between ligand and analyte. The choice of regeneration solution is vital, since it 
should leave the ligand intact for hundreds of analysis cycles but at the same time should 
remove the analyte quantitatively. Then the surface is again conditioned with running buffer 
for the next analysis cycle (Figure 5). Typical interactions that are analyzed by SPR include 
antibody-antigen, ligand-receptor, and protein-nucleic acid interactions [Rich and Myszka 
2000]. 
 
Figure 5. Steps of an analysis cycle, modified from Cooper (2002). First, the ligands are 
conditioned with buffer (baseline), then the analyte is injected and binds to the ligand 
(association), which can be observed by the increasing resonance signal. After a certain time 
the injection is stopped and buffer is flowed over the sensor surface, inducing dissociation. 
Finally, the left-over analytes (in case of strong ligand-analyte complexes) are cleared from 
the surface by injecting a regeneration solution, leaving the ligands intact for the next analysis 
cycle. 
 
6  
 
Although there are many possible applications for SPR, it is used predominately to determine 
the kinetics of a one-to-one binding process, in which the ligand (A) captures the analyte (B), 
forming the complex (AB). Global analysis of the shape of the sensorgram for multiple 
concentrations give the kinetic parameters listed in Table 1. 
Parameter Reaction Unit 
ka or kon A + B  AB [M
-1
*s
-1
] 
kd or koff AB  A + B [s
-1
] 
KD [A]*[B]/[AB] = kd/ka [M] 
Table 1. Kinetic parameters obtained from the global analysis of multiple sensorgrams over a 
wide concentration range. 
However, some binding events, especially weak ones (e.g. fragments binding to proteins), 
cannot be resolved into on- and off-rates by the instrument’s sampling frequency (typically 
10 Hz), since they equilibrate too quickly [Giannetti 2011]. 
 
1.1.3 Biosensors in drug discovery 
Apart from simple drug target analysis, there are numerous other applications for SPR in the 
drug development pipeline, as summarized in Figure 6.  
As matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF 
MS) and electrospray ionization-mass spectrometry (ESI-MS) are particularly powerful tools 
in protein analysis and thereby target identification, MS was fused with SPR for proteome 
analysis [Williams and Addona 2000]. In this setup SPR is used for affinity-purification of the 
protein sample. Additionally, SPR-MS is applicable for an approach called ligand fishing. 
Here, crude tissue extracts or cell homogenates are screened for possible ligands mostly of 
orphan receptors [Catimel et al. 2000]. 
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Figure 6. Applications of SPR in the drug development pipeline. HTS, high-throughput 
screening; SBBA, structure-based biophysical analysis; (Q)SAR, (quantitative) structure-
activity relationship; ADME, absorption distribution metabolism excretion; PPB, plasma-
protein binding. 
 
Furthermore, SPR improves in vitro assay development by buffer screening and establishment 
of regeneration conditions that help elucidating the compound’s mode of action. An optimized 
assay is suitable for direct screening of small molecules with high information content, such 
as kinetic rate constants and equilibrium response for affinity ranking. This concept was 
introduced in 2000 by Hämalainen et al. searching for HIV-1 protease inhibitors. However, 
the primary applications for SPR in the pharmaceutical industry are secondary screening to 
confirm hits and their kinetic characterization [Cooper 2002, Huber 2005]. In most cases – 
e.g. enzyme inhibitors – compounds with fast association and slow dissociation rate constants 
are preferred. Another application of SPR is the identification of compounds that truly bind to 
the target’s active/binding site by using mutated target proteins as references in SPR studies. 
Huber termed the integration of bioinformatics approaches in SPR “structure-based 
biophysical analysis” (SBBA) [Huber 2005]. At Hoffman-La Roche, selective 
hydroxymethyl-pterin pyrophosphokinase inhibitors were identified by an SBBA attempt. 
Based on the crystal structure of the target protein in complex with a substrate-analog, a 
pharmacophore was generated and virtual screening hits selected. In order to identify substrat 
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pocket binders only, a mutant target protein was produced and served as reference in the SPR 
assay. Thus, only compounds with high affinity to the wildtype and impaired affinity to the 
mutant were selected for further development. [Huber 2005]. An example for an SPR-assisted 
QSAR study is given by Markgren et al. (2002). They demonstrated how structural changes 
of HIV-1 protease inhibitors affect not only the activity but also the kinetic parameters. 
Further applications of SPR during drug development are early ADME studies. Especially for 
larger numbers of compounds it is convenient to screen them for their affinity to the plasma 
proteins human serum albumin (HSA) and α1-acid glycoprotein (AGP). The equilibrium 
dissociation constant KD can then be converted into “% bound” as carried out in Nyberg et al. 
(2002). Lipid interaction models to predict membrane permeability are reviewed in Heyse et 
al. (1998).   
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1.2 RNA polymerase 
The first step of gene expression is called transcription. During transcription, which is divided 
in three steps – initiation, elongation, and termination – the RNA polymerase generates an 
RNA copy from a DNA template. The transcription process is highly conserved in all living 
cells [Artsimovitch and Vassyleyev 2006]. 
 
1.2.1  Structure and function 
Bacterial RNA polymerase (RNAP) is a multi-subunit enzyme. Core RNAP is comprised of 
five subunits α2ββʹω with a molecular weight of 378 kDa in E. coli. The two α subunits are 
required for enzyme assembly. The big β and βʹ subunits – connected by the bridge helix – 
together form the active site, where β is involved in chain initiation and elongation and β’ in 
binding of the DNA template [Chopra 2007, Mariani and Maffioli 2009]. The small ω subunit 
supports assembly of core RNAP. This subunit composition makes it one of the most complex 
enzymes yet studied [Burgess 1971]. Together with a dissociable σ-factor (σ70 in Escherichia 
coli), which is responsible for promoter recognition and transcription initiation [Saecker et al. 
2011], the holo enzyme is formed (458 kDa). The crystal structure of the E. coli holo enzyme 
was solved in 2013 by Murakami. Its overall shape resembles a crab claw (Figure 7). 
 
Figure 7. Composition of the E. coli RNA polymerase holo enzyme with bound DNA 
(homology model created by M. Negri, HIPS-DDOP). α subunits in green and red, β subunit 
in magenta, βʹ subunit in blue, ω subunit in orange, and σ70 in yellow. 
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Transcription initiation is a multi-step process during which RNAP and DNA undergo several 
conformational changes [Saecker et al. 2011]. After holo enzyme formation, RNAP binds 
specifically to the promoter duplex DNA region, forming the closed RNAP-promoter 
complex (RPc) [Artsimovitch and Vassylyev 2006]. Then the “transcription bubble” is 
formed by unwinding and actively opening 13-15 base pairs (bp) of DNA [Gruber and Gross 
2003], including the start site. The DNA template strand is loaded into the active site, forming 
the stable open RNAP-promoter (RPo) complex [Saecker et al. 2011]. Then either productive 
or abortive transcription starts. Abortive RNA transcripts are usually 3-12 nucleotides (nt) in 
length [Hsu 2002] and have been detected also in vivo [Goldman et al. 2009]. These abortive 
products may rebind and function as primer for transcription [Goldman et al. 2009]. When the 
RNA transcript reaches 12 nt the promoter contacts are loosened and the σ-factor is released 
[Hsu 2002, Mooney et al. 2005], transcription moves on to the elongation phase. During 
elongation, several nucleotide (NTP) addition cycles are carried out by a two-metal 
mechanism [Steiz and Steiz 1993]. One Mg
2+
 ion remains tightly bound in the active center, 
coordinated by three aspartates, and a second Mg
2+
 ion is delivered with each incoming NTP 
substrate through the secondary channel. A schematic representation of the transcription 
elongation complex can be found in Figure 8. 
 
Figure 8. Transcription elongation complex modified from Mariani and Maffioli (2009). 
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When RNAP encounters a terminator sequence or the terminator factor Rho [Artsimovitch 
and Vassylyev 2006], transcription is stopped and RNAP released from the DNA. 
 
σ-factors 
Although core RNAP alone is capable to transcribe DNA from ends or nicks, it requires a σ-
factor to specifically initiate transcription from a promoter [Burgess et al. 1969, Travers and 
Burgess 1969]. The primary σ-factor in E. coli is σ70, an acidic protein with a size of 70 kDa. 
This “housekeeping” σ-factor is sufficient for growth under nutrient rich conditions [Saecker 
et al. 2011]. However, when the bacteria suffer from stress, alternative σ-factors such as σH 
(heat shock), σN (nitrogen assimilation) or σE (extracellular stress) take over [Gruber and 
Gross 2003, Paget and Helmann 2003, Gourse et al. 2006]. 
σ70 consists of four independently folded domains (regions 1.1, 1.2, 2 and 4) that are 
connected by regions of variable length [Helmann and Chamberlin 1988, Lonetto et al. 1992]. 
Region 1.1 of free σ binds to region 4.2, forming a compact structure, and thereby also auto-
inhibits region 4.2 from binding to DNA [Schwartz et al. 2008]. Regions 2.1 and 2.2 of σ70 
(residues 361-390) [Lesley and Burgess 1989] are responsible for the tight binding to the βʹ 
coiled-coil (residues 260-309) [Arthur et al. 2000]. Regions 2.3 and 2.4 however recognize 
the -10 promoter element [Siegele et al. 1989, Waldburger et al. 1990, Saecker et al. 2011], 
whereas region 4.2 binds to the -35 consensus sequence [Gardella et al. 1989, Saecker et al. 
2011]. Region 3 interacts with DNA upstream of the Pribnow box [Villain-Guillot et al. 
2007a] and the residues 1060-1240 of the β subunit of core RNAP [Burgess and Anthony 
2001]. Functions and interaction partners of σ70 are also illustrated in Figure 9. 
 
Figure 9. Schematic representation of E. coli σ70 modified from Burgess and Anthony (2001). 
Conserved regions are colored and their functions indicated as described in the text. 
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1.2.2  RNAP as drug target 
According to the World Health Organization (WHO) and experts in the field of anti-infective 
research, resistance against antibacterial drugs is an increasing problem all over the world 
[WHO.int 05/15/2014, Chopra 2003, Thomson and Bonomo 2005, McGowan 2006, Rice 
2006, Talbot et al. 2006]. Especially the so-called ESKAPE strains (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella species, Acinetobacter baumannii, Pseudomonas 
aeruginosa, and Enterobacter species) are often multi-drug resistant [Boucher et al. 2009, 
Rice 2008]. For the drug discovery it is wise to inhibit established targets with existing proof-
of-principle, but search for new modes of action [Chopra 2007, Payne et al. 2007]. RNAP is 
such a validated target protein, since the RNAP inhibitor rifampicin is approved in the clinical 
treatment of tuberculosis since many years. The effectivity is explained by the essentiality of 
RNAP for bacterial growth and survival [Ji et al. 2001, Xu et al. 2005, Artsimovitch and 
Vassylyev 2006]. Furthermore, RNAP is highly conserved among pathogenic bacteria, 
allowing the development of broad-spectrum antibiotics [Darst 2004, Ho et al. 2009]. 
Selectivity towards eukaryotic RNAPs – especially mammalian RNAP II – is possible due to 
only partially homologous sequences as well as different surface properties and shape 
[Cramer 2002, Artsimovitch and Vassylyev 2006]. The clinically used rifampicins and 
fidaxomicin are described in more detail in the following. 
As stated in Ma et al. (2013), the majority of RNAP inhibitors bind to the active site, which is 
a large cleft offering multiple binding sites. The most important anti-transcription drugs that 
are used in the treatment of tuberculosis and leprosy are rifampicin, rifapentin and rifabutin 
[Villain-Guillot et al. 2007a]. The first of these rifamycins were discovered in 1959 as a 
fermentation product of actinomycetes and differ only in the C3 or C3/C4 substitutions 
[Artsimovitch and Vassylyev 2006]. They bind with high affinity to the β subunit in the DNA 
channel only 12 Å away from the active site. Thereby, the ansa-ring forms polar and van der 
Waals interactions with 12 amino acid residues of β [Campbell et al. 2001]. Rifamycins 
inhibit transcription initiation by inducing a steric clash with the nascent RNA/DNA-hybrid 
strand (3-4 bp) [Campbell et al. 2001, Feklistov et al. 2008, McClure and Cech 1978] and are 
active against Gram-positive and Gram-negative bacteria [Artsimovitch & Vassylyev 2006]. 
However, the resistance frequency – due to mutations in the rpoB gene, encoding for β – is 
relatively high [Villain-Guillot et al. 2007a]. The most frequent substitutions that account for 
more than 75 % of rifampicin-resistance in clinical isolates of Mycobacterium tuberculosis 
are βD441V, βH451D/Y, and βS456L (D516, H526, S531 in E. coli) [Ramaswamy and 
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Musser 1998]. Other transcription inhibitors that bind to one of the multiple sites within the 
active center cleft are sorangicin [Campbell et al. 2005], streptolydigin [Crum et al. 1955, 
Temiakov et al. 2005, Kyzer et al. 2005], microcin J25 [Salomón and Farías 1992, Blond et 
al. 2001, Villain-Guillot et al. 2007a], GE-23077 [Zhang et al. 2014], tagetitoxin 
[Artsimovitch et al. 2011], and α-amanitin [Bushnell et al. 2002]. 
Further binding sites on the RNAP are the switch region [Srivastava et al. 2011], the σ70:core 
interface (described in the next section) and allosteric sites, such as a cavity between the βʹ 
subunit and the bridge helix where the CBR-703 antimicrobials and salinamide A bind to 
[Artsimovitch et al. 2003, Malinen et al. 2014, Degen et al. 2014] or the interface of βʹ and ω 
to which the alarmone ppGpp binds that regulates RNAP function under harsh environmental 
conditions [Ross et al. 2013, Zuo et al. 2013].  
Switch region binders are reported to be the natural products myxopyronin [Mukhopadhyay et 
al. 2008, Belogurov et al. 2009, Ho et al. 2009], corallopyronin [Haebich and von Nussbaum 
2009], ripostatin [Haebich and von Nussbaum 2009], and lipiarmycin/fidaxomicin (Figure 10) 
as well as the synthetic ureidothiophenes [Arhin et al. 2006, Sahner et al. 2013], pyridyl-
benzamides [McPhillie et al. 2011], and squaramides [Buurman et al. 2012]. Lipiarmycin 
which is structurally very similar to fidaxomicin, is a macrocyclic antibiotic discovered in 
1975 produced by a fermentation mix [Sergio et al. 1975, Arnone and Nasini 1987, Cavalleri 
et al. 1988]. They specifically inhibit the initiation step [Sonenshein et al. 1977] by binding to 
the βʹ subunit [Gualtieri et al. 2006] within the switch region. The switch region can be 
imagined as a hinge that connects the catalytic subunits (β and βʹ) and interacts with the 
template DNA [Artsimovitch et al. 2012]. It is U-shaped and located between two 
hydrophobic pockets [McPhillie et al. 2011]. Fidaxomicin was found to be particularly active 
against Clostridium difficile RNAP in vivo [Swanson et al. 1991] and was therefore approved 
by the FDA in May 2011 for the treatment of C. difficile infections [FDA.gov 05/19/2014]. 
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Figure 10. Clinically used RNAP inhibitors rifampicin (the common modification positions 
C3 and C4 are labeled in orange) and fidaxomicin. 
 
σ70:core interface as target site 
Although the protein-protein interaction of core RNAP and the σ70 factor does not offer any 
clefts as binding sites for small molecules, the inhibition of this interaction is still very 
attractive for the antibiotics drug discovery [Bergendahl et al. 2003, André et al. 2004, Ma et 
al. 2013]. Firstly, σ factors are unique to bacteria and are indispensable to initiate 
transcription [Murakami and Darst 2003], that means bacterial growth is impossible upon 
complete disruption of this essential interaction. Secondly, the interface including the βʹ 
coiled-coil and region 2.1-2.2 of σ70 are highly conserved among bacteria (Figure 11) [Sharp 
et al. 1999, Vassylyev et al. 2002, Lesley and Burgess 1989, Owens et al. 1998]. Thirdly, 
eukaryotic transcription factors – except for σ factors in mitochondria [Tracy and Stern 1995] 
and chloroplasts [Allison 2000], which are more related to viral transcription systems [Glaser 
et al. 2007] – diverge from their prokaryotic counterparts. Hence, by targeting this protein-
protein interaction not only broad-spectrum activity but also selectivity may be gained. Fourth 
and finally, the σ70 interaction site on β’ is used by several other σ factors. Therefore, the 
development of drug resistance by point mutations is unlikely, since these mutations would 
affect the interaction with essential protein partners as well [Bergendahl et al. 2003, André et 
al. 2004]. 
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Figure 11. Conserved sequences of the σ70:βʹ interface (* identical amino acids, : homolog 
amino acids). 
 
1.2.3 σ70:core RNAP inhibitors 
Since one decade researchers are developing assays [Bergendahl et al. 2003, André et al. 
2004] in order to screen natural product and small molecule libraries for inhibitors targeting 
the interaction between σ70 and core RNAP. For example the group of Burgess developed a 
robust luminescence resonance energy transfer (LRET)-based high-throughput assay and 
screened a chemical library to interrupt the tight interaction between βʹ100-309 and σ
70
 (KD 10-
50 nM) [Glaser et al. 2007]. They identified four hits that also inhibited transcription. 
However, they had serious problems with compound insolubility. Further σ70:core inhibitors 
are described below. 
SB series. The SB series of compounds are phenyl-furanyl-rhodanines. They have been 
discovered as σ70:core RNAP assembly inhibitors in 2004 by the group of Leonetti [André et 
al. 2004] in an ELISA-based screening. One of the most potent compounds was SB2 (Figure 
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12) with an IC50 of 2 µM [André et al. 2006]. This compound class was also active in an in 
vitro transcription assay. Since SB2 also inhibited σ-independent transcription, it was 
concluded, that the binding site has to be on the core side [André et al. 2006]. However, the 
specific target site remained unknown. Bactericidal effects were reported for Gram-positive 
cells, whereas no toxicity against several eukaryotic cells was detected [André et al. 2006]. 
Structure-activity relationship (SAR) studies pointed out the importance of the carboxylic acid 
moiety for the inhibitory activity, as well as the allyl moiety for the antibacterial effect 
[Villain-Guillot et al. 2007b]. Despite the good activity on RNAP, a major problem of the SB 
series is their promiscuity. They are described to inhibit malate dehydrogenase, chymotrypsin 
[Mariner et al. 2010], β-lactamase [Grant et al. 2000], penicillin-binding protein 2a [Zervosen 
et al. 2004], and many more, making them unattractive drug candidates. 
Bis-indoles. Recently, a structure-based approach was applied to identify new σ:core RNAP 
inhibitors. Ma et al. created a pharmacophore model based on the structural data of the 
protein-protein interface and screened a peptidomimetic library. Some bis-indoles reached the 
highest scores and were synthesized. Most effective disruption of transcription initiation 
complexes was reported for the 7,7ʹ-linked amides and glyoxylamides (best GKL003, Figure 
12) [Mielczarek et al. 2014]. By performing isothermal titration calorimetry (ITC) 
experiments with wildtype and mutant proteins, it was shown that GKL003 binds to the 
coiled-coil of the βʹ subunit [Ma et al. 2013]. Additionally, in vivo activity on both Gram-
positive and Gram-negative bacteria was claimed [Ma et al. 2013, Mielczarek et al. 2014], 
however inhibitory concentrations were very high with around 1 mM. 
 
Figure 12. The σ:core assembly inhibitor SB2 [André et al. 2006] and the initiation complex 
formation inhibitor GKL003 [Ma et al. 2013].  
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2  Aims of the thesis 
Infectious diseases are a constant threat for human and animal health, especially nowadays 
with multiple antibiotic drug resistances. Hence, new antibiotics with novel modes of action 
and target sites – in order to avoid cross-resistances with existing antimicrobial drugs – are 
urgently needed. We focus on bacterial RNA polymerase as a validated drug target. A 
promising target site within this enzyme is the essential protein-protein interaction between 
core and the σ70 factor, which is indispensable for specific initiation of transcription (see 
chapter 1.2 of the introduction). This interaction surface is highly conserved and has no 
overlaps with the binding sites of the clinically used rifamycins and fidaxomicin. 
In order to identify, characterize, and classify such σ70:core RNAP inhibitors, we need robust 
in vitro assays. They provide a solid basis for the hit selection and the rational design and 
optimization of new drugs. For the structure-based drug design and optimization, the exact 
binding site is of utmost importance. Therefore, the following binding and functional assays 
have been planned to be developed and evaluated in the course of this thesis: 
 Transcription assay variations of the existing in vitro transcription assay with separate 
addition of σ70 to study the effect on diverse DNA templates as well as RNAP 
inhibitors. For this purpose recombinant production of the σ70 is required. 
 ELISA-based σ70:core assembly inhibition assay to identify and classify inhibitors of 
holo enzyme formation. 
 HPLC-based initiation inhibition assay to verify the concept of σ70:core inhibition 
leading to inhibition of transcription initiation and classify the protein-protein 
interaction inhibitors. 
 SPR screening assay to identify small molecule compounds binding to the coiled-coil 
and/or lid-rudder-system of the βʹ subunit (amino acids 200-341, abbreviated βʹ CC-
LRS) of RNAP which is mostly responsible for the interaction with σ70. Therefore, 
cloning, expression, and purification of this truncated βʹ subunit is necessary. 
 SPR competition assay to show the direct inhibition of the protein-protein interaction 
hot spot between βʹ and σ70 (not mediated through an allosteric effect). 
 SPR-based binding site identification using wildtype βʹ CC-LRS and site-directed 
mutant proteins. 
 SPR kinetic profiling: Determination of association and dissociation rates, as well as 
equilibrium dissociation constants to characterize and rank βʹ CC-LRS binders. 
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3  Results 
3.1  Surface plasmon resonance – more than a screening technology: 
Insights in the binding mode of σ70:core RNAP inhibitors 
Kristina Hüsecken, Stefan Hinsberger, Walid A. M. Elgaher, Jörg Haupenthal, and Rolf W. 
Hartmann 
Full text article in Future Med. Chem. 2014, 8, 1551-65.  
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Publication I 
 
ABSTRACT:  
Background: Antibiotic resistance has become a major health problem. The σ70:core 
interface of bacterial RNA polymerase is a promising drug target. Recently, the coiled-coil 
and lid-rudder-system of the βʹ subunit has been identified as an inhibition hot spot. 
Results/Methodology: By using surface plasmon resonance-based assays, inhibitors of the 
protein-protein interaction were identified and competition with σ70 was shown. Effective 
inhibition was verified in an in vitro transcription and a σ70:core assembly assay. For one hit 
series we found a correlation between activity and affinity. Mutant interaction studies suggest 
the inhibitors’ binding site. Conclusion: Surface plasmon resonance is a valuable technology 
in drug design, that has been used in this study to identify and evaluate σ70:core RNA 
polymerase inhibitors. 
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3.2  Peptide-based investigation of the Escherichia coli RNA polymerase 
σ70:core interface as target site 
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Jörg Haupenthal 
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Publication II 
 
ABSTRACT: The number of bacterial strains that are resistant against antibiotics increased 
dramatically during the past decades. This fact stresses the urgent need for the development of 
new antibacterial agents with novel modes of action targeting essential enzymes such as RNA 
polymerase (RNAP). Bacterial RNAP is a large multi-subunit complex consisting of a core 
enzyme (subunits: α2ββ′ω) and a dissociable sigma factor (σ
70; holo enzyme: α2ββ′ωσ
70
) that 
is responsible for promoter recognition and transcription initiation. The interface between 
core RNAP and σ70 represents a promising binding site. Nevertheless, detailed studies 
investigating its druggability are rare. Compounds binding to this region could inhibit this 
protein−protein interaction and thus holo enzyme formation, resulting in inhibition of 
transcription initiation. Sixteen peptides covering different regions of the Escherichia coli 
σ70:core interface were designed; some of them − all derived from σ70 2.2 region − led to a 
strong RNAP inhibition. Indeed, an ELISA-based experiment confirmed the most active 
peptide P07 to inhibit the σ70:core interaction. Furthermore, an abortive transcription assay 
revealed that P07 impedes transcription initiation. In order to study the mechanism of action 
of P07 in more detail, molecular dynamics simulations and a rational amino acid replacement 
study were performed, leading to the conclusion that P07 binds to the coiled-coil region in β′ 
and that its flexible N-terminus inhibits the enzyme by interaction with the β′ lid-rudder-
system (LRS). This work revisits the β′ coiled-coil as a hot spot for the protein−protein 
interaction inhibition and expands it by introduction of the LRS as target site. 
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Introduction 
As bacterial RNA polymerase (RNAP) is essential for bacterial growth and survival, it is an 
attractive target for drug development.
1,2
 RNAP is highly conserved among bacteria, enabling 
the development of broad spectrum antibiotics. Along with the recently (May 2011) FDA 
approved RNAP inhibitor Lipiarmycin (fidaxomicin/Dificid),
3
 the Rifamycins are the only 
RNAP inhibitors that are in clinical use.
2
 However, the use of the Rifamycins led to the 
occurrence of single point mutations in the rpoB gene (encoding for the beta subunit of the 
enzyme), resulting in strains that exhibit highly elevated MIC values.
4,5
 Also resistance 
mechanisms other than target mutation have been reported for Rifampicin.
6
 Besides the 
Rifamycin binding site, numerous other binding sites in RNAP for diverse inhibitors are 
known.
7−11
 In this context several new inhibitors of RNAP have been discovered in in vitro 
tests, ranging from highly active natural products
12−14
 to small organic molecules.
7,8,15,16
 
However, these compounds also bear several disadvantages, such as poor antibacterial 
activity,
8
 insufficient specificity for RNAP,
17
 minimal absorption into mammalian cells,
18
 or 
inadequate physicochemical properties,
19,20
 which impede their use in the clinic. A strategy to 
overcome these drawbacks is the development of new antibacterial agents with novel and 
defined modes of action. In this study we focus on the interface between the Escherichia coli 
(E. coli or Ec) RNAP core enzyme and σ70 as a potential binding site in order to inhibit their 
assembly, which is essential for transcription initiation. As no σ70 homologue has been found 
in mammalian cells except some specificity factors in mitochondria that seem to be more 
related to viral transcription systems,
21
 we do not expect side effects of a drug targeting this 
assembly step. We applied a peptide approach to provide a basis for the generation of new 
classes of RNAP inhibitors that interfere with a defined binding site within this interface. The 
recent identification of a peptidic RNAP inhibitor
22
 and the structural studies of Sharp and 
colleagues
23
 motivated us to rationally design a set of peptides derived from different 
interface regions (taken from β, β′, and σ70 subunits). The peptides were chosen on the basis 
of mutagenesis data
23−27
 and 3D information of the enzyme (e.g., PDB 3IYD). In a 
transcription assay utilizing RNAP core and holo enzyme in parallel we identified two 
peptides with IC50’s in the low micromolar range, both of them derived from the σ
70
 2.2 
region. They inhibited RNAP holo enzyme more strongly than the core enzyme, supporting 
our idea of their mode of action. ELISA-based binding experiments confirmed the most active 
peptide P07 to inhibit the interaction between σ70 and the core enzyme. Furthermore, an 
abortive transcription assay revealed that P07 impedes the initiation of transcription. 
Molecular dynamics (MD) simulations, which were accompanied by studies in which mutated 
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variants of P07 were examined, suggested P07 to target the β′ coiled-coil and lid-rudder-
system (β′CC-LRS) hot spot. In this work we revisited the β′CC, which was already proposed 
by the group of Burgess as a promising binding site,
16,28
 and expanded it by introducing the 
LRS as target site, resulting in a hot spot for potent inhibition of the protein−protein 
interaction. Our data might lead to the generation of new antibacterial drugs targeting RNAP 
with a novel mode of action. 
 
Results and Discussion 
Design of Peptides. In order to inhibit the σ70:core protein−protein interaction, we designed 
16 peptides derived from the most promising regions in the σ70:core interface of E. coli 
RNAP. Their sequences span from 15 to 24 amino acids (aa) (Table 1). The bases for their 
selection were published mutagenesis data
23−27
 and structural information. In detail, 12 
peptides were selected from Ec σ70 (P01−12). We considered all aa that were reported to elicit 
at least 5-fold core binding defects, which were Leu384, Val387, Leu402, Asp403, Gln406, 
Glu407, Asn409, Met413, Pro453, Pro504, Glu555, Arg562, Ile565, and Leu598 (Table 1, aa 
highlighted in red).23 Furthermore, σ70 residues 361−390 (P01−06) were reported to be 
important for efficient core-binding activity (Table 1, underlined aa).24 Peptides P13−15 are 
derived from Ec β′260−309, a coiled-coil region (β′CC) that is reported as binding hot spot for 
σ70.22,25,26,29,30 Amino acid mutations R275Q, E295K, and A302D led to inviable cells in an in 
vivo assay and prevented holo enzyme formation.
25
 These relevant aa are present in P13−15 
(Table 1, highlighted in red). P16 represents the Ec β flap-tip helix (underlined aa) and 
contains a hydrophobic patch described to interact with the σ70 region 4.27 Four more peptides 
were chosen as control peptides that should not inhibit RNAP. The aa sequence of control 
peptide C01 was chosen randomly, whereas C02−04 are reported to have antimicrobial 
activity.
31−36
  
 
Table 1. List of designed peptides; details concerning selected peptides are given 
Peptide Subunita Amino acid sequenceb Length 
(aa) 
P01 σ70 (375-390) AKKEMVEANLRLVISI 16 
P02 σ70 (380-395)             VEANLRLVISIAKKYT 16 
P03 σ70 (385-402)                         RLVISIAKKYTNRGLQFL 18 
P04 σ70 (385-408)                         RLVISIAKKYTNRGLQFLDLIQEG 24 
P05 σ70 (387-404)                              VISIAKKYTNRGLQFLDL 18 
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P06 σ70 (390-407)                                    IAKKYTNRGLQFLDLIQE 18 
P07 σ70 (395-413)                                              TNRGLQFLDLIQEGNIGLM 19 
P08 σ70 (400-416)                                                          QFLDLIQEGNIGLMKAV 17 
P09 σ70 (440-457) TRSIADQARTIRIPVHMI 18 
P10 σ70 (492-507) DKIRKVLKIAKEPISM 16 
P11 σ70 (552-568) TAREAKVLRMRFGIDMN 17 
P12 σ70 (594-609) ALRKLRHPSRSEVLRS 16 
P13 β’ (265-280) LNDLYRRVINRNNRLK 16 
P14 β’ (275-290) RNNRLKRLLDLAAPDI 16 
P15 β’ (291-306) IVRNEKRMLQEAVDAL 16 
P16 β (893-907) TQLTPEEKLLRAIFG 15 
C01c - LATKALYIERLASATA 16 
C02c - RQRVEELSKFSKKGAAARRRK 21 
C03c - SIGSALKKALPVAKKIGKIALPIAKAALP 29 
C04c - GWGSFFKKAAHVGKHVGKAALTHYL 25 
aσ70, β, and β′ subunits; in brackets: amino acid (aa) positions according to the E. coli RNAP 
subunit sequences. 
bUnderlined and in red: aa that are most important for σ70:core interaction, 
according to the literature.
23−27
 P01-08 are shifted in their lines for comparability reasons. 
c
Control peptides. 
 
Activity in Transcription Assay. In order to investigate whether these peptides inhibit the 
σ70:core interaction, transcription reactions with either core or holo RNAP were performed. 
We first tested the RNAP inhibitors Rifampicin, Corallopyronin, and CBR703,
6,8,13
 which are 
described to inhibit the RNAP core enzyme, as well as Lipiarmycin (Lpm) and SB2, 
described to target the σ70:core interaction.7,37−39 As our results illustrate (Table 2), the IC50 
values of the core enzyme inhibitors were around 2-fold lower for the core enzyme (compared 
to holo), while SB2 and Lpm inhibited the holo enzyme to a higher extent. On the basis of the 
results of these reference compounds, we expected the peptides to show a stronger inhibition 
of the holo enzyme. Four out of the 16 interface-derived peptides showed >50% inhibition at 
50 μM (Table 2B). Surprisingly, also the control peptide C01 showed moderate activity. As a 
consequence, five mutant C01 peptides were designed indicating interactions with a (still 
unknown) target site (Supplementary Scheme SI1). For the most active interface-derived 
peptides, IC50 values were determined. All of them inhibited the holo enzyme more strongly 
than core RNAP. Interestingly, the most active peptides are all derived from σ70 2.1−2.2 
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regions (aa 375−416; P01−08) with P07 being the most potent one with an IC50 of 4.6 μM in 
the holo enzyme assay. 
 
Table 2. Transcription Assay with Reference Compounds and Peptides
c
 
A. 
Compound 
Inhibition of 
RNAP core 
(IC50) 
Inhibition of 
RNAP holo 
(IC50) 
Ratio 
(IC50 core:holocompd / 
IC50 core:holorif) 
Rifampicin 15.7 nM 27.4 nM 1.0 
Corallopyronin 408.0 nM 649.8 nM 1.1 
CBR703 6.5 µM 13.3 µM 0.9 
SB2 56.8 µM 37.9 µM 2.6 
Lipiarmycin 3.11 µM 0.90 µM 6.1 
B. 
Peptide 
Inhibition of 
RNAP core 
(IC50 in µM)
1
 
Inhibition of 
RNAP holo 
(IC50 in µM)
1
 
Ratio 
(IC50 core:holopeptide / 
IC50 core:holorif) 
P01 45.3 39.9 2.0 
P02 24.1 22.9 1.8 
P03 15.5 %
1
 10.5 %
1
 
a 
P04 9.8 5.8 3.0 
P05 21.0 %
1
 22.5 %
1
 
a 
P06 21.0 %
1
 11.0 %
1
 
a 
P07 5.5 4.1 2.4 
P08 25.5 %
1
 18.0 %
1
 
a 
P09 n.i. n.i. 
a 
P10 10.3 %
1
 n.i. 
a 
P11 31.4 %
1
 32.6 %
1
 
a 
P12 n.i. n.i. a 
P13 n.i. n.i. a 
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P14 n.i. n.i. a 
P15 n.i. n.i. a 
P16 16.0 %
1
 n.i. 
a 
C1 42.2 32.2 2.3 
C2 n.i. n.i. a 
C3 n.i. n.i. a 
C4 n.i. n.i. a 
aWhere a % inhibition value is given, the peptide was tested at 50 μM. bNot determined; n.i., 
no inhibition (inhibition <10% at 50 μM); bold designates the lower of the two compared IC50 
values (core vs holo). Given values are in round figures; ratios are based on exact values. 
c
Comparison of Ec RNAP inhibition (RNAP core and holo) of selected reference compounds 
(A) and peptides (B). IC50 values were determined. The core to holo IC50 ratios were related 
to the Rifampicin core to holo IC50 ratios. 
 
Although some linear peptides are known to exhibit antibacterial activity,
31−36
 our peptides 
P01−16 did not inhibit growth of Ec TolC. 
σ70:core Inhibition Leads to Inhibition of Transcription Initiation. To validate P07 
inhibiting the interaction between σ70 and RNAP core, we performed an ELISA-based RNAP 
assembly assay similar to the one published by André and colleagues.7 In this binding 
experiment P07 prevented core enzyme from binding to σ70 in a concentration-dependent 
manner, whereas P14 displayed no significant inhibition of the protein−protein interaction 
(Figure 1). 
 
Figure 1. ELISA binding experiments. The binding inhibition of RNAP core to σ70 is shown 
in the presence of different concentrations of P07 and P14. Standard deviations from two 
independent experiments are given (black bars). 
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These results support our idea for the σ70:core interface region as binding site for the peptide. 
Nevertheless we are aware that such an effect could be also observed in the case of a 
conformational change within the core enzyme induced by the peptide binding to an allosteric 
site. As the inhibition of σ70:core interaction by P07 should inhibit promoter recognition and 
thus transcription initiation, an HPLC-based assay was performed aiming at the quantification 
of tritium-labeled abortive transcripts that are usually formed during the initiation process. As 
shown in Figure 2, in contrast to P14 and C03 that were inactive in the transcription assay, 
P07 led to a drastic reduction of abortive transcript formation, supporting again our proposed 
mode of action for P07. 
 
Figure 2. Primed abortive transcription assay. Inhibition of transcription initiation was 
measured by quantification of abortive transcripts (ApUpC*) that have been formed using 
CTP* and ApU as substrates. Asterisk (*) designates 
3
H labeling. Standard deviations from 
three independent experiments are given (black bars). 
 
MD Simulations To Elucidate Mode of Action. In the Thermus thermophilus holo RNAP 
structure (e.g., PDB 2BE5) and in our Ec RNAP homology model P07 is derived from a σ70 
region that exhibits a helix-turn-helix motif (Figure 3A, “folding”). In order to elucidate the 
mechanism of action of P07 in more detail and to gain information about whether this peptide 
and the other peptides derived from this region (P01−08) maintain the secondary structure 
embodied in the holo RNAP structures, generalized Born implicit solvent simulations 
(100−250 ns) were carried out. The average secondary structure elements obtained are shown 
in Figure 3 and Supplementary Figure SI1. While P01 and P02 almost completely maintained 
their helical structure during these simulations, in P03−05 only a short segment of this N-
terminal helix is preserved. An explanation for the good activity of P04 could be that its rigid 
N-terminus is stabilized by interactions with its own apparently helical C-terminus. This was 
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even more evident in the MD simulation of P04 in complex with a β′ truncated construct.22 In 
this MD simulation, amino acids Gln400−Glu407 of P04 moved slightly toward the β′-LRS, 
allowing interactions of the 2.1−2.2 turn residues (Tyr394−Gln400) with lid and rudder. 
Shortening of P04 at both ends (P05 and P06) led to a dramatic loss of activity, possibly by 
losing contacts to the core enzyme and/or the LRS. P06 is identical to a peptide that was 
described by Sharp et al.
23
 to inhibit transcription initiation, if σ70 was present in unsaturated 
concentration. This effect was abolished if excess σ70 was added to the reaction. These results 
emphasize the competing behavior between such a peptide and σ70. In contrast to the good 
results for P06 in the assay performed by Sharp et al.,
23
 we found only a low inhibition, 
presumably due to sigma saturation in the holo enzyme assay. During the MD simulations, 
P07 and P08 preserved the long α-helix seen in the holo RNAP structures for σ70 2.2. 
 
 
Figure 3. MD simulation results of P01−08. (A) The folding of the E. coli σ70 region 
375−416 is illustrated according to our Ec RNAP homology model. (B) The folding of each 
aa in P01−08 is given as a result of our MD simulations. H, helix; T, turn; L, loop; B, beta-
sheet. Bold: >40% occurrence of this folding in the MD simulations; nonbold: 18−40%. 
Asterisk (*) designates most active peptides in the transcription assay. 
 
Interestingly, P07 was much more potent than P08, although the β′CC binding affinity of the 
latter peptide should be more efficient. On the other hand P08 lacks the five N-terminal 
residues (compared to P07), hinting at the N-terminal loop to be responsible for the drastic 
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difference in activity. We speculate the LRS to be targeted by this flexible loop (instead of the 
rigid turn motif of P04) and decided to examine this hypothesis in more detail. To analyze 
whether specific interactions are formed, GPU accelerated MD simulations (30 ns) were 
performed for P07 in complex with a truncated version of β′ (aa 94−346) containing the β′CC 
and LRS. The absence of σ70 allows an increased flexibility of the lid, which in the presence 
of P07 moves upward, tightening the fork formed with the rudder (distance between Cα of 
Asp256 and Gly318 decreases from 23.7 to 13.8 Å) (Figure 4 and Supplementary Figure SI2). 
A polar network involves the C-term-core residues Gln400, Asp403, Gln406, and Glu407 and 
the cationic hot spot residues of β′CC Arg275, Arg278, and Arg281 (Supplementary Scheme 
SI2 and Supplementary Figures SI3 and SI5). In this simulation interactions can be observed 
between the C-terminal residues of P07 and the hydrophobic patch on the top of β′CC, which 
ensure an optimal placement of the peptide along the β′CC axis. As seen from the energy 
contribution data (Supplementary Figures SI1 and SI3), other residues strongly contributing to 
the binding affinity are located on the N-terminal loop of P07: Arg397 forms an ion-pair to 
Asp257 (lid), whereas Asn396 forms hydrogen bonds to Thr317 and Ser319 (rudder) (Figure 
4). Consequently, the LRS is stabilized in a closed conformation, which is now unavailable 
for σ binding. 
 
 
Figure 4. Binding of P07 to the β′trunc subunit. (A) The molecular surface representation of the 
β′trunc subunit (hydrophilic, magenta; neutral, white; lipophilic, dark green) is shown in 
complex with P07 (cartoon, green). Important residues of P07 are labeled. (B) Schematic 
representation of the interactions between P07 (gray cartoon) residues and the β′ coiled-coil 
and LRS. Residues of P07 that were varied in this study are rendered as sticks, others as lines. 
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Interaction Analysis by Peptide Mutants. To confirm these hypothesized binding 
mechanisms and to establish a clear structure−function relationship, P07 was subjected to 
further in vitro experiments. In a first step, we designed eight mutant peptides with single-
point mutations of the residues Asn396, Arg397, Gln400, Asp403, Gln406, Glu407 (all into 
Ala), and Gly411 (into Gln/Arg). Additionally, a truncated version of P07 lacking the six C-
terminal residues was synthesized (Table 3). The P07 mutants N396A and R397A were 
generated in order to prove the interactions of the N-terminal part of P07 with the LRS. 
Interestingly, both of these mutants showed a significant loss of activity (Table 3A), 
confirming the MD predictions. The four mutated residues of the helix2.2-core (Gln400, 
Asp403, Gln406, Glu407) are regarded as key amino acids: they exhibited the highest binding 
energy contributions in the P07-β′CC-LRS MD simulation due to interactions with Arg275, 
Arg278, Arg281, and Glu295 (Figure 4B, Supplementary Figure SI3 and Supplementary 
Scheme SI2). Indeed, our in vitro results show a significant increase of the IC50 values 
confirming the modeling results. Especially substitution D403A led to a more than 10-fold 
increase of the IC50 value compared to that of P07 (Table 3B). Finally, we examined the C-
terminal part of P07 and its interactions with the hydrophobic patch at the tip of the β′CC by 
mutating Gly411 to Arg and Gln (Table 3C). In particular, we speculated that a neutral 
glutamine stabilizes the helical structure of the peptide, whereas for G411R a decreased helix 
stability and, notably, a repulsion with the β′CC cationic hot spot residues Arg278 and 
Arg281 was expected. Indeed, while the IC50 of G411Q was similar to that of P07, the IC50 of 
G411R increased around 7-fold (Table 3C). As expected a truncated version of P07 lacking 
the six C-terminal aa exhibits a reduced activity (26 μM, Table 3C), suggesting that it might 
still target β′trunc.  
 
Table 3. Transcription Inhibition by P07 Mutants
b
 
A. 
Peptide aa sequence 
Inhibition of 
RNAP core 
(IC50 in µM) 
Inhibition of 
RNAP holo 
(IC50 in µM) 
Ratio 
(IC50 core:holopeptide 
/ IC50 core:holorif) 
P07 TNRGLQFLDLIQEGNIGLM 6.2 4.6 2.4 
N396A
1
 TARGLQFLDLIQEGNIGLM 35.3 21.0 2.9 
R397A
1
 TNAGLQFLDLIQEGNIGLM 39.4 18.8 3.7 
B. 
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Peptide aa sequence 
Inhibition of 
RNAP core 
(IC50 in µM) 
Inhibition of 
RNAP holo 
(IC50 in µM) 
Ratio 
(IC50 core:holopeptide 
/ IC50 core:holorif) 
P07 TNRGLQFLDLIQEGNIGLM 6.2 4.6 2.4 
Q400A TNRGLAFLDLIQEGNIGLM 11.7 8.0 2.6 
D403A TNRGLQFLALIQEGNIGLM > 50 > 50 n.d. 
Q406A TNRGLQFLDLIAEGNIGLM 18.6 8.3 3.9 
E407A TNRGLQFLDLIQAGNIGLM 17.2 16.3 1.9 
C. 
Peptide aa sequence 
Inhibition of 
RNAP core 
(IC50 in µM) 
Inhibition of 
RNAP holo 
(IC50 in µM) 
Ratio 
(IC50 core:holopeptide 
/ IC50 core:holorif) 
P07 TNRGLQFLDLIQEGNIGLM 6.2 4.6 2.4 
G411Q TNRGLQFLDLIQEGNIQLM 9.3 4.5 3.6 
G411R TNRGLQFLDLIQEGNIRLM 44.1 31.0 2.5 
395-407
a
 TNRGLQFLDLIQE 31.9 26.0 2.2 
a
Short version of P07 (aa positions referring to E. coli σ70). n.d., not determined. bSelected aa 
of P07 were substituted (underlined). Modifications were performed in the (A) Nterm loop 
region, (B) helix2.2 core, and (C) hydrophobic Cterm. IC50 values (inhibition of core and holo 
RNAP) were determined for these peptides. 
 
To further investigate the roles of the peptides D403A, G411Q, and G411R, they were 
simulated alone as well as in complex with the truncated β′ construct. The helical structure of 
D403A was not altered compared to P07, but in contrast to P07, which is oriented parallel to 
the β′CC-axis with closed LRS, in the D403A-β′trunc simulation D403A is rotated 
perpendicularly along the β′CC axis (Figure 5). 
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Figure 5. Binding of P07 and selected mutants to the β′trunc subunit. (A) Superimposition of 
the simulated peptides-β′trunc complexes: P07 (green), D403A (red), G411Q (blue), G411R 
(yellow). (B) The shorter dLRS values for P07 and G411Q correlate with more favorable 
ΔGbind and IC50 values. 
 
The lack of interactions with lid or rudder leads to an opened LRS conformation (dLRS = 22.6 
Å), which is likely accessible for σ. The decreased predicted binding energy is in agreement 
with the reduced inhibition, the energy contribution data (Supplementary Figure SI3), and the 
hydrogen bonds (Supplementary Scheme SI2). Notably, for the G411Q complex the peptide is 
oriented along the β′CC axis as seen for P07 with its N-terminal loop fitted in between a 
closed LRS (dLRS = 13.2 Å) (Figure 5B and Supplementary Figure SI2). Moreover, for this 
complex the binding energy was in agreement with the inhibitory potency. For the G411R-
β′trunc simulation the ionpair network formed by Asp403 with Arg275 and Arg278 is 
maintained holding the helix2.2 core in place. However, it is rotated with respect to the β′CC 
axis (as seen for D403A). Arg411 is pulled away from the β′ hydrophobic patch, leading to 
unfolding of the C-terminal helix. Along with the observation that the LRS is found in an 
opened conformation, these data explain the reduced RNAP inhibition by G411R. 
Accordingly, our MD-based hypothesis for the mechanism of action of P07 are consistent 
with our in vitro data. 
 
 
RESULTS 31 
 
Conclusions. 
In the present work we examined rationally designed peptides as inhibitors of σ70:core 
interaction. We focused on peptide P07, which showed the best inhibitory activity. ELISA-
based binding experiments as well as successful inhibition of transcription initiation by P07 
strongly support the σ70:core interface as a target site. After performing MD simulations and 
detailed mutagenesis studies, we conclude that P07 binds to the β′CC and to the LRS. Our 
results indicate that both interaction sites are essential for potent inhibition. Notably, P07 also 
led to a significant inhibition of the RNAP core enzyme. Although this result is at a first 
glance surprising, an explanation is found in the MD simulations and the mutagenesis results. 
In particular, interference of P07 with the conformational flexibility of the LRS might be the 
cause for the observed core RNAP inhibition. This hypothesis is supported by the fact that 
mutagenesis and deletion experiments of lid
40
 and/or rudder
41,42
 affected the initiation step (as 
expected for pure sigma-core inhibitors), but also other transcription events such as open 
promoter complex formation and RNA exit. These data might be used as a valuable starting 
point for the structure-based design of small organic molecules addressing this target site. 
 
Methods 
Transcription Assay. Core and holo enzyme of E. coli RNA polymerase were purchased 
from Epicenter Biotechnologies. Final concentrations in a total volume of 30 μL were 20 units 
of RNase inhibitor (RiboLock, Fermentas), 10 mM DTT, 40 mM Tris HCl (pH 7.5), 150 mM 
KCl, 10 mM MgCl2, 0.01% (v/v) Triton-X-100, 400 μM ATP, CTP, and GTP, as well as 100 
μM UTP. As enzymes and for detection, 1 unit of RNAP holo enzyme was used along with 
0.53 μM 3H-UTP and 1 unit of RNAP core enzyme was used along with 1.33 μM 3H-UTP. As 
template for the transcription reactions 425 ng of T7A1 (for holo) or T7 (for core) promoter 
containing PCR fragments served as templates, respectively. Prior to starting the experiment, 
the compounds were dissolved in DMSO, and the peptides were dissolved in a 1:1 mixture of 
acetonitrile (ACN) and ddH2O. The final DMSO concentration during the experiments was 
2% (v/v) (1% (v/v) for ACN). Dilution series of compounds were prepared using a liquid 
handling system (Janus, Perkin-Elmer). Further steps including the preincubation, 
transcription reaction, purification, and quantification were performed as described 
previously.
43
 To obtain inhibition values for each sample, their counts were related to DMSO 
or ACN/ddH2O controls, respectively. 
Preparation of DNA Templates. To obtain the T7A1 template, a two-step PCR was 
performed using Taq DNA polymerase (New England Biolabs). First, a part of the neomycin 
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gene of pcDNA3.1 was amplified. The 3′ primer (ttctcggcaggagcaaggtgag) was used along 
with a 5′ oligo which was flanked by a T7A1 promoter 
(gactcagtgatatcaaaaagagtattgacttaaagtctaacctataggatacttacagccatcgagaggctgatcaagagacaggatga
gg) resulting in a PCR product containing the 59-bp T7A1 promoter on the 5′ end. The total 
size of the PCR product was 437 bp. To obtain the T7 promoter template the same procedure 
as above was followed with the difference that the T7A1 promoter sequence was substituted 
by the T7 promoter sequence. The PCR products were gel purified (kit from PEQLAB) and 
elongated in a second PCR using the same 3′ oligos and a 5′ oligo increasing the size by 13 bp 
(cagaccatgatcagactcagtgatatc). The PCR products were purified (kit from Fermentas) and 
served as templates in our transcription assays. 
Determination of IC50 Values. Three different concentrations of a compound/peptide were 
chosen for the determination of an IC50 value (two samples for each concentration). The 
calculation of the IC50 value was performed by plotting the percent inhibition versus the 
concentration of inhibitor on a semilog plot. From this the molar concentration causing 50% 
inhibition was calculated. At least three independent determinations were performed for each 
compound. 
RNA Polymerase Inhibitors and Peptides That Were Used. Rifamycin was purchased 
from Sigma-Aldrich. Corallopyronin was donated by K. Gerth (HZI). CBR703 
(benzenecarboximidamide, N-hydroxy-N′-phenyl-3-(trifluoromethyl)) was synthesized 
according to a published procedure (WO 01/51456 A2). SB2 (benzoic acid, 3-[5-[[4-oxo-3-(2-
propen-1-yl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]) was synthesized as described 
in the literature.
44
 Lipiarmycin was a generous gift from Novartis. Peptides were purchased 
from intavis, peptides&elephants, or were synthesized by our in house Platform Peptide 
Synthesis. Peptide sequences are given in Table 1. 
ELISA Experiments. The procedure was performed as described in André et al.7 with slight 
modifications regarding quantification. The cloning and purification of Ec σ70 was performed 
as described in Haupenthal et al.
43
 As primary antibody for the detection of core enzyme 
binding, a monoclonal anti-α subunit antibody was purchased from NeoClone Biotechnology. 
This antibody was used in a 1:1000 dilution as recommended by the manufacturer. The 
secondary antibody, a goat anti-mouse IgG labeled with fluorescein (Santa Cruz 
Biotechnology) was used diluted 1:200. Fluorescein was excited at 485 nm, and fluorescence 
read out at 520 nm on a microplate reader (POLARstar Omega by BMG Labtech). 
HPLC-Based Abortive Transcription Assay. E. coli RNA polymerase (RNAP) holo 
enzyme was purchased from Epicenter Biotechnologies. Final concentrations in a total 
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volume of 30 μL were 1 unit of RNAP along with 20 units of RNase inhibitor (RiboLock, 
Fermentas), 10 mM DTT, 40 mM Tris-HCl (pH 7.5), 150 mM KCl, 10 mM MgCl2, and 0.1% 
(w/v) CHAPS. The peptides were dissolved in a 1:1 mixture of acetonitrile (ACN) and water 
(final ACN concentration during experiments: 1% (v/v)). In the presence of the above-
mentioned RNAP mixture they were incubated for 10 min at 25 °C prior to starting the 
experiment. Each transcription reaction was started by the addition of a mixture containing 1 
μCi of [5-3H]-CTP (Perkin-Elmer), 100 μM of ApU dinucleotide (IBA), and 450 ng of the 
T7A1 promoter containing PCR product T7A1_437 serving as the DNA template.
43
 The 
transcription reactions were carried out at 37 °C for 60 min. The subsequent sample 
preparation and HPLC-based quantification of ApUpC formation were carried out as 
described in the Supporting Information. 
Molecular Dynamics (MD) Simulations, MM-GBSA Calculations, and Minimal 
Inhibitory Concentration (MIC) Determinations. The description of these methods can be 
found in the Supporting Information. 
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This material is available free of charge via the Internet at http://pubs.acs.org. 
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Abstract: The bacterial RNA polymerase (RNAP) is a validated target for broad spectrum 
antibiotics. However, the efficiency of drugs is reduced by resistance. To discover novel 
RNAP inhibitors, a pharmacophore based on the alignment of described inhibitors was used 
for virtual screening. In an optimization process of hit compounds, novel derivatives with 
improved in vitro potency were discovered. Investigations concerning the molecular 
mechanism of RNAP inhibition reveal that they prevent the protein−protein interaction (PPI) 
between σ70 and the RNAP core enzyme. Besides of reducing RNA formation, the inhibitors 
were shown to interfere with bacterial lipid biosynthesis. The compounds were active against 
Gram positive pathogens and revealed significantly lower resistance frequencies compared to 
clinically used rifampicin. 
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Introduction 
The increasing resistance of bacteria against antibiotics has become a major public health 
problem.
1
 Therefore, new potent antibacterial drugs are required.
2
 RNA polymerase (RNAP) 
catalyzes the formation of RNA from a DNA template
3
 and is essential for growth and 
survival of bacteria. It is highly conserved among various bacterial species but is different in 
eucaryotes.
4
 Hence, inhibiting RNAP is an attractive strategy for the treatment of bacterial 
infections.
4
 In spite of the fact that several inhibitors of bacterial RNA polymerase are known, 
only rifamycins and fidaxomicin (lipiarmycin) are currently approved for clinical use.
3,5−7
 
Because of an increasing amount of bacterial strains resistant to rifamycins, there is an urgent 
need to discover new RNAP inhibitors for clinical use which should not show cross-resistance 
to rifamycins, especially rifampicin (Rif). In this work, a flexible alignment of structurally 
similar selected synthetic molecules (I−VII) that are known to inhibit bacterial RNAP8−12 was 
performed (Figure 1). The resulting pharmacophore model was subsequently used to virtually 
screen an in-house database. Thus, three hit compounds, containing an anthranilic acid core, 
were identified and experimentally validated. In the following, the compounds were 
optimized to improve the inhibitory profile and their mode of action was determined. 
Additionally, the compounds revealed good antibacterial activities. 
 
Pharmacophore-based virtual screening and hit compound discovery. 
Seven synthetic bacterial RNAP inhibitors (I−VII) that exhibit similar structural features, 
although belonging to different classes and acting via different binding modes, were retrieved 
from literature (Figure S1, Supporting Information (SI)).
8−12
 Compound I inhibits 
Staphylococcus aureus RNAP, but its binding site is not known.
8
 II and III are described as 
inhibitors of Escherichia coli RNAP binding to a surface exposed groove at the junction of 
the β′-bridge helix and the β-subunit.9 IV−VI are known to prevent the protein−protein 
interaction (PPI) between σ70 and the RNAP core enzyme.10,11 VII shows structural similarity 
to known RNAP inhibitors but has only been described as an inhibitor of transcription and 
translation (TT) without any information about its mode of action.
12
 We resynthesized VII 
and were able to demonstrate its inhibition of E. coli RNAP in vitro (SI). I−VII were 
employed in a flexible alignment with the aim to identify the common features of these 
molecules. The alignment with the best similarity score was used to generate an initial 
pharmacophore model, which was then manually refined. The resulting model derived from 
these differently acting compounds is not restricted to the identification of hits binding to one 
special site. It should rather support the discovery of an increased number of RNAP inhibitors 
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independent of their binding mode. The final model consisted of four core features (two 
aromatic, one HBD/HBA/aromatic and one O2/anion). Besides, one accessory feature 
(hydrophobic) and two aromatic projections were identified (Figure 1, Figure S2, SI). The fit 
of each inhibitor I−VII into the pharmacophore model is depicted in Figure S3, SI. The 
virtual screening of an in-house database comprising of approximately 2000 compounds using 
this pharmacophore model afforded 64 hits. A virtual hit had to match at least the core 
features and the aromatic projections, while the presence of the accessory feature was not 
mandatory. 
 
 
Figure 1. (A) Selected synthetic inhibitors of bacterial RNAP (I−VII) were used to perform a 
flexible alignment. (B) A pharmacophore model with four core features (aromatic, orange; 
HBD/HBA/aromatic, violet; O2/anion, rose), one accessory feature (hydrophobic, green), and 
two aromatic projections (one hatched orange, one hidden behind a core feature) was created 
and used for virtual screening. For an overlay of I−VII with the pharmacophore model, see 
Figure S3, SI. (C) Validated hit compounds 1−3 possessing an RNAP in vitro inhibition 
>20% at a concentration of 200 μM. 
 
Eleven of these hit compounds originating from five different structural classes were 
experimentally confirmed to be active in our in vitro RNAP assay
13
 (>20% inhibition at 200 
μM) (Figure S4, SI). Out of these, three promising compounds (1−3), containing an 
anthranilic acid core, were chosen for further optimization. They displayed 31% (1), 23% (2), 
and 100% (3, IC50 20 μM) inhibition at 200 μM, respectively. 
 
Chemistry 
The synthesis of the target compounds was carried out starting from the appropriate 
anthranilic acids. The methyl 2-benzamidobenzoate intermediates 1a−34a were synthesized 
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via coupling reaction with the benzoyl chloride derivatives (Scheme 1). The methyl esters 
were hydrolyzed to yield the target compounds. A Suzuki coupling with phenylboronic acid 
was performed with the appropriate brominated intermediates to obtain compounds 31 and 32. 
The hydroxy substituted compound 24 was obtained from the methoxy intermediate 24a by 
ether cleavage using boron tribromide. 
 
Scheme 1. Synthetic Route to Compounds 1−34a 
 
a
Reagents and conditions: (a) SOCl2, MeOH, reflux; (b) pyridine, DMAP, rt or TEA, CH2Cl2, 
rt or toluene, reflux; (c) NaOH, THF/MeOH/H2O, rt; (d) PhB(OH)2, Pd(PPh3)4, Cs2CO3, 
DME/H2O, reflux. 
 
Results and Discussion 
Compounds 1−3 contain a 2-benzamidobenzoic acid partial structure which perfectly fits into 
the pharmacophore model. In addition, the structures contain a phenyl ring in para- and/or a 
phenoxy substituent in meta-position, respectively, which does not correspond to any feature 
of the pharmacophore model. Hence, the hit compounds were reduced in size to investigate 
whether these lipophilic residues are necessary for activity. Although the unsubstituted 2-
benzamidobenzoic acid (4) fits the pharmacophore model, no activity was observed for this 
compound. This resulted in the conclusion that the features included in the first 
pharmacophore model are insufficient to differentiate between active and inactive substances. 
To provide a remedy, two new accessory hydrophobic/aromatic features were added on the 
eastern side of the pharmacophore model (representing the phenyl and the phenoxy 
substituents) (Figure S5, SI). Using this extended model, a compound will be defined as a hit 
if, beside the four core features, at least one of the new accessory features is present. As the 
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extended model is more limiting, its use should improve efficacy and reduce the occurrence of 
false positives in future screenings. An overlay of inhibitors with the extended pharmacophore 
model can be found in Figure S6, SI. To explore the structure−activity relationship (SAR) 
around the anthranilic acid core, substituents were introduced in 4- and 5-position where the 
pharmacophore model contains a lipophilic accessory feature. As the most potent hit 
compound 3 has a relatively high molecular weight, optimization efforts were started 
modifying the two smaller hits 1 and 2. For each hit, a small series was synthesized 
introducing 4-Cl (6 and 7), 5-F (11 and 12), 5-Br (16 and 17), and 4,5-dimethoxy (19 and 20) 
substituents. The introduction of these substituents resulted in an increased in vitro activity, 
especially for the compounds with 4-Cl (6 and 7) and 5-Br (16 and 17) substituents. Aside 
from that, most 4-phenyl and 3-phenoxy compounds displayed very similar activities. To 
investigate whether the oxygen of the phenylether group has a beneficial effect as HBA, we 
synthesized compound 18 containing a 3-benzyl instead of the 3-phenoxy substituent. The 
removal of the oxygen did not affect the potency, indicating that a HBA is not necessary for 
in vitro activity. Therefore we regarded it as sufficient to continue the SAR studies 
introducing further substituents into the 4-phenyl series. To determine which kind of 
substituents could improve activity, substituents differing in electronic properties and 
lipophilicity were introduced in 5-position. The incorporation of the lipophilic, electron 
withdrawing chloro substituent resulted in the most potent compound 8 while a hydrophilic 
and electron donating hydroxy group (24) decreased activity in comparison to 1. Introduction 
of a lipophilic and electron donating substituent (30, CH3) or a hydrophilic electron 
withdrawing substituent (26, CN) was tolerated and led to moderately active compounds. In a 
next step, the best position for a substitution at the anthranilic acid moiety was determined. 
Considering the good activity of chloro compound 8, especially lipophilic, electron 
withdrawing substituents in different positions of the anthranilic acid moiety were introduced. 
A chloro substituent in 3-position (5) led to a total loss of activity. Similar results were found 
for the chloro, fluoro, and methoxy substituents in 6-position (9, 13, 23) (Table 1). As 
expected, the introduction of an electron donating methoxy substituent in 4- and 5-position 
afforded only a moderate improvement of activity. In contrast all the compounds bearing a 
lipophilic, electron withdrawing substituent in 4- or 5- position (6, 8, 10, 11, 14, 16, 25, 
27−29) possess a highly improved in vitro potency. Especially the introduction of a large 
lipophilic phenyl substituent in 4- or 5-position generated very potent inhibitors of RNAP (31, 
14 μM; 32, 13 μM). Interestingly, almost no difference in activity was observed between 
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compounds with a substituent in 4-position and compounds with the same substituent in 5-
position (6 and 8, 10 and 11, 14 and 16, 27, and 28). 
 
Table 1. Inhibitory activity against E. coli RNA polymerase in vitro and antibacterial activity 
 
compd R
1
 R
2
 
IC50 or % inhibition of 
E. coli RNAP
a
 
MIC E. coli TolC 
(µg/ml)
b
 
1 H 4-Ph 31% 13 
2 H 3-OPh 23% 9 
3 H 3-OPh, 4-PH 20 µM 13 
4 H H ni >100 
5 3-Cl 4-Ph ni 55 
6 4-Cl 4-Ph 37 µM 3 
7 4-Cl 3-OPh 44 µM 3 
8 5-Cl 4-Ph 46 µM 2 
9 6-Cl 4-Ph ni 57 
10 4-F 4-Ph 98 µM 4 
11 5-F 4-Ph 138 µM 7 
12 5-F 3-OPh 98 µM 5 
13 6-F 4-Ph 14% 34 
14 4-Br 4-Ph 28 µM 2 
15 4-Br 3-OPh 34 µM 3 
16 5-Br 4-Ph 31 µM 3 
17 5-Br 3-OPh 34 µM 3 
18 5-Br 3-CH2Ph 37 µM 2 
19 4-,5-OMe 4-Ph 35% 19 
20 4-,5-OMe 3-OPh 154 µM 6 
21 4-OMe 4-Ph 162 µM 9 
22 5-OMe 4-Ph 52% 8 
23 6-OMe 4-Ph ni 58 
24 5-OH 4-Ph 17% 31 
25 4-NO2 4-Ph 36 µM >25 
26 5-CN 4-Ph 23% @ 50 µM 7 
27 4-CF3 4-Ph 27 µM 5 
28 5-CF3 4-Ph 28 µM 2 
29 5-OCF3 4-Ph 31 µM 4 
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30 5-Me 4-Ph 139 µM 7 
31 4-Ph 3-OPh 14 µM 8 
32 5-Ph 3-OPh 13 µM 2 
33 4-F 3-OPh, 4-Ph 13 µM >25 
34 4-Cl 3-OPh, 4-Ph 9 µM >25 
Rif   0.03 µM 10 
Myx
c
   0.35 µM 1 
 
a
IC50 value (SD <20%) or percentage inhibition at 200 μM (SD <40%); Data represent the 
mean values of at least three experiments. ni: no inhibition. 
b
Minimum inhibitory 
concentration; data represent the mean values of at least two independent experiments (three 
for MIC <10 μg/mL). cMyx: myxopyronin B. 
 
From these results, it is obvious that especially lipophilic electron withdrawing substituents 
attached to the anthranilic acid core in 4- or 5-position are favorable, whereas substituents in 
3- or 6-position strongly reduce the in vitro activity. After all, the acquired SAR information 
of the anthranilic acid core was used for the optimization of 3. As it was not eligible to make 
the compounds too large and lipophilic, only F and Cl were introduced (33 and 34). As 
expected, these modifications had a beneficial effect on the activity and afforded the best in 
vitro compound of this series (34, 9 μM). As the pharmacophore model is not restricted to one 
special binding site, it remains to be clarified where our compounds bind to RNAP. 
Comparing the structures of the optimized hit compounds and the inhibitors I−VII, used to 
create the pharmacophore model, it becomes apparent that the new compounds are very 
similar to VII. This suggests that VII and our compounds are likely to interact with the same 
RNAP site. However, the binding mechanism of VII is not known. One possible mechanism 
of action could be the inhibition of the PPI between σ70 and the RNAP core enzyme because 
this has been demonstrated to be the way compounds IV−VI function.10,11 Hence, selected 
compounds (3, 9, 14, 28, 32, 34) as well as TT inhibitor VII were tested in an ELISA-based 
RNAP assembly assay.
14
 Rif and V were used as negative and positive controls, respectively. 
In contrast to Rif and inactive compound 9, inhibitors 3, 14, 28, 32, 34, and VII, which had 
been active in the transcription assay, inhibit PPI between σ70 and the RNAP core enzyme to a 
similar extent as positive control V (Table 2). 
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Table 2. Results of the ELISA-Based Assembly Inhibition Assay and the Core/Holo 
Transcription Assay 
compd 
assembly inhibition 
σ70/RNAP core (ELISA) 
(IC50)
a
 
inhibition of 
RNAP holo (IC50)
a
 
inhibition of 
RNAP core (IC50)
a
 
ratio
b
 
Rif
c
 ni 27 nM 16 nM 1 
V
c
 30 µM 38 µM 57 µM 2.6 
VII 97 µM 52 µM 81 µM 2.6 
3 41 µM 20 µM 36 µM 3.0 
9 ni nd nd  
14 68 µM 27 µM 39 µM 3.0 
28 60 µM 28 µM 67 µM 4.0 
32 47 µM 16 µM 27 µM 2.8 
34 33 µM 7 µM 12 µM 2.9 
a
IC50 value (SD <20%); Data represent the mean values of at least two experiments. ni: no 
inhibition; for 9 inhibition <10% at 50 μM; for Rif inhibition <5% at 10 μM. nd: not 
determined. 
b
(IC50 core:holocompd/IC50 core:holoRif). The core:holo IC50 ratios were related 
to the Rif core:holo ratio. 
c
Inhibition values of core/holo transcription assay by Hüsecken et 
al.
14
 
 
Inhibitors acting via such a mechanism would be expected to show a stronger effect in a σ70-
dependent transcription assay using holo enzyme than in a σ70-independent transcription assay 
with core enzyme. To further confirm PPI interruption as RNAP inhibitory mechanism, we 
tested our compounds in both assays in parallel. Indeed, 3, 14, 28, 32, 34, and VII were found 
to be more active in the assay using holo enzyme than in the core enzyme assay (Table 2). To 
normalize interassay conditions, ratios of IC50 values (core:holo) were calculated in relation to 
IC50 ratio (core:holo) of Rif, which was used as negative control not acting via PPI inhibition. 
The calculated IC50 ratios (core:holo) of the tested compounds are within the range of 2−4, 
comparable or even higher than the ratio of described PPI inhibitor V (Table 2). These results 
confirm the assumption that the mechanism of action of our compounds and TT inhibitor VII 
is the interference with the interaction between σ70 and RNAP core enzyme. 
 
Antibacterial activity 
For investigation of antibacterial activity, minimum inhibitory concentration (MIC) values 
were determined for all compounds. Two described RNAP inhibitors were used as references: 
Rif, which reveals a good antibacterial activity against Gram-positive and negative 
strains,
15−18
 and the natural product myxopyronin B, only active against Gram-positive 
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bacteria.
19
 To evade effects associated with drug efflux, initial MIC tests were performed 
using E. coli TolC mutant, deficient in the AcrAB−TolC multidrug efflux system. There are 
several compounds possessing high antibacterial activity comparable to the reference 
compounds, especially 6−8, 14−18, 28, and 32, with MIC values in the range of 2−3 μg/mL. 
For most compounds, antibacterial activity roughly correlates with in vitro RNAP inhibition. 
However, for some highly potent inhibitors, compounds 25, 33, and 34, bacterial growth 
inhibition was less than expected, a finding which possibly was caused by permeability 
problems. To further explore the antibacterial profile, MIC values for E. coli K12, 
Pseudomonas aeruginosa, Bacillus subtilis, and Staphylococcus aureus were determined for 
selected compounds (6, 7, 12, 15, 28, 32, 33; Table 3). None of the tested inhibitors reduced 
the growth of Gram-negative strains (E. coli K12 and P. aeruginosa). These results suggest 
that the compounds are either not able to penetrate the cell membranes of the Gram-negative 
bacteria or are discharged by efflux pumps. The latter mechanism is more probable 
considering the differences between the MIC values for E. coli K12 and E. coli TolC. On the 
other hand, the inhibitors were in general effective against Gram-positive bacteria; especially 
against Bacillus subtilis excellent MIC values were determined. 
 
Table 3. Minimum Inhibitory Concentration (MIC) for Selected Compounds 
compd 
MIC (µg/ml)
a
 
E. coli K12 PAO1
b
 B. subtilis S. aureus 
Rif
c
 7 13 5 0.02 
Myx
c
 >25 >25 0.9 0.5 
6 >50 >50 2 24 
7 >50 >50 3 14 
12 >100 >100 4 48 
15 >25 >25 3 8 
28 >50 >50 4 5 
32 >25 >25 3 6 
33 >25 >25 >25 17 
a
Minimum inhibitory concentration; Data represent the mean values of at least two 
independent experiments (three for MIC <10 μg/mL). bP. aeruginosa. cRif, rifampicin; Myx, 
myxopyronin B. 
 
It is striking that our compounds show very low MIC values comparable to the reference 
compounds although their RNAP inhibitory activities are less pronounced than those of the 
references. To confirm the mechanism of antibacterial activity, the impact on macromolecular 
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biosynthesis in E. coli TolC was examined. While exerting no appreciable effect on DNA and 
protein synthesis at 4 × MIC, 32 displayed an inhibition of RNA formation comparable to the 
clinically used RNAP inhibitor Rif (Figure 2). In addition, a strong decrease in lipid 
biosynthesis was observed (Figure 2). In this regard, it is also of interest that 
benzamidobenzoic acids, including compounds 2 and 3, have been described in the context of 
antiinfective research. While compound 3 was shown to inhibit PqsD, an enzyme associated 
with the Pseudomonas quorum sensing system,
20
 compounds 2 and 3 have been published as 
inhibitors of FabH, an enzyme involved in fatty acid synthesis.
21
 Therefore, it can be 
supposed that the good antibacterial activity is due to an additional FabH inhibition. 
 
 
Figure 2. Effects of 32 at 4 × MIC on macromolecular synthesis in E. coli TolC. Controls: 
cerulenin (Cer), chloramphenicol (Cam), ciprofloxacin (Cipro), and rifampicin (Rif). 
 
As it is our aim to develop compounds which are less susceptible to bacterial resistance 
development, the spontaneous resistance frequencies in E. coli TolC were determined in vitro 
for compounds 28 and 32 at 2 × MIC. Importantly, a lower resistance frequency (<4.5 × 
10
−11
) of both novel compounds compared to Rif (8.3 × 10
−8
) was observed. One explanation 
for this remarkable observation could be the dual target effects of our compounds. 
 
Conclusion 
RNAP is an attractive antibacterial target, but due to emerging resistance, new types of RNAP 
inhibitors are urgently needed. For the discovery of those, we performed a flexible alignment 
with a series of selected RNAP inhibitors
8−12
 and developed a pharmacophore model which is 
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not focused on one particular binding site. Using this model, a virtual screening was 
performed, hit compounds were identified, and 11 of those subsequently experimentally 
validated. On the basis of three hits of one structural class, an optimization approach was 
performed, resulting in enhanced inhibitory potencies. Concerning the mechanism of RNAP 
inhibition, we could demonstrate that the new inhibitors prevent the PPI between σ70 and the 
RNAP core enzyme. Determination of MIC values revealed that the best compounds are 
highly active against E. coli TolC and the Gram-positive pathogens B. subtilis as well as the 
clinically relevant S. aureus. The wild-type Gram-negative strains P. aeruginosa and E. coli 
K12 were not affected, probably due to pharmacokinetic reasons. Regarding the effects of our 
compounds on macromolecule synthesis in E. coli TolC, an inhibition of bacterial lipid 
biosynthesis was observed beside the reduced RNA formation. This highly interesting dual 
target effect could explain the good MIC values and the significantly lower resistance rate 
compared to the clinically used inhibitor Rif. These findings are presently further elucidated. 
In conclusion, we consider the new compounds promising for further development. 
 
Experimental Section 
Chemistry. All tested compounds have >95% chemical purity as measured by HPLC. 
Spectroscopic data for all compounds are provided in the SI. 
Procedure for the Synthesis of the Acyl Chlorides Used for Amide Coupling Reaction. 
Benzoyl chlorides, if not commercially available, were obtained from the corresponding 
carboxylic acid via reaction with thionyl chloride (2.5 equiv) in CH2Cl2 in the presence of 
catalytic amounts of dimethylformamide (4 h reflux). 
General Procedure for the Synthesis of Methyl 2-Aminobenzoates 5b, 21b−23b, 25b, 
27b, 29b, and 30b. Method A. A solution of the appropriate 2-aminobenzoic acid (1 equiv) 
in MeOH was cooled to 0 °C followed by a dropwise addition of thionyl chloride (2.5 equiv). 
The mixture was refluxed for 24 h. After evaporation of the solvent and neutralization by 
addition of a saturated aqueous NaHCO3 solution, the mixture was extracted with EtOAc and 
the combined organic layers were dried over MgSO4. Purification by CC (n-hexane/EtOAc) 
provided the title compounds (yields, physical, and spectral data are reported in SI). 
General Procedure for the Synthesis of Methyl 2-Benzamidobenzoate Derivatives 
1a−34a (Amide Coupling Reaction). Method B. Three different procedures were used to 
obtain the title compounds: BI. The appropriate methyl 2-aminobenzoate (1 equiv) was added 
to a solution of the acyl chloride (1.2 equiv) in CH2Cl2 under a N2 atmosphere. After the 
addition of TEA (2 equiv), the reaction mixture was stirred for 18 h at room temperature. BII. 
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The appropriate methyl 2-aminobenzoate (1 equiv) and a catalytic amount of DMAP were 
added to a suspension of the acyl chloride (1.5 equiv) in pyridine under a N2 atmosphere. The 
reaction mixture was stirred for 18 h at room temperature, and 2 M HCl was added. The 
mixture was extracted with EtOAc, and the combined organic layers washed with saturated 
NaHCO3 and dried over MgSO4. BIII. The appropriate methyl 2-aminobenzoate (1 equiv) 
and the acyl chloride (1.2 equiv) were dissolved in toluene and refluxed for 4 h (except for 5a 
and 33a−34a, which were refluxed for 18 or 72 h). For purification, the solvent was removed 
under reduced pressure and the remaining solid suspended in MeOH (except for 5a and 
31a−32a). After filtration, the precipitate was washed with MeOH to yield the pure 
compound. For compounds 5a and 31a−32a, the purification step was performed by CC or 
preparative TLC. 
General Procedure for the Synthesis of 2-Benzamidobenzoate Derivatives 1−34. Method 
C. The methyl esters of the title compounds (1a−34a) were hydrolyzed with 5 M NaOH in 
THF/MeOH (2:1) at room temperature (18 h). The mixture was acidified by the addition of 1 
M HCl and filtered, and the precipitate was washed with 1 M HCl to provide the title 
compounds. If the compound was not pure at this stage of the procedure, it was washed with 
MeOH and CH2Cl2 or was purified by CC or preparative TLC. 
General Procedure for Suzuki Coupling. Method D. A mixture of the appropriate methyl 
bromo-2-benzamidobenzoate (1 equiv), phenylboronic acid (1.5 equiv), Cs2CO3 (3 equiv), 
and tetrakis-(triphenylphosphine)-palladium (0.01 equiv) in a degassed DME/water (1:1) 
solution was refluxed under a nitrogen atmosphere for 4 h. The reaction mixture was cooled 
to room temperature. The mixture was extracted with EtOAc. The combined organic layers 
were washed with 1 M HCl and dried over MgSO4. The product was purified by CC or 
preparative TLC. 
General Procedure for Ether Cleavage Using Boron Tribromide. Method E. To a 
solution of the appropriate methoxy substituted methyl 2-benzamidobenzoate derivative (1 
equiv) in anhydrous CH2Cl2 at −78 °C (dry ice/acetone bath), boron tribromide (1 M in 
CH2Cl2, 6 equiv) was added dropwise. The reaction mixture was stirred for 18 h at room 
temperature under a nitrogen atmosphere. Water was added, and the aqueous layer was 
extracted with EtOAc. The combined organic layers were washed with brine and dried over 
MgSO4. The product was purified by CC followed by preparative TLC. 
Biology. Transcription Assay. Transcription assay was performed as described 
previously.
13,22
 During the transcription time of 10 min, the substrate concentration as well as 
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the enzyme activity were not limiting the transcription reaction. Consequently, the reaction 
process in our assay was linear. 
Determination of IC50 Values. For the determination of IC50 values, three different 
concentrations of a compound were chosen (duplicate determination) in the linear range of the 
log dose response curve (20−80% inhibition) including concentrations above and below the 
IC50 value. The calculation of the IC50 value was performed by plotting the percent inhibition 
versus the concentration of inhibitor on a semilog plot. From this, the molar concentration 
causing 50% inhibition was calculated. At least three independent determinations were 
performed for each compound. Standard deviation was less than 20%. 
Minimal Inhibitory Concentration (MIC) Determinations. These experiments were 
performed as described recently.
22
 Given MIC values are means of two independent 
determinations (three if MIC <10 μg/mL) and are defined as the lowest concentration of 
compounds that reduced OD600 by ≥95%. 
Determination of Resistance Frequencies. Defined amounts of E. coli TolC cells were 
incubated in LB in presence of the 2 × MIC of compounds 28 and 32 in parallel (16 h, 37 °C, 
50 rpm, 0.5% DMSO). On each of the three following days, a fraction of each of the samples 
was supplemented with fresh compound containing LB followed by recultivation (conditions 
as before). The final cultures were plated on LB agar to select spontaneous resistant mutants. 
The bacterial start concentration which was needed to yield at least one colony on the plates 
was determined. The reciprocal value of this threshold was defined to be the resistance 
frequency. For 28 and 32, no colonies were detected at the highest possible bacterial start 
concentration, resulting in a resistance frequency <4.5 × 10−11. 
Macromolecular Biosynthesis Assay. E. coli TolC was cultured in lysogeny broth (LB) 
medium. 
3
H labeled precursors (1−1.25 μCi/mL) were added during the logarithmic growth 
phase and several min (3 min for uridine and thymidine, 5 min for acetic acid, 12 min for 
glutamine) before the addition of compound 32 and the controls chloramphenicol (Cam), 
cerulenin (Cer), ciprofloxacin (Cipro), and rifampicin (Rif) at four times their MICs. For 
DNA, RNA, and protein synthesis, 300 μL of the cultured bacteria were harvested 0 and 30 
min after addition of the inhibitors and supplemented with 2 volumes of 10% TCA. After 45 
min at 4 °C, the precipitates were collected and washed using 96-well glass fiber filter plates 
(Multiscreen GFB) (Millipore, Billerica, MA). After adding Optiphase Supermix (Perkin-
Elmer, Waltham, MA), the quantification of radioactivity was performed using a Wallac 
MicroBeta TriLux system (Perkin-Elmer). For determination of lipid synthesis, cells were 
treated with CHCl3/MeOH (1:1) and water, subsequently. The organic phase was collected, 
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evaporated, redissolved in cyclohexane, and supplemented with Opti-Fluor O (Perkin-Elmer) 
before measuring the radioactivity in the MicroBeta TriLux. 
ELISA-Based RNAP Assembly Assay. The procedure was performed as described by 
Hüsecken et al.
14
 
Core/Holo Transcription Assay. The procedure was performed as described by Hüsecken et 
al.
14
 
 
Supporting Information 
Synthesis, compound characterization, and computational chemistry. This material is 
available free of charge via the Internet at http://pubs.acs.org. 
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Publication IV 
 
Abstract: In recent decades, quantitative transcription assays using bacterial RNA 
polymerase (RNAP) have been performed under widely diverse experimental conditions. We 
demonstrate that the template choice can influence the inhibitory potency of RNAP inhibitors. 
Furthermore, we illustrate that the sigma factor (σ70) surprisingly increases the transcription 
efficiency of templates with non-physiological non-prokaryotic promoters. Our results might 
be a useful guideline in the early stages of using RNAP for drug discovery. 
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4  Final discussion 
The aim of this thesis was to generate a test system for the identification and characterization 
of σ70:core RNAP inhibitors. The more information about the structure of the target, the 
binding site and mode of action of the inhibitor are available, the more likely rational drug 
design will be successful. To gain the information, reliable assays are essential. The assays 
developed in the course of this thesis are discussed and evaluated in the following section. 
Finally, the future perspectives of our in house σ70:core RNAP inhibitors are discussed. 
 
4.1  Evaluation of σ70:core RNAP inhibitor test system 
4.1.1  In vitro transcription assay and core/holo assay 
For the evaluation of potential RNAP inhibitors regarding their inhibitory activity, an in vitro 
transcription assay using commercially available RNAP holo enzyme was developed 
[Haupenthal et al. 2012]. Inhibition in this functional assay is absolutely required for hit 
compounds that could be developed into future bactericidal drugs. The assay was modified to 
study the role of σ70 factor during the transcription of templates lacking prokaryotic promoter 
sequences. Therefore, the σ70 factor was recombinantly expressed and purified, allowing the 
separate addition to purchased RNAP core enzyme in various ratios as well as order of 
addition experiments. Although the purification procedure is tedious, since the protein is 
expressed in inclusion bodies, the obtained yield (~10 mg/L culture), purity (> 95 % with only 
one affinity purification step), and stability (at least 8 h at room temperature; over years at -80 
°C) are satisfying. Using this σ70 factor in various ratios in the transcription assay, revealed 
that equal stoichiometric amounts of σ70 and RNAP core enzyme give the highest 
transcription rates. Further addition of σ70 factor leads to no more increase. Surprisingly, the 
addition of σ70 factor increased the transcription efficiency of different DNA templates with 
non-physiological and non-bacterial promoters. Thus, we reasoned that σ70 is needed for 
stabilization of the transcription bubble which is formed during initiation [Haupenthal et al. 
2012]. Furthermore, we performed order-of-addition experiments. Usually, holo enzyme 
formation is allowed first, before adding the inhibitor and starting transcription. For the order-
of-addition experiments we also tested preincubation of core RNAP with the inhibitor, before 
adding σ70. Here, we expected equal inhibitory potencies for core RNAP inhibitors like 
rifampicin and higher potencies for σ70:core inhibitors like SB2. We reasoned that small 
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organic compounds with weaker affinities than σ70 might have an advantage in binding to the 
core enzyme, when σ70 is not present. However, in both cases similar IC50 values were 
obtained when using the same DNA template (Figure 13). This fact could be due to low 
affinity (and/or a high dissociation rate) for SB2 to core RNAP compared to the high affinity 
binding of σ70. Since this assay variant is not suitable to distinguish between the two inhibitor 
types, a new assay was needed. 
 
Figure 13. Order of addition experiments with the core RNAP inhibitor rifampicin and the 
σ70:core inhibitor SB2. IC50 values for rifampicin are given in nM, whereas IC50s of SB2 are 
in µM. 
The core/holo assay uses core RNAP with T7 template which can be transcribed 
independently of promoter-specific recognition elements such as σ70 and holo RNAP with 
T7A1 promoter. For this template σ70 is required to initiate transcription. As shown in 
chapters 3.2 and 3.3, this assay provides a first hint in the direction of σ70:core inhibitors. 
However, in some cases core RNAP can also be inhibited significantly by σ70:core inhibitors, 
as observed for P07 (see chapter 3.2) due to interference with the lid-rudder system which is 
somehow involved in RPo formation [Kuznedelov et al. 2002, Toulokhonov and Landick 
2006]. Hence, the results from the core/holo assay should always be confirmed in another 
assay such as the σ70:core assembly inhibition assay. 
 
4.1.2  σ70:core assembly inhibition assay 
The ELISA-based σ70:core assembly inhibition assay is indispensable when it comes to 
identifying the mode of action of RNAP inhibitors. It uses the recombinant σ70 factor which is 
adsorbed to the bottom of a well-plate. Then the inhibitor and core enzyme are added 
simultaneously and after a few washing steps, bound core RNAP is detected. Thus, it directly 
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determines interference of a small molecule or peptide with the protein-protein interaction. 
But neither the ELISA nor the core/holo assay can tell if the protein-protein interface is really 
the target site, since positive results due to allosteric binding and induction of conformational 
changes in the core enzyme are also imaginable. However, such conformational changes need 
to be extensive in order to diminish core binding to σ70 since there are multiple contact sites 
(see also chapter 1.2). Thus, most likely disruption of the σ70:core assembly means that the 
inhibitor binds in the interface between the β’ coiled-coil and the σ70 factor region 2.1-2.2. 
Additionally, the allosteric inhibitor CBR-703 did not influence the σ70:core assembly when 
tested in concentrations up to 200 µM, underlining that the disruption of the holo enzyme 
formation due to conformational changes is only a theoretical possibility. When IC50 values of 
the transcription assay and the ELISA are plotted (Figure 14), a fairly good correlation is 
observed. 
 
Figure 14. Inter-assay correlation of inhibitors from publications I-III between in vitro 
transcription and σ70:core assembly inhibition assay. 
Usually the IC50 values from the ELISA are twice as high as in the transcription assay. One 
explanation could be inter-assay differences such as the σ70:core ratio (30:1 in the ELISA 
versus 1:1 in the transcription assay). Another explanation is the existence of a second target 
site within the RNAP. Since most of the plotted compounds belong to the benzamidobenzoic 
acid and the ureidothiophene carboxylic acids that target also the switch region [Sahner et al. 
2013, Fruth et al. 2014], the steepness of the correlation might be erroneous, especially when 
considering that SB2 is the outlier underneath the curve, for which both IC50s are equal. 
Further evidence that the switch region binding does not affect the protein-protein interaction 
is given by the negative performance of the specific switch region binders myxopyronin, 
corallopyronin and ripostatin in the ELISA. 
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4.1.3  Initiation inhibition assay 
The initiation inhibition assay was developed in order to quantify inhibitory potencies 
regarding transcription initiation not only of σ70:core inhibitors but also switch region binders. 
As described in chapter 1.2, in this first phase of transcription, promoter melting and synthesis 
of abortive products takes place [Hsu 2002]. For the assay, we modified an existing protocol 
[Smagowicz and Scheit 1978], but avoided the use of high energy radiolabels and simplified 
abortive transcript quantification by using reversed phase HPLC for separation combined with 
scintillation flow detection. Altogether this primed abortive initiation inhibition assay is 
favorable over existing methods, due to improved handling, quantification and safety. The 
exact quantification of the abortive products allows inhibitor ranking, which is needed for 
structure-activity-based inhibitor optimization. One major disadvantage of the assay is, that it 
does not really help to identify a compound’s mode of action, since it works not exclusively 
for RNAP inhibitors that bind to the switch region or the σ70:core interface, but also for 
nucleotide addition inhibitors, explaining almost identical inhibitory activities for the 
initiation and the transcription assay of all tested compounds. The only RNAP inhibitors that 
do not give positive results are streptolydigin and the rifamycins that inhibit elongation of 
transcripts longer than three nucleotides [Campbell et al. 2001]. Thus, this assay may support 
initiation inhibition but does not prove it as mode of action. 
 
4.1.4  SPR screening assay 
Since the aim of the thesis was not only to characterize existing RNAP inhibitors but also to 
identify new compounds in high-throughput that potentially inhibit the σ70:core interaction by 
binding to the inhibition hot spot on the βʹ subunit, a suitable assay was needed. SPR was 
chosen as it offers several advantages. First, it directly measures binding – without binding, 
no inhibition is possible – in real-time, delivering the whole interaction and not only single 
point observations. Second, it does not require any labels. On the other side, the absence of 
labels means also the detection of non-specific binding to the sensor surface. Although this 
non-specific binding is usually referenced out by using a reference channel, it decreases data 
quality as the signal to noise ratio increases [Tudos and Schasfoort 2008].  
As target protein for the screening, a truncated E. coli βʹ subunit (amino acids 200-341) 
including the coiled-coil and the lid-rudder system was cloned, expressed, and purified. This 
part of the βʹ subunit was chosen, since it is the major binding site of core RNAP for σ70 
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[Arthur and Burgess 1998, Arthur et al. 2000, chapter 3.2]. Furthermore, the whole core 
enzyme is not suitable for SPR-based small molecule screening, due to its large size and 
complex structure. It completely loses activity when immobilized by amine-coupling. Using 
only parts of a protein is always critical, since the structure determines its function. Thus, the 
βʹ CC-LRS expression conditions were optimized towards soluble protein, which are more 
likely folded correctly. Although the obtained yields were not as good as for the σ70 factor (βʹ 
CC-LRS: ~5 mg/l culture; >90 % pure; for σ70 see chapter 4.1.1), mostly due to the high 
isoelectric point (11.9, calculated with ExPASy ProtParam tool) that causes charge repulsion 
during Ni
2+
 affinity chromatography, they were still sufficient for the low amounts needed for 
SPR. 
As βʹ CC-LRS contains many lysines, first amine-coupling was tried for immobilization. 
However, immobilization levels were not reproducible, possibly due to multiple coupling sites 
of some and only few coupling sites of other target proteins. Hence, βʹ CC-LRS was 
biotinylated and complexed on streptavidin sensor chips, giving very reproducible loading 
capacities. Next, the protein’s integrity had to be verified. This was initially done by 
interaction with σ70 factor and then with SB2 during the screening (Publication I). Usually, 
the tethered protein was stable for 4-5 days at 18 °C. The concentration for the small molecule 
library compounds in the screening was set to 100 µM. This is a good compromise, since high 
concentrations are needed to detect the usually low affinity binding of small molecules – 
corresponding to low signal intensities – and increased non-specific binding at very high 
concentrations [Giannetti 2011]. The screening of roughly 2,000 compounds with molecular 
weights smaller than 500 g/mol identified 59 βʹ CC-LRS binders. Of these initial hits 5 
compounds were active in the functional transcription assay and in the ELISA-binding assay. 
The other 54 compounds presumably did not bind the inhibition hot spot formed by the 
coiled-coil and lid-rudder system. More likely they bound to parts of the protein that are 
usually buried within the core RNAP or they form a sandwich complex together with the σ70 
factor which did not impair holo enzyme function. 
Surprisingly, P07 (Publication II) did not show an interaction with βʹ CC-LRS under all tested 
conditions despite the specific interactions in the molecular dynamics simulation with a very 
similar part of βʹ (amino acids 94-346) which was also supported by the decreased activities 
of the P07 mutants. So far, there is no satisfying explanation for this phenomenon. If the 
structure of the peptide was incorrect, it would not have inhibited the enzyme. The protein 
structure on the other hand can be assumed to be correct, since σ70 binds with reasonably high 
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affinity to it. Although it might be that the binding site of P07 was predicted wrong, the very 
supportive results from the mutagenesis study would be a too big coincidence. Possibly, the 
different assay conditions have a negative effect on the peptide folding. On the other hand this 
seems unlikely, since various conditions have been tested. 
 
4.1.5  SPR competition assay 
The aim of this assay is to clearly identify inhibitors of the βʹ CC-LRS and the σ70 factor 
interaction. Since the βʹ CC-LRS is much smaller than the core RNAP, which is used in the 
ELISA-based protein-protein interaction inhibition assay, the chance of disruption of the 
interaction due to an allosteric effect in this SPR-based competition assay is very small. When 
saturating βʹ CC-LRS with either SB2, compound 1 (Publication I) or compound 4 
(Publication I), the interaction with σ70 was significantly reduced. Although competition of 
the compounds and σ70 factor for their binding to the βʹ CC-LRS was shown this way, it 
would be more feasible to add σ70 to the running buffer and then inject the test compounds to 
reach a higher throughput. Additionally, this scenario would be closer to the in vivo situation, 
but would consume much higher amounts of σ70 factor. 
 
4.1.6  Binding site identification using wild type and mutant proteins 
The knowledge of a hit compound’s exact binding site is of utmost importance for the rational 
optimization of its affinity to the target protein. The gold standard for the identification of a 
compound’s binding site is crystallography. An alternative approach is the generation of 
mutant target proteins. This can be either done by creating spontaneous mutants in vitro and 
sequencing of the genomic DNA or by introducing site-directed mutations at positions that are 
most likely important for the interaction. We chose to generate seven site-directed mutants of 
the βʹ CC-LRS. These amino acid residues have been predicted to be of high relevance for the 
interaction with the RNAP inhibiting P07 (Publication II). Six of them were obtained in 
sufficient amounts and used for SPR interaction studies. In order to compare the hit 
compounds’ affinities towards wild type and mutant proteins, immobilization levels have to 
be nearly identical. Therefore, proteins were diluted to the same concentration and injected for 
identical time periods during immobilization. If then a hit compound exhibits lower affinity 
towards one of the mutant proteins, the amino acid that has been substituted by alanine is 
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important for binding of the hit compound. For each σ70:core RNAP inhibitors class (SB, 
benzamidobenzoic acids, ureidothiophenes) binding to the βʹ coiled-coil arginine mutants 
R271A, R275A, and R278A was more or less decreased, as well binding to the βʹ rudder 
mutant T317A. Based on the results, probable binding modes were proposed. For SB2 and 
compound 1 (Publication I) it is likely that they bind parallel to the βʹ CC, whereas compound 
4 (Publication I) seems to be oriented vertically to the βʹ CC. In all cases, the carboxylic acid 
moiety was predicted to interact with the before mentioned arginines. 
One major point of discussion in this assay is the folding of the target protein. For the wild 
type βʹ CC-LRS we used σ70 factor and SB2 as positive control binders to control the integrity 
of the immobilized protein. However, for the mutant βʹ CC-LRS proteins, no such positive 
control exists. Hence, circular dichroism (CD) spectroscopy was applied. Although the 
obtained spectra are not identical, they have the same pattern with α-helical and random coil 
portions. Based on the conformation in the RNAP crystal structure, this pattern was expected 
for this particular segment of the βʹ subunit. Quantitative secondary structure estimations were 
not carried out, since the storage buffer disturbs detection of the characteristic signal increase 
of the α-helix between 190 and 195 nm [Greenfield 2006]. Thus, the absolute conformational 
integrity remains to be clarified, but there is evidence, that wild-type and mutant βʹ CC-LRS 
are folded alike. 
A similar approach was followed to elucidate the binding site of P07 (Publication II). Here, 
the RNAP holo enzyme was left unchanged. Mutations – based on interactions predicted in a 
molecular dynamics simulation – were introduced on the peptide side. Decreased or lacking 
inhibitory potencies of the mutant peptides were in good accordance with the binding model 
but are no absolute proof. In future studies, further evidence could be obtained by site-
directed mutations on the RNAP side. If however the βʹ CC-LRS is not the binding site of 
P07, this would probably explain the missing SPR-signal in interaction studies with this 
portion of core RNAP. 
 
4.1.7  Affinity ranking and kinetic profiling 
As stated in Markgren et al. (2002) association and dissociation rates are important 
parameters for drug-target interactions. A desired inhibitor profile exhibits a fast association 
and slow dissociation rate. In the study, significant differences in the kinetic rates for HIV-1 
protease inhibitors were found. Thus, despite similar inhibitory activities, structural changes 
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do alter drug-target interactions, underlining the relevance of SPR-based investigations. 
Hence, we aimed to characterize our σ70:core RNAP inhibitors accordingly. We could 
determine koff rates for the inhibitors and found a linear correlation between their inhibitory 
potency and their affinity (koff) as shown in Publication I. This finding confirms specific 
binding to the βʹ CC-LRS since slow dissociation rates can only be achieved by interactions 
with the target, whereas association rates can be influenced by the concentration at the target 
[Markgren et al. 2002]. Unfortunately, no reliable KD values could be determined due to 
atypical association trends for some compounds. Moreover, solubility limitations in 
combination with low affinities impeded the intention (usually at least five different 
concentration duplicates below and above the equilibrium dissociation constant are required). 
In conclusion, kinetic analysis and affinity ranking are of high interest as they allow 
interaction-guided compound optimization and lead selection.  
 
4.2  Future of σ70:core RNAP inhibitors 
P07. The σ70-derived peptidic inhibitor P07 (Publication II) was predicted to bind in silico to 
the βʹ CC-LRS. This model was supported by selected P07 mutants that exhibited 
significantly lower inhibitory potencies as the wild type P07. On the other hand, no binding in 
the SPR-based interaction study was detected. Additionally, macro-cyclization of the helical 
part – also based on the binding model – resulted in a loss of activity [Kamal 2013]. Now, 
further attempts to verify the binding site, such as an alanine scan of the peptide, mutations of 
key amino acid residues on the core site and ideally crystallization of the P07-core RNAP 
complex are necessary to follow a structure-based optimization strategy. These options are 
currently investigated by our group. If the binding mode is established, further improvements 
of the activity in vitro and in vivo are required. To this end, truncation, rigidization, side chain 
modifications, and addition of penetration enhancers may be successful. Even 
peptidomimetics should be considered, as they are usually more stable under physiological 
conditions. 
Benzamidobenzoic acids and ureidothiophene carboxylic acids. These low molecular 
weight RNAP inhibitor classes are described to act not only on RNA polymerase but also on 
additional bacterial targets, such as FabH, an enzyme involved in fatty acid synthesis 
(Publication III) and PqsD, an enzyme in the production of Pseudomonas aeruginosa quorum 
sensing signal molecules HHQ and PQS [Sahner et al. 2014, Hinsberger et al. 2014]. This fact 
60  
 
brings up the question whether these compounds are promiscuous or can act selectively on 
multiple targets. Based on the molecular properties there are arguments pro and contra 
promiscuity. The high clogP values – most of the compounds have a clogP of around 5 – 
usually mark compounds that are more likely frequent hitters, whereas the carboxylic acid 
moiety in both classes stands in contrast to generally basic (pKa [base] > 7) promiscuous 
compounds [Peters 2013]. Moreover, the compounds do not only bind concentration 
dependent to βʹ CC-LRS in SPR-based assays but also to σ70 when immobilized by amine 
coupling. This might indicate unspecific binding due to high lipophilicity but may also 
indicate another specific binding site, since there seems to be a correlation between activity 
and affinity (Figure 16). 
 
Figure 16. Linear correlation of in vitro transcription activity (IC50) and the dissociation rate 
constant (koff) from σ
70
 for the benzamidobenzoic acids. 
If this second binding site would be opposite of the βʹ CC-LRS within the σ70:core interface, 
this would actually be beneficial for the compound’s inhibitory activity. However, given the 
current data this remains speculation. Further arguments against promiscuous behavior are 
different SAR for the different target proteins, no correlation of lipophilicity and activity, as 
well as activities in the nM range for the top PqsD inhibiting compounds [Sahner et al. 2014].  
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6  Supporting information 
6.1  Supporting information to Publication I 
Supporting figures 
 
Figure S1. Kinetic evaluation of σ70 binding to βʹ CC-LRS. Curves were fitted individually to 
a 1:1 binding model. Higher concentrations were excluded since σ70 tends to aggregate. 
Kinetic rate constants are given in the box. 
 
 
Figure S2. BSA (125-1,000 nM) was flowed over the βʹ CC-LRS sensor surface. No binding 
detectable. 
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Figure S3. Maybridge fragment CC34301 binds dose-dependently to βʹ CC-LRS. However, 
double values are bad due to unsuitable regeneration with 5 mM hydrochloric acid. A Dose-
response curves. B Equilibrium response. 
 
 
Figure S4. Interchim compound 5572295 binds dose-dependently to βʹ CC-LRS. Atypical 
association phase for the highest concentration (20 µM) due to precipitation. Hence, KD is not 
reliable. A Dose-response curves. B Equilibrium response. 
 
 
Figure S5. Compounds 3 (A) and 4 (B) binding to the βʹ CC-LRS subunit. Analytes were 
injected to sensor surface in 6.25-100 µM. 
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Compound R
1
 R
2
 
1 4-Cl 4-Ph 
2 5-Ph 3-OPh 
5 4-F 4-Ph 
6 H 3-OPh, 4-Ph 
7 4-Br 4-Ph 
8 5-CF3 4-Ph 
9 5-Me 4-Ph 
10 4-Cl 3-OPh, 4-Ph 
11 6-OH 4-Ph 
Figure S6. Structures of the 2-benzamidobenzoic acid compounds, re-numbered from [35]. 
 
 
Figure S7. No linear correlation of in vitro transcription activity (IC50) and the dissociation 
rate constant (koff) for ureidothiophene carboxylic acid compounds. 
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Figure S8. CD spectra of βʹ CC-LRS wild-type and mutants show similar patterns with α-
helical and random coil portions. 
 
 
Figure S9. Visualization of possible binding poses for SB2 (A), Compound 1 (B), and 
Compound 4 (C) binding to the βʹ CC-LRS of T. thermophilus (e.g. PDB 3EQL). For 
comparison with the mutant studies, E. coli numbering was used. 
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6.2  Supporting information to Publication II 
Supplemental methods 
Molecular dynamics (MD) simulations. All atomic coordinates were taken from our E. coli 
holo RNAP homology model (EcRNAP) (1). Peptides P01–P16 as well as the P07 mutant 
derivatives D403A, G411Q, and G411R were extracted from the holo complex preserving 
their secondary structure. For C01 a linear unfolded structure was used as starting point. The 
four complexes with P07 (and with the three P07 mutants) and the βʹ truncated segment 
(βʹtrunc; Gln94–Arg346) (P07-βʹtrunc) were extracted as well from EcRNAP. The protonation 
states were determined at pH 7.4 with the Protonate3D module of MOE. The solvated systems 
were set up using the AMBER11 suite program xLeap (2) with AMBER99SB force field (3). 
For the four P07-βʹtrunc constructs a 10 Å pad of TIP3P waters was added to solvate each 
system as octahedral box. Neutralizing counter ions were added to each system. Simulations: 
For the peptides P01–16, C01 and their mutants generalized Born implicit solvent simulations 
of 100-250 ns were performed using the parallelized sander module of AMBER 11 on a 32 
CPU opteron linux_x86_64 system. Minimization and equilibration phases were performed. 
The systems were heated to 325 K increasing the temperature of 50 K after 20, 40, 60, 80, 
100, 120 and 200 ps. Production runs were made in the NPT ensemble at 325 K. All MD 
simulations were carried out using the pmemd.cuda module of AMBER11 using a GeForce 
GTX 280 NVIDIA graphic card. Minimization and equilibration phases were performed with 
backbone atoms restricted by harmonic restraints, which were progressively reduced (from 5 
kcal mol
−1
 Å–2 to 4, 3, 2 1, and 0 kcal mol–1). The systems were heated to 300 K in the 
canonical NVT ensemble using a Langevin thermostat, with collision frequency of 3.0 ps
−1
 
Å−2, and increasing temperature of 50 K after 60, 120, 180, 240, and 300 ps. Production runs 
were made in the NPT ensemble at 300 K (temperature was controlled with Langevin 
thermostat with a 1.0 ps
−1
 collision frequency). The time step used for all stages was 2 fs and 
with hydrogen atoms constrained using the SHAKE algorithm (4). Long-range electrostatics 
were included on every step using the Particle Mesh Ewald algorithm with a 4th order B-
spline interpolation (5). Trajectory analysis and secondary structure determination were 
performed using the ptraj tool of AmberTools 1.5 (2) and VMD 1.9.1 (6). 
MM-GBSA calculations. Binding energies ΔG for P07 and the three mutants were estimated 
using MM-GBSA methods (Molecular Mechanic – General Born Surface Area) (7) using 
snapshots of the simulations sampled every 20 ps. 
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HPLC-based abortive transcription assay. All chemicals were purchased from Sigma 
Aldrich or from other suppliers as stated in the sample preparation section. All HPLC solvents 
were of chromatographic grade, Quickszint Flow 302 LSC Cocktail was used for scintillation. 
Prior to every experimental sequence the solvent channels of the HPLC were extensively 
flushed with RNase free solvents and the injection needle and the injection port were treated 
with RNase inhibitor (RNase AWAY wipes, MBP). The experiment was performed using an 
Agilent 1200 HPLC system consisting of a binary pump, an autosampler, a multi-wavelength 
detector (MWD; Agilent Technologies, Inc.) and a RAMONA® scintillation radio detector 
(Raytest GmbH). ChemStation software was used for control and report. The injection 
volume was 25 µl. A RP C18 NUCLEODUR® 100-3 (125  30 mm) column (Macherey-
Nagel GmbH) was used as stationary phase. The solvent system consisted of 100 mM 
ammonium acetate buffer, containing 0.1 % (v/v) trifluoroacetic acid (A) and 0.1 % (v/v) 
formic acid in acetonitrile (B). HPLC-Method: Flow rate 1.2 ml min
–1
; gradient run of initial 
0 % (v/v) of B in A. In 3.5 min the ratio was changed to 50 % (v/v) of B followed by a rapid 
increase of 100 % (v/v) of B at 3.51 min, keeping B at 100 % (v/v) for 0.5 min. The 
scintillation pump was set to a flow of 2.0 ml min
–1
. The MWD was used for method 
development with the unlabeled substrate at higher concentration. Quantification was 
performed by automatic integration of the peaks in the radioactive count chromatogram. 
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Figure SI1. Fluctuations per residue for the MD simulations P07-βʹtrunc (green), D403A-βʹtrunc 
(yellow), G411Q-βʹtrunc (red), and G411R-βʹtrunc (blue). In (A) the b-factor for the βʹCC-LRS 
region of the βʹtrunc segment is shown, while in (B) the b-factors for the peptide amino acids 
are shown. 
 
 
Figure SI2. Flexibility of the LRS depends on the interactions with the N-terminal loop of 
peptides P07, D403A, G411Q, and G411R. The distance between the Cα of Asp256 (lid) and 
of Gly318 (rudder) is used as a measure of the open/closed state of the “lid-rudder-system”: 
(A) it closes in the P07-βʹtrunc (black) and in the G411Q- βʹtrunc (red) MD simulations; (B) it 
fluctuates massively from open-to-closed-to-open in the D403A-βʹtrunc (black) and in the 
G411R- βʹtrunc (red) MD simulations, where no interactions with the LRS take place. 
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Figure SI3. Binding energy contributions per residue estimated by MM-GBSA methods for 
the MD simulations of the four P07-βʹtrunc complexes (P07, D403A, G411Q, and G411R). In 
(A) the energy contributions per residue for the lid (250-263)-βʹ coiled-coil (CC1: 264-281; 
hydrophobic turn: 282-287; CC2: 288-309)-rudder (310-326) segment are reported, whereas 
in (B) the energy contributions (kcal mol
–1
) for the peptide amino acids of the four 
complexes D403A (orange), G411R (blue), G411Q (red), and P07 (green) are compared. 
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Figure SI4. (A) Overlay of chromatograms displaying separated peaks of substrate ³H-CTP 
and product ApUp³H-C for method validation; (B) Time-dependent product formation, 
amount of 90 min transcription sample was set to 100 % and other transcription sample yields 
were calculated accordingly. Standard deviations from three independent experiments are 
indicated by black bars. 
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Figure SI5. Binding of peptide P07 to the βʹtrunc subunit. (A) Detailed side-view of the 
interface residues of P07 (green cartoon) and βʹCC (pink cartoon, residues as white sticks). 
Residues of P07 that have been varied are rendered as sticks and color-coded according to 
their position in P07: -T395NRG399- loop – yellow, helix2.2-core – cyan, hydrophobic Cterm – 
green). Hydrogen bonds are shown by orange dotted lines. (B) Zoomed-view of the lid-
rudder-system with the N-terminal residues of P07. 
 
Supplemental schemes 
 aa sequence Inhibition of RNAP holo  
(IC50 in µM) 
C01 LATKALYIERLASATA 32.2 
C01-K4A LATAALYIERLASATA 12.5 
C01-Y7A LATKALAIERLASATA 16.1 
C01-E9A LATKALYIARLASATA >50 
C01-E9P LATKALYIPRLASATA >50 
C01-R10A LATKALYIEALASATA 14.6 
Scheme SI1. Modifications of control peptide C01. List and sequences of peptides that were 
modified based on peptide C01. IC50 values are given. In black: unpolar/hydrophobic aa; in 
green: polar/neutral aa; in blue: basic aa; in red: acidic aa; underlined: substituted aa. The 
mutants K4A, Y7A and R10A led to increased activity suggesting that making C01 more 
hydrophobic leads to favourable interactions with the enzyme. On the other hand the 
substitution of E9 to A or P led to a drastic reduction of activity. Thus we assume that this 
glutamic acid is important for the RNAP inhibitory activity of C01. 
 
pept βʹtrunc P07 D403A G411Q G411R 
T395 D256 lid 39.71%  18.22%  
R397 D256 lid 62.06%  31.71%  
       
Q400 R271 CC1 15.88%    
Q400 R275 CC1   11.34%  
D403 R275 CC1 53.91%  53.53% 85.29% 
D403 R278 CC1 92.78%  72.28% 61.69% 
E407 N274 CC1 65.84%  56.30% 44.09% 
E407 R278 CC1 57.93% 64.16% 63.50% 60.96% 
Q411 R281 CC1   15%  
M413 N274 CC1  47.05%   
M413 R278 CC1  35.77%   
       
Q406 I291 hydro  67.77%  29.17% 
N409 A286 hydro  16.49%   
       
Q406 N294 CC2  30.80% 12.17% 19.47% 
Q406 E295 CC2 52.82% 75.91% 67.46% 81.05% 
Q400 E301 CC2   15.18%  
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Q400 I316 rudder 16.26%    
N396 T317 rudder 59.24%  54.52%  
N396 S319 rudder 64.57%  56.01%  
Scheme SI2. Hydrogen bonds formed between the peptides P07, D403A, G411Q, and G411R 
and the truncated βʹ segment (βʹtrunc). Their occurrence along the trajectory of the P07-βʹ trunc 
complexes is calculated with the plugin of VMD (6) and expressed in % (given if >10 %; max 
distance 3.5 Å, max angle difference from optimum 25 degrees). The order of the peptide 
residues reflects their interactions with lid, CC1 (first helix of the βʹCC), hydro (hydrophobic 
patch at the tip of βʹCC), CC2 (second helix of the β’CC), and rudder of the βʹtrunc. 
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6.3  Supporting information to Publication III 
General directions 
Chemical names follow IUPAC nomenclature. Starting materials were purchased from 
Sigma-Aldrich, Acros, Maybridge, Combi Blocks, Fluka, ABCR, Alfa Aesar, Apollo and 
were used without purification. 
Column chromatography (CC) was performed on silica gel (70200 μm), preparative thin 
layer chromatography (TLC) on 1 mm SIL G-100 UV254 glass plates (Macherey-Nagel), and 
reaction progress was monitored by TLC on Alugram SIL G UV254 (Macherey-Nagel). 
1
H NMR and 
13
C NMR spectra were recorded on a Bruker AM500 spectrometer (500 MHz 
and 125 MHz) at 300 K in CDCl3 or CD3SOCD3. Chemicals shifts are reported in  values 
(ppm), the hydrogenated residues of deuterated solvent were used as internal standard 
(CDCl3:  = 7.27 ppm in 
1
H NMR and  = 77.0 ppm in 13C NMR, DMSO-d6:  = 2.50 ppm in 
1
H NMR and  = 39.5 ppm in 13C NMR). Signals are described as s, d, t, dd, ddd, dt and m for 
singlet, doublet, triplet, doublet of doublet, doublet of doublet of doublet, doublet of triplet 
and multiplet, respectively. Coupling constants (J) are given in Hertz (Hz).  
The reported yields are the isolated yields of purified material and are not optimized. 
Purity of compounds 1 to 34 was determined using LC/MS as follows: 
The SpectraSystems®-LC-system consisted of a pump, an autosampler, and a UV detector. 
Mass spectrometry was performed on a MSQ® electro spray mass spectrometer (Thermo 
Fisher, Dreieich, Germany). The system was operated by the standard software Xcalibur®. 
A RP C18 NUCLEODUR® 100-5 (125 x 3 mm) column (Macherey-Nagel GmbH, Duehren, 
Germany) was used as stationary phase. All solvents were HPLC grade. 
Solvent system: 
In a gradient run the percentage of acetonitrile (containing 0,1 % triflouro-acetic acid) in 0,1 
% triflouro-acetic acid was increased from an initial concentration of 0 % at 0 min to 100 % at 
15 min and kept at 100 % for 5 min. 
The injection volume was 10 µL and flow rate was set to 800 µL/min. MS analysis was 
carried out at a spray voltage of 3800 V, a capillary temperature of 350 °C and a source CID 
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of 10 V. Spectra were acquired in positive mode from 100 to 1000 m/z and at 254 nm for the 
UV trace. 
Melting points were determined on a Stuart Scientific melting point apparatus SMP3 and are 
uncorrected.  
 
Experimental and spectroscopic data of all compounds 
 
 
4-(N,N-dipropylsulfamoyl)benzoic acid (Vb). To a solution of 4-(chlorosulfonyl)benzoic 
acid (1 equiv) in anhydrous CH2Cl2 at 0° C dipropylamine (3 equiv) was added slowly by 
means of a syringe. The reaction mixture was stirred at room temperature for 18 h followed 
by extraction with 1N HCl. The organic layer was washed with H2O and dried over MgSO4. 
Evaporation of the solvent provided the title compound; yield: 99 %. 
1
H NMR (500 MHz, 
CD3COCD3)  = 8.248.19 (m, 2 H), 7.997.94 (m, 2 H), 3.173.12 (m, 4 H), 1.611.51 (m, 
4 H), 0.86 (t, J = 7.4 Hz, 6 H) ppm. 
13
C NMR (125 MHz, CD3COCD3)  = 166.6, 145.3, 134.9, 131.3, 128.1, 50.9, 22.8, 11.4 
ppm. 
LC/MS: m/z = 286 [M + H
+
]; tR = 11.58 min; 94.8 % pure (UV). 
 
 
4-(4-oxo-4H-naphtho[2,3-d][1,3]oxazin-2-yl)-N,N-dipropylbenzenesulfonamide (Va). 4-
(N,N-dipropylsulfamoyl)benzoic acid (Vb, 1.5 equiv) was converted to the corresponding 
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benzoyl chloride via reaction with thionyl chloride (3.75 equiv) in CH2Cl2 in the presence of 
catalytic amounts of dimethylformamide (4 h reflux). After evaporation of the solvent the 
resulting benzoyl chloride and 3-amino-2-naphthoic acid (1 equiv) were suspended in toluene 
and the mixture was refluxed for 18 h. The product was purified by CC (n-hexane/EtOAc 
8:2); yield: 28 %. 
1
H NMR (500 MHz, CDCl3)  = 8.89 (s, 1 H), 8.498.44 (m, 2 H), 8.19 (s, 
1 H), 8.098.00 (m, 2 H), 7.997.94 (m, 2 H), 7.747.69 (m, 1 H), 7.667.60 (m, 1 H), 
3.193.12 (m, 4 H), 1.611.55 (m, 4 H), 0.90 (t, J = 7.4 Hz, 6 H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 159.4, 153.8, 143.6, 140.8, 137.6, 133.9, 132.4, 131.4, 
129.9, 129.7, 128.7, 128.3, 127.5, 127.3, 125.8, 115.4, 49.9, 21.9, 11.2 ppm. 
LC/MS: m/z = 437 [M + H
+
], 478 [M
+
 + CH3CN]; tR = 17.57 min; 98.0 % pure (UV). 
 
 
3-(4-(N,N-dipropylsulfamoyl)benzamido)-2-naphthoic acid
1
 (V). 4-(4-oxo-4H-
naphtho[2,3-d][1,3]oxazin-2-yl)-N,N-dipropylbenzenesulfonamide (Va) was dissolved in a 
mixture of THF/MeOH (2:1) and hydrolyzed by an aqueous solution containing 1 mol/L 
LiOH at room temperature (18 h). The mixture was acidified by the addition of 1 M HCl, 
filtered and the precipitate was successively washed with 1 M HCl. The product was purified 
by preparative TLC (CH2Cl2/MeOH 9:1); yield: 24 %.  
 1
H NMR (500 MHz, CD3SOCD3)  = 
12.63 (br. s., 1 H, NH), 9.09 (s, 1 H), 8.76 (s, 1 H), 8.218.14 (m, 2 H), 8.06 (d, J = 8.2 Hz, 1 
H), 8.047.99 (m, 2 H), 7.94 (d, J = 8.2 Hz, 1 H), 7.687.59 (m, 1 H), 7.567.47 (m, 1 H), 
3.07 (t, J = 7.6 Hz, 4 H), 1.551.43 (m, 4 H), 0.82 (t, J = 7.4 Hz, 6 H, CH3) ppm. 
13
C NMR (125 MHz, CD3SOCD3)  = 169.9, 163.5, 142.4, 138.2, 136.1, 135.4, 133.2, 129.2, 
129.1, 128.6, 128.1, 127.5, 127.3, 125.8, 118.7, 117.0, 49.7, 21.7, 11.0 ppm. 
LC/MS: m/z = 455 [M + H
+
]; tR = 15.80 min; 99.0 % pure (UV). 
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methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)benzoate (1a) was prepared according to 
method BIII. For purification the solvent was evaporated and the remaining solid was 
suspended in MeOH. After filtration the precipitate was washed with MeOH to provide the 
pure compound; yield: 58 %. 
1
H NMR (500 MHz, CDCl3)  = 12.11 (br. s, 1 H, NH), 8.98 
(dd, J = 8.5, 0.9 Hz, 1 H), 8.168.13 (m, 2 H), 8.11 (dd, J = 8.2, 1.6 Hz, 1 H), 7.787.75 (m, 2 
H), 7.687.61 (m, 3 H), 7.517.47 (m, 2 H), 7.457.39 (m, 1 H), 7.187.12 (m, 1 H), 3.99 (s, 
3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 169.1, 165.4, 144.7, 141.9, 140.0, 134.9, 133.6, 131.0, 
128.9, 128.0, 127.9, 127.5, 127.2, 122.6, 120.5, 115.1, 52.5 (OCH3) ppm. 
LC/MS: m/z = 332 [M + H
+
], 373 [M + H
+
 CH3CN], 663 [2M + H
+
]; tR = 14.92 min; 100.0 % 
pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)benzoic acid
2
 (1) was prepared according to method C. 
Sufficient purity was achieved without further purification; yield: 74 %. Mp: 190 °C 
(decomposition). 
1
H NMR (500 MHz, DMSO-d6)  = 12.26 (br. s, 1 H, NH), 8.74 (dd, J = 
8.5, 0.9 Hz, 1 H), 8.07 (dd, J = 7.9, 1.5 Hz, 1 H), 8.068.02 (m, 2 H), 7.907.86 (m, 2 H), 
7.777.74 (m, 2 H), 7.707.63 (m, 1 H), 7.537.49 (m, 2 H), 7.467.40 (m, 1 H), 7.277.17 
(m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 163.8, 163.7, 143.0, 143.0, 140.9, 140.7, 138.9, 133.9, 
133.8, 131.5, 131.4, 130.9, 128.9, 128.0, 127.8, 126.8, 121.8, 121.7, 118.5, 118.4 ppm. 
LC/MS: m/z = 318 [M + H
+
], 635 [2M + H
+
]; tR = 12.38 min; 99.4 % pure (UV). 
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methyl 2-(3-phenoxybenzamido)benzoate (2a) was prepared according to method BI. For 
purification the solvent was evaporated and the remaining solid was suspended in MeOH. 
After filtration the precipitate was washed with MeOH to provide the pure compound; yield: 
45 %. 
1
H NMR (500 MHz, CDCl3)  = 12.02 (br. s, 1 H, NH), 8.91 (dd, J = 8.5, 1.3 Hz, 1 H), 
8.09 (dd, J = 8.0, 1.7 Hz, 1 H), 7.777.74 (m, 1 H), 7.717.69 (m, 1 H), 7.61 (ddd, J = 8.6, 
7.2, 1.9 Hz, 1 H), 7.49 (dd, J = 7.9, 7.9 Hz, 1 H), 7.427.36 (m, 2 H), 7.21 (ddd, J = 8.2, 2.5, 
0.9 Hz, 1 H), 7.187.11 (m, 2 H), 7.117.07 (m, 2 H), 3.96 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 169.0, 165.1, 158.1, 156.5, 141.7, 136.9, 134.8, 130.9, 
130.2, 129.9, 123.8, 122.7, 122.0, 121.5, 120.5, 119.5, 117.6, 115.2, 52.5 (OCH3) ppm. 
LC/MS: m/z = 348 [M + H
+
], 389 [M + H
+
 CH3CN], 695 [2M + H
+
]; tR = 15.88 min; 96.9 % 
pure (UV). 
 
 
2-(3-phenoxybenzamido)benzoic acid
3
 (2) was prepared according to method C. Sufficient 
purity was achieved without further purification; yield: 85 %. Mp: 204206 °C. 1H NMR (500 
MHz, DMSO-d6)  = 14.64 (br. s, 1H, NH), 8.70 (dd, J = 8.2 Hz, 0.9 Hz, 1H), 8.18 (dd, J = 
7.9 Hz, 1.6 Hz, 1H), 7.847.82 (m, 1H), 7.63 (t, J = 1.9 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 
7.437.39 (m, 3H), 7.197.15 (m, 2H), 7.077.03 (m, 3H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 171.7, 163.4, 157.2, 156.2, 140.8, 137.2, 131.6, 131.2, 
130.4, 130.2, 123.9, 123.1, 122.0, 121.7, 121.5, 118.6, 119.0, 117.2 ppm. 
LC/MS: m/z = 334 [M + H
+
]; tR = 13.73 min; 96.9 % pure (UV). 
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2-(2-phenoxy-[1,1'-biphenyl]-4-ylcarboxamido)benzoic acid
3
 (3) was prepared using the 
procedure described by Nie et al.
3
 
1
H NMR (500 MHz, Acetone-d6)  = 12.32 (br. s, 1 H, 
NH), 7.89 (dd, J = 8.5, 1.9 Hz, 1 H), 8.18 (dd, J = 7.9, 1.6 Hz, 1 H), 7.89 (dd, J = 8.2, 1.9 Hz, 
1 H), 7.71 (d, J = 7.9 Hz, 1 H),  7.657.63 (m, 4 H), 7.447.41 (m, 2 H), 7.377.34 (m, 3 H), 
7.237.20 (m, 1 H), 7.117.08 (m, 1 H), 7.037.00 (m, 2 H) ppm. 
13
C NMR (125 MHz, CDCl3)  = 171.0, 164.9, 158.3, 155.0, 143.2, 138.1, 127.9, 136.7, 
135.6, 132.8, 132.5, 131.0, 130.1, 129.2, 128.8, 124.3, 123.7, 123.3, 120.9, 120.8, 120.1, 
119.2 ppm. 
LC/MS: m/z = 410 [M + H
+
]; tR = 14.40 min; 95.2 % pure (UV). 
 
 
methyl 2-benzamidobenzoate (4a) was prepared according to method BIII. For purification 
the solvent was evaporated and the remaining solid was resolved in a small amount of 
CH2Cl2. After addition of MeOH the CH2Cl2 was evaporated. Crystals formed overnight in 
the remaining MeOH provided the pure compound; yield: 69 %. 
1
H NMR (500 MHz, CDCl3) 
 = 12.05 (br. s, 1 H, NH), 8.95 (dd, J = 8.5, 1.3 Hz, 1 H), 8.10 (dd, J = 7.9, 1.6 Hz, 1 H), 
8.088.04 (m, 2 H), 7.647.60 (m, 1 H), 7.607.50 (m, 3 H), 7.177.09 (m, 1 H), 3.98 (s, 3 
H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 169.1, 165.7, 141.9, 134.9, 134.8, 131.9, 130.9, 128.8, 
127.4, 122.6, 120.5, 115.2, 52.5 (OCH3) ppm. 
LC/MS: m/z = 256 [M + H
+
], 511 [2M + H
+
]; tR = 12.32 min; 100.0 % pure (UV). 
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2-benzamidobenzoic acid
4
 (4) was prepared according to method C. Sufficient purity was 
achieved without further purification; yield: 94 %. Mp: 179181 °C. 1H NMR (500 MHz, 
DMSO-d6)  = 12.18 (br. s, 1 H, NH), 8.72 (dd, J = 8.2, 0.9 Hz, 1 H), 8.06 (dd, J = 7.9, 1.6 
Hz, 1 H), 7.987.94 (m, 2 H), 7.697.63 (m, 2 H), 7.627.57 (m, 2 H), 7.237.19 (m, 1 H) 
ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 170.0, 164.7, 141.1, 134.5, 134.3, 132.2, 131.3, 129.0, 
127.0, 122.9, 119.9, 116.5 ppm. 
LC/MS: m/z = 242 [M + H
+
], 483 [2M + H
+
]; tR = 9.88 min; 100.0 % pure (UV). 
 
 
methyl 2-amino-3-chlorobenzoate (5b) was prepared according to method A. The product 
was purified by CC (n-hexane/EtOAc 1:1); yield: 60 %. 
1
H NMR (500 MHz, CDCl3)  = 7.82 
(dd, J = 7.9, 1.6 Hz, 1 H), 7.41 (dd, J = 7.9, 1.6 Hz, 1 H), 6.59 (dd, J = 7.9, 7.9 Hz, 1 H), 6.28 
(br. s, 2 H, NH2), 3.89 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.1, 146.6, 133.78, 129.9, 120.2, 115.7, 111.8, 51.8 
(OCH3) ppm. 
LC/MS: m/z = 186 [M + H
+
], 227 [M + H
+
 CH3CN]; tR = 11.68 min; 98.4 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-3-chlorobenzoate (5a) was prepared 
according to method BIII. For purification the solvent was evaporated and the remaining solid 
was resolved in a small amount of CH2Cl2. After addition of MeOH the CH2Cl2 was 
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evaporated. Crystals formed overnight in the remaining MeOH provided the pure compound; 
yield: 40 %. 
1
H NMR (500 MHz, CDCl3)  = 9.51 (br. s, 1 H, NH), 8.128.06 (m, 2 H), 7.90 
(dd, J = 7.9, 1.6 Hz, 1 H), 7.777.72 (m, 2 H), 7.68 (dd, J = 7.9, 1.6 Hz, 1 H), 7.677.63 (m, 2 
H), 7.527.46 (m, 2 H), 7.447.39 (m, 1 H), 7.27 (dd, J = 7.9, 7.9 Hz, 1 H), 3.90 (s, 3 H, 
OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.1, 165.0, 145.1, 140.0, 135.7, 134.3, 132.5, 131.2, 
129.1, 128.9, 128.2, 128.1, 127.5, 127.3, 126.0, 126.0, 52.7 (OCH3) ppm. 
LC/MS: m/z = 365 and 367 [M + H
+
], 731 and 733 [2M + H
+
]; tR = 13.00 min; 93.8 % pure 
(UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-3-chlorobenzoic acid (5) was prepared according to 
method C. The product was purified by preparative TLC (n-hexane/EtOAc 1:1); yield: 93 %. 
Mp: 203205 °C. 1H NMR (500 MHz, DMSO-d6)  = 10.33 (br. s, 1 H, NH), 8.118.07 (m, 2 
H), 7.867.75 (m, 6 H), 7.547.49 (m, 2 H), 7.477.40 (m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 166.8, 165.1, 143.3, 139.2, 134.7, 132.8, 132.7, 131.9, 
129.9, 129.0, 128.5, 128.2, 127.6, 127.0, 126.7 ppm. 
LC/MS: m/z = 352 [2 + H
+
], 703 [2M + H
+
]; tR = 11.55 min; 99.2 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-4-chlorobenzoate (6a) was prepared 
according to method BI. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 59 %. 
1
H NMR (500 MHz, CDCl3)  = 12.13 (br. s, 1 H, NH), 9.08 
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(d, J = 2.1 Hz, 1 H), 8.148.09 (m, 2 H), 8.01 (d, J = 8.8 Hz, 1 H), 7.787.74 (m, 2 H), 
7.697.61 (m, 2 H), 7.537.45 (m, 2 H), 7.447.38 (m, 1 H), 7.10 (dd, J = 8.8, 2.1 Hz, 1 H), 
3.98 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.5, 165.4, 144.9, 142.7, 141.2, 139.9, 133.0, 132.0, 
128.9, 128.1, 127.9, 127.5, 127.2, 122.8, 120.3, 113.3, 52.6 (OCH3) ppm. 
LC/MS: m/z = 367 [M + H
+
], 733 [2M + H
+
]; tR = 16.36 min; 98.2 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-4-chlorobenzoic acid (6) was prepared according to 
method C. Sufficient purity was achieved without further purification; yield: 55 %. Mp: 
323324 °C. 1H NMR (500 MHz, DMSO-d6)  = 15.29 (br. s, 1 H, NH), 8.81 (d, J = 2.2 Hz, 
1 H), 8.158.08 (m, 3 H), 7.847.78 (m, 2 H), 7.747.68 (m, 2 H), 7.527.45 (m, 2 H), 
7.447.38 (m, 1 H), 7.09 (dd, J = 8.2, 2.2 Hz, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.6, 164.2, 143.3, 142.0, 139.0, 134.8, 133.6, 133.1, 
129.0, 128.2, 127.9, 126.9, 126.9, 122.8, 121.5, 117.9 ppm. 
LC/MS: m/z = 351 and 353 [M + H
+
]; tR = 14.11 min; 99.1 % pure (UV). 
 
 
methyl 4-chloro-2-(3-phenoxybenzamido)benzoate (7a) was prepared according to method 
BI. For purification the solvent was evaporated and the remaining solid was suspended in 
MeOH. After filtration the precipitate was washed with MeOH to provide the pure compound; 
yield: 71 %. 
1
H NMR (500 MHz, CDCl3)  = 12.07 (br. s, 1 H, NH), 9.02 (d, J = 2.2 Hz, 1 H), 
8.00 (d, J = 8.8 Hz, 1 H), 7.757.71 (m, 1 H), 7.707.65 (m, 1 H), 7.49 (dd, J = 8.2, 8.2 Hz, 1 
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H), 7.417.37 (m, 2 H), 7.22 (ddd, J = 8.2, 2.2, 0.9 Hz, 1 H), 7.197.15 (m, 1 H), 7.147.07 
(m, 3 H), 3.96 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.4, 165.1, 158.2, 156.4, 142.5, 141.2, 136.3, 133.0, 
130.2, 130.0, 124.0, 123.0, 122.2, 121.4, 120.4, 119.5, 117.5, 113.4, 52.6 (OCH3) ppm. 
LC/MS: m/z = 382 [M + H
+
]; tR = 15.99 min; 95.5 % pure (UV). 
 
 
4-chloro-2-(3-phenoxybenzamido)benzoic acid (7) was prepared according to method C. 
Sufficient purity was achieved without further purification; yield: 61 %. Mp: 205206 °C. 1H 
NMR (500 MHz, DMSO-d6)  = 12.26 (br. s, 1 H, NH), 8.75 (d, J = 1.9 Hz, 1 H), 8.03 (d, J = 
8.5 Hz, 1 H), 7.727.66 (m, 1 H), 7.61 (dd, J = 7.9, 7.9 Hz, 1 H), 7.52 (s, 1 H), 7.477.41 (m, 
2 H), 7.337.25 (m, 2 H), 7.237.17 (m, 1 H), 7.167.02 (m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.3, 164.2, 157.4, 155.9, 141.9, 138.7, 136.0, 132.9, 
130.9, 130.3, 124.1, 123.0, 122.3, 121.6, 119.2, 119.1, 116.9, 115.4 ppm. 
LC/MS: m/z = 368 [M + H
+
], 409 [M + H
+
 CH3CN]; tR = 13.98 min; 100.0 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-chlorobenzoate (8a) was prepared 
according to method BII. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 86 %. 
1
H NMR (500 MHz, CDCl3)  = 12.02 (br. s, 1 H, NH), 8.97 
(d, J = 9.1 Hz, 1 H), 8.138.10 (m, 2 H), 8.07 (d, J = 2.5 Hz, 1 H), 7.787.75 (m, 2 H), 
7.677.64 (m, 2 H), 7.57 (dd, J = 9.1, 2.5 Hz, 1 H), 7.527.47 (m, 2 H), 7.457.37 (m, 1 H), 
4.00 (s, 3 H, OCH3) ppm. 
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13
C NMR (125 MHz, CDCl3)  = 168.1, 165.3, 144.9, 140.5, 139.9, 134.7, 133.2, 130.5, 
128.9, 128.1, 127.9, 127.6, 127.5, 127.2, 121.9, 116.3, 52.8 (OCH3) ppm. 
LC/MS: m/z = 366 [M + H
+
], 731 [2M + H
+
]; tR = 16.76 min; 97.0 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-5-chlorobenzoic acid (8)   was prepared according to 
method C. For purification the remaining solid was washed with MeOH and CH2Cl2 to 
provide the pure compound; yield: 96 %. Mp: 274276 °C. 1H NMR (500 MHz, DMSO-d6)  
= 12.14 (br. s, 1 H, NH), 8.74 (d, J = 9.1 Hz, 1 H), 8.058.02 (m, 2 H), 8.00 (d, J = 2.5 Hz, 1 
H), 7.917.86 (m, 2 H), 7.797.75 (m, 2 H), 7.73 (dd, J = 9.1, 2.5 Hz, 1 H), 7.547.48 (m, 2 
H), 7.477.41 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.8, 164.4, 143.8, 139.9, 138.8, 133.9, 132.9, 130.4, 
129.1, 128.3, 127.8, 127.2, 127.0, 126.5, 121.8, 118.6 ppm. 
LC/MS: m/z = 352 and 354 [M + H
+
]; tR = 14.32 min; 99.3 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-6-chlorobenzoate (9a) was prepared 
according to method BII. The product was purified by CC (n-hexane/EtOAc 8:2); yield: 76 %. 
1
H NMR (500 MHz, CDCl3)  = 10.27 (br. s, 1 H, NH), 8.56 (dd, J = 8.2, 0.9 Hz, 1 H), 
8.048.01 (m, 2 H), 7.777.74 (m, 2 H), 7.677.64 (m, 2 H), 7.527.41 (m, 4 H), 7.24 (dd, J 
= 8.2, 0.9 Hz, 1 H), 4.03 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.9, 165.0, 145.1, 139.8, 139.7, 133.6, 132.9, 132.6, 
129.0, 128.2, 127.8, 127.6, 127.2, 125.9, 120.2, 119.9, 52.8 (OCH3) ppm. 
LC/MS: m/z = 366 [M + H
+
], 731 [2M + H
+
]; tR = 13.90 min; 98.2 % pure (UV). 
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2-([1,1'-biphenyl]-4-ylcarboxamido)-6-chlorobenzoic acid (9) was prepared according to 
method C. For purification the remaining solid was washed with CH2Cl2 to provide the pure 
compound; yield: 79 %. Mp: 218219 °C. 1H NMR (500 MHz, DMSO-d6)  = 10.36 (br. s, 1 
H, NH), 8.048.01 (m, 2 H), 7.867.83 (m, 2 H), 7.787.75 (m, 2 H), 7.617.58 (m, 1 H), 
7.537.49 (m, 3 H), 7.467.40 (m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 166.2, 165.2, 143.4, 139.0, 136.9, 132.7, 130.8, 130.5, 
129.6, 129.1, 128.3, 128.2, 126.9, 126.8, 126.7, 125.1 ppm. 
LC/MS: m/z = 352 [M + H
+
], 705, 707 [2M + H
+
]; tR = 12.25 min; 100.0 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-4-fluorobenzoate (10a) was prepared 
according to method BI. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 42 %. 
1
H NMR (500 MHz, CDCl3)  = 12.25 (br. s, 1 H, NH), 8.80 
(dd, J = 11.8, 2.4 Hz, 1 H), 8.218.03 (m, 3 H), 7.827.72 (m, 2 H), 7.727.61 (m, 2 H), 
7.577.48 (m, 2 H), 7.487.39 (m, 1 H), 6.966.79 (m, 1 H), 3.99 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.5, 166.1 (d, J = 253.9 Hz), 165.6, 145.0, 144.1 (d, JCF = 
12.8 Hz), 139.9, 133.3 (d, JCF = 11.0 Hz), 133.1, 128.9, 128.1, 127.9, 127.5, 127.2, 111.3 (d, 
JCF = 2.7 Hz), 109.9 (d, JCF = 22.9 Hz), 107.6 (d, JCF = 28.4 Hz), 52.5 ppm (OCH3). 
LC/MS: m/z = 350 [M + H
+
], 391 [M + H
+
 CH3CN], 699 [2M + H
+
]; tR = 15.69 min; 96.4 % 
pure (UV). 
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2-([1,1'-biphenyl]-4-ylcarboxamido)-4-fluorobenzoic acid (10) was prepared according to 
method C. For purification the compound was recrystallized from MeOH; yield: 24 %. Mp: 
258260 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.47 (br. s, 1 H, NH), 8.59 (dd, J = 12.3, 
2.5 Hz, 1 H), 8.14 (dd, J = 9.0, 6.8 Hz, 1 H), 8.078.00 (m, 2 H), 7.937.87 (m, 2 H), 
7.817.72 (m, 2 H), 7.577.49 (m, 2 H), 7.497.41 (m, 1 H), 7.107.01 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.4, 165.1 (d, JCF = 248.0 Hz), 164.6, 143.9, 143.3 (d, 
JCF = 12.8 Hz), 138.8, 134.0 (d, JCF = 11.0 Hz), 132.7, 129.1, 128.3, 127.7, 127.2, 127.0, 
112.8 (d, JCF = 2.7 Hz), 109.9 (d, JCF = 22.0 Hz), 106.3 (d, JCF = 28.4 Hz) ppm. 
LC/MS: m/z = 336 [M + H
+
], 377 [M + H
+
 CH3CN], 671 [2M + H
+
]; tR = 13.94 min; 100.0 % 
pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-fluorobenzoate (11a) was prepared 
according to method BI. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 64 %. 
1
H NMR (500 MHz, CDCl3)  = 11.94 (br. s, 1 H, NH), 8.99 
(dd, J = 9.1, 4.7 Hz, 1 H), 8.168.05 (m, 2 H), 7.817.71 (m, 3 H), 7.707.60 (m, 2 H), 
7.547.45 (m, 2 H), 7.457.38 (m, 1 H), 7.387.30 (m, 1 H), 4.00 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.1, 165.3, 157.4 (d, JCF = 244.0 Hz), 144.8, 140.0, 138.3 
(d, JCF = 2.7 Hz), 133.3, 128.9, 128.1, 127.9, 127.5, 127.2, 122.3 (d, JCF = 6.4 Hz), 121.9 (d, 
JCF = 22.0 Hz), 117.0, (d, JCF = 23.8 Hz), 116.4 (d, JCF = 7.3 Hz), 52.8 ppm (OCH3). 
LC/MS: m/z = 350 [M + H
+
], 391 [M + H
+
 CH3CN], 699 [2M + H
+
]; tR = 15.11 min; 96.7 % 
pure (UV). 
94  
 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-5-fluorobenzoic acid (11) was prepared according to 
method C. Sufficient purity was achieved without further purification; yield: 61 %. Mp: 
259263 °C. 1H NMR (500 MHz, DMSO-d6)  = 14.97 (br. s, 1 H, NH), 8.75 (dd, J = 9.1, 5.4 
Hz, 1 H), 8.158.07 (m, 2 H), 7.85 (dd, J = 9.9, 3.3 Hz, 1 H), 7.837.79 (m, 2 H), 7.757.70 
(m, 2 H), 7.537.45 (m, 2 H), 7.447.37 (m, 1 H), 7.287.19 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.9 (d, JCF = 1.8 Hz), 163.7, 156.9 (d, JCF = 239.2 
Hz), 143.1, 139.1, 137.4 (d, JCF = 1.8 Hz), 134.0, 129.1, 128.1, 127.8, 126.9, 126.6 (d, JCF = 
7.3 Hz), 120.1 (d, JCF = 7.3 Hz), 117.3 (d, JCF = 22.9 Hz), 117.2 (d, JCF = 22.9 Hz), 117.0 
ppm. 
LC/MS: m/z = 334 [M - H
+
]; tR = 12.89 min; 96.8 % pure (UV). 
 
 
methyl 5-fluoro-2-(3-phenoxybenzamido)benzoate (12a) was prepared according to method 
BI. For purification the solvent was evaporated and the remaining solid was suspended in 
MeOH. After filtration the precipitate was washed with MeOH to provide the pure compound; 
yield: 20 %. 
1
H NMR (500 MHz, CDCl3)  = 11.86 (br. s, 1 H, NH), 8.92 (dd, J = 9.4, 5.0 Hz, 
1 H), 7.777.71 (m, 2 H), 7.717.65 (m, 1 H), 7.49 (dd, J = 7.9, 7.9 Hz, 1 H), 7.427.35 (m, 2 
H), 7.32 (ddd, J = 9.4, 7.5, 3.0 Hz, 1 H), 7.21 (ddd, J = 8.1, 2.4, 0.8 Hz, 1 H), 7.197.12 (m, 1 
H), 7.127.07 (m, 2 H), 3.97 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.9 (d, JCF = 2.7 Hz), 164.9, 158.1, 157.6 (d, JCF = 242.9 
Hz), 138.1 (d, JCF = 1.8 Hz), 136.5, 130.2, 129.9, 123.9, 122.2 (d, J = 7.3 Hz), 122.0, 121.8 
(d, J = 22.0 Hz), 121.4, 120.8, 119.4, 117.5, 117.0 (d, JCF = 23.8 Hz), 116.4 (d, JCF = 7.3 Hz), 
52.8 (OCH3) ppm. 
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LC/MS: m/z = 366 [M + H
+
]; tR = 14.93 min; 93.7 % pure (UV). 
 
 
5-fluoro-2-(3-phenoxybenzamido)benzoic acid (12) was prepared according to method C. 
Sufficient purity was achieved without further purification; yield: 87 %. Mp: 186187 °C. 1H 
NMR (500 MHz, DMSO-d6)  = 12.02 (br. s, 1 H, NH), 8.62 (dd, J = 9.4, 5.2 Hz, 1 H), 7.74 
(dd, J = 9.4, 3.2 Hz, 1 H), 7.727.68 (m, 1 H), 7.59 (dd, J = 7.9, 7.9 Hz, 1 H), 7.567.50 (m, 2 
H), 7.497.39 (m, 2 H), 7.27 (ddd, J = 7.9, 2.6, 0.9 Hz, 1 H), 7.237.16 (m, 1 H), 7.147.04 
(m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.7 (d, JCF = 1.8 Hz), 163.8, 157.3, 157.0 (d, JCF = 
242.0 Hz), 156.0, 137.2 (d, JCF = 1.8 Hz), 136.3, 130.8, 130.2, 124.1, 122.3 (d, JCF = 7.3 Hz), 
122.0, 121.6, 120.9 (d, JCF = 22.0 Hz), 119.4 (d, JCF = 7.3 Hz),119.1, 117.0 (d, JCF = 22.0 
Hz), 116.9 ppm. 
 LC/MS: m/z = 351 [M + H
+
], 392 [M + H
+
 CH3CN]; tR = 12.87 min; 96.2 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-6-fluorobenzoate (13a) was prepared 
according to method BII. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 90 %. 
1
H NMR (500 MHz, CDCl3)  = 11.68 (br. s, 1 H, NH), 8.70 
(d, J = 8.8 Hz, 1 H), 8.128.07 (m, 2 H), 7.787.73 (m, 2 H), 7.687.64 (m, 2 H), 7.577.52 
(m, 1 H), 7.517.47 (m, 2 H), 7.457.39 (m, 1 H), 6.89 (ddd, J = 11.0, 8.8, 0.9 Hz, 1 H), 4.03 
(s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.9 (d, JCF = 3.7 Hz), 165.3, 162.4 (d, JCF = 258.4 Hz), 
144.9, 142.1 (d, JCF = 2.7 Hz), 139.9, 134.8 (d, JCF = 11.0 Hz), 133.2, 128.9, 128.1, 127.9, 
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127.5, 127.2, 116.5 (d, JCF = 3.7 Hz), 111.1 (d, JCF = 23.8 Hz), 106.2 (d, JCF = 12.8 Hz), 52.9 
(OCH3) ppm. 
LC/MS: m/z = 350 [M + H
+
], 699 [2M + H
+
]; tR = 15.22 min; 97.5 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-6-fluorobenzoic acid (13) was prepared according to 
method C. Sufficient purity was achieved without further purification; yield: 87 %. Mp: 
232233 °C. 1H NMR (500 MHz, DMSO-d6)  = 11.23 (br. s, 1 H, NH), 8.058.00 (m, 3 H), 
7.907.84 (m, 2 H), 7.797.73 (m, 2 H), 7.61 (td, J = 8.3, 6.1 Hz, 1 H), 7.537.49 (m, 2 H), 
7.467.41 (m, 1 H), 7.11 (ddd, J = 10.6, 8.4, 0.9 Hz, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 166.5 (d, JCF = 1.8 Hz), 164.7, 160.8 (d, JCF = 254.0 
Hz), 143.6, 139.7 (d, JCF = 4.6 Hz), 138.9, 133.2 (d, JCF = 11.0 Hz), 132.9, 129.1, 128.3, 
128.0, 126.9, 118.3 (d, JCF = 3.7 Hz), 112.0 (d, JCF = 14.7 Hz), 111.8 (d, JCF = 22.9 Hz) ppm. 
LC/MS: m/z = 336 [M + H
+
], 671 [2M + H
+
]; tR = 12.85 min; 100.0 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-4-bromobenzoate (14a) was prepared 
according to method BII. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 69 %. 
1
H NMR (500 MHz, CDCl3)  = 12.12 (br. s, 1 H, NH), 9.25 
(d, J = 1.9 Hz, 1 H), 8.148.09 (m, 2 H), 7.94 (d, J = 8.5 Hz, 1 H), 7.797.74 (m, 2 H), 
7.687.63 (m, 2 H), 7.527.47 (m, 2 H), 7.457.39 (m, 1 H), 7.27 (dd, J = 8.5, 1.9 Hz, 1 H), 
3.99 (s, 3 H, OCH3) ppm. 
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13
C NMR (125 MHz, CDCl3)  = 168.7, 165.4, 145.0, 142.7, 139.9, 133.0, 132.0, 129.9, 
128.9, 128.1, 127.9, 127.5, 127.2, 125.8, 123.3, 113.7, 52.7 (OCH3) ppm. 
LC/MS: m/z = 409 and 411 [M + H
+
]; tR = 17.07 min; 100.0 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-4-bromobenzoic acid (14) was prepared according to 
method C. For purification the remaining solid was washed with MeOH and CH2Cl2 to 
provide the pure compound; yield: 81 %. Mp: 246250 °C. 1H NMR (500 MHz, DMSO-d6)  
= 12.30 (br. s, 1 H, NH), 8.99 (d, J = 1.9 Hz, 1 H), 8.058.00  (m, 2 H), 7.97 (d, J = 8.5 Hz, 1 
H), 7.937.87 (m, 2 H), 7.807.73 (m, 2 H), 7.557.48 (m, 2 H), 7.477.41 (m, 1 H), 7.41 
(dd, J = 8.5, 1.9 Hz, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.5, 164.6, 143.9, 142.1, 138.8, 133.0, 132.7, 129.1, 
128.3, 127.8, 127.8, 127.2, 127.0, 125.8, 122.1, 115.5 ppm. 
LC/MS: m/z = 793 [2M + H
+
]; tR = 14.71 min; 96.4 % pure (UV). 
 
 
methyl 4-bromo-2-(3-phenoxybenzamido)benzoate (15a) was prepared according to 
method BII. For purification the solvent was evaporated and the remaining solid was 
suspended in MeOH. After filtration the precipitate was washed with MeOH to provide the 
pure compound; yield: 61 %. 
1
H NMR (500 MHz, CDCl3)  = 12.04 (br. s, 1 H, NH), 9.18 (d, 
J = 2.2 Hz, 1 H), 7.92 (d, J = 8.5 Hz, 1 H), 7.73 (dd, J = 1.6, 0.9 Hz, 1 H), 7.697.65 (m, 1 
H), 7.49 (dd, J = 7.9, 7.9 Hz, 1 H), 7.427.35 (m, 2 H), 7.26 (dd, J = 8.5, 2.2 Hz, 1 H), 7.22 
(ddd, J = 8.2, 2.5, 0.9 Hz, 1 H), 7.197.14 (m, 1 H), 7.127.07 (m, 2 H), 3.96 (s, 3 H, OCH3) 
ppm. 
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13
C NMR (125 MHz, CDCl3)  = 168.5, 165.0, 158.2, 156.3, 142.5, 136.3, 132.0, 130.2, 
130.0, 129.9, 126.0, 124.0, 123.3, 122.2, 121.4, 119.5, 117.4, 113.8, 52.7 (OCH3) ppm. 
LC/MS: m/z = no ionization; tR = 16.93 min; 99.8 % pure (UV). 
 
 
4-bromo-2-(3-phenoxybenzamido)benzoic acid (15) was prepared according to method C. 
For purification the remaining solid was washed with MeOH and CH2Cl2 to provide the pure 
compound; yield: 74 %. Mp: 194195 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.22 (br. s, 1 
H, NH), 8.90 (d, J = 2.2 Hz, 1 H), 7.95 (d, J = 8.5 Hz, 1 H), 7.707.68 (m, 1 H), 7.61 (dd, J = 
7.9, 7.9 Hz, 1 H), 7.537.51 (m, 1 H), 7.467.40 (m, 3 H), 7.29 (ddd, J = 8.2, 2.5, 0.9 Hz, 1 
H), 7.21 (tt, J = 7.4, 1.1 Hz, 1 H), 7.117.08 (m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.4, 164.1, 157.4, 155.9, 141.8, 136.0, 132.9, 130.9, 
130.3, 127.7, 125.9, 124.1, 122.3, 122.2, 121.6, 119.1, 116.8, 115.8 ppm. 
LC/MS: m/z = 823 and 825 and 827 [2M + H
+
]; tR = 14.65 min; 100.0 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-bromobenzoate (16a) was prepared 
according to method BI. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 26 %. 
1
H NMR (500 MHz, CDCl3)  = 12.01 (br. s, 1 H, NH), 8.91 
(d, J = 9.1 Hz, 1 H), 8.22 (d, J = 2.5 Hz, 1 H), 8.158.08 (m, 2 H), 7.797.74 (m, 2 H), 7.71 
(dd, J = 9.1, 2.5 Hz, 1 H), 7.687.62 (m, 2 H), 7.547.46 (m, 2 H), 7.457.38 (m, 1 H), 4.00 
(s, 3 H, OCH3) ppm. 
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13
C NMR (125 MHz, CDCl3)  = 168.0, 165.4, 144.9, 141.0, 139.9, 137.5, 133.5, 133.1, 
128.9, 128.1, 127.9, 127.5, 127.2, 122.1, 116.6, 115.0, 52.8 (OCH3) ppm. 
LC/MS: m/z = 409 and 411 [M + H
+
], 820 and 822 [2M + H
+
]; tR = 16.41 min; 98.4 % pure 
(UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-5-bromobenzoic acid
5
 (16) was prepared according to 
method C. Sufficient purity was achieved without further purification; yield: 31 %. Mp: 
289293 °C. 1H NMR (500 MHz, DMSO-d6)  = 15.22 (br. s, 1 H, NH), 8.68 (d, J = 8.8 Hz, 
1 H), 8.23 (d, J = 2.5 Hz, 1 H), 8.158.06 (m, 2 H), 7.877.82 (m, 2 H), 7.797.70 (m, 2 H), 
7.54 (dd, J = 8.8, 2.5 Hz, 1 H), 7.537.47 (m, 2 H), 7.457.39 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.3, 163.9, 143.2, 140.2, 139.0, 133.8, 133.8, 132.9, 
129.0, 128.2, 127.9, 126.9, 120.6, 117.4, 115.8, 113.5 ppm. 
LC/MS: m/z = 395 [2M - H
+
]; tR = 13.90 min; 98.3 % pure (UV). 
 
 
methyl 5-bromo-2-(3-phenoxybenzamido)benzoate (17a) was prepared according to 
method BI. For purification the solvent was evaporated and the remaining solid was 
suspended in MeOH. After filtration the precipitate was washed with MeOH to provide the 
pure compound; yield: 78 %. 
1
H NMR (500 MHz, CDCl3)  = 11.94 (br. s, 1 H, NH), 8.83 (d, 
J = 9.1 Hz, 1 H), 8.19 (d, J = 2.5 Hz, 1 H), 7.747.71 (m, 1 H), 7.707.66 (m, 2 H), 7.48 (dd, 
J = 7.9 7.9 Hz, 1 H), 7.427.36 (m, 2 H), 7.21 (ddd, J = 7.9, 2.5, 0.9 Hz, 1 H), 7.197.14 (m, 
1 H), 7.117.07 (m, 2 H), 3.96 (s, 3 H, OCH3) ppm. 
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13
C NMR (125 MHz, CDCl3)  = 167.8, 165.0, 158.1, 156.4, 140.7, 137.5, 136.4, 133.4, 
130.2, 129.9, 123.9, 122.1, 122.1, 121.4, 119.5, 117.5, 116.7, 115.1, 52.8 (OCH3) ppm. 
LC/MS: m/z = no ionization; tR = 16.15 min; 95.1 % pure (UV). 
 
 
5-bromo-2-(3-phenoxybenzamido)benzoic acid
5
 (17) was prepared according to method C. 
For purification the remaining solid was washed with hot MeOH to provide the pure 
compound; yield: 52 %. Mp: 240242 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.05 (br. s, 1 
H, NH), 8.59 (d, J = 9.1 Hz, 1 H), 8.10 (d, J = 2.5 Hz, 1 H), 7.83 (dd, J = 9.1, 2.5 Hz, 1 H), 
7.727.67 (m, 1 H), 7.637.57 (m, 1 H), 7.537.50 (m, 1 H), 7.477.40 (m, 2 H), 7.307.26 
(m, 1 H), 7.247.17 (m, 1 H), 7.147.06 (m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.6, 163.9, 157.3, 156.0, 140.0, 136.7, 136.2, 133.2, 
130.8, 130.2, 130.1, 124.1, 122.2, 122.1, 121.6, 119.0, 116.9, 114.5 ppm. 
LC/MS: m/z = 409 and 411  [M - H
+
]; tR = 13.90 min; 95.2 % pure (UV). 
 
 
3-benzylbenzoic acid (18d). A mixture of methyl 3-(bromomethyl)benzoate (1 equiv), 
phenylboronic acid (1.5 equiv), CsCO3 (3 equiv) and tetrakis(triphenylphosphine)-palladium 
(0.01 equiv) in a degased DME/water (1:1) solution was refluxed under a nitrogen atmosphere 
for 18 h. The reaction mixture was cooled to room temperature. The mixture was extracted 
with EtOAc. The combined organic layers were washed with 1 M HCl and dried over MgSO4. 
The product was purified by CC (CH2Cl2); yield: 81 %. 
1
H NMR (500 MHz, Acetone-d6)  =  
7.937.92 (m, 1H), 7.897.87 (m, 1H), 7.527.50 (m, 1H), 7.447.41 (m, 1H), 7.317.26 (m, 
4H), 7.227.17 (m, 1H), 4.07 (s, 2H, CH2) ppm. 
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13
C NMR (125 MHz, Acetone-d6)  = 167.7, 143.0, 141.9, 134.3, 131.7, 130.9, 129.8, 129.5, 
129.5, 128.3, 127.1, 42.1 (CH2) ppm. 
LC/MS: m/z = no ionization; tR = 11.15 min; 98.4 % pure (UV). 
 
 
methyl 2-(3-benzylbenzamido)-5-bromobenzoate (18a)   was prepared according to method 
BII. For purification the solvent was evaporated and the remaining solid was suspended in 
MeOH. After filtration the precipitate was washed with MeOH to provide the pure compound; 
yield: 23 %. 
1
H NMR (500 MHz, CDCl3)  = 11.94 (s, 1H), 8.87 (d, J = 9.0 Hz, 1H), 8.21 (d, 
J = 2.4 Hz, 1H), 7.937.89 (m, 1H), 7.897.82 (m, 1H), 7.69 (dd, J = 2.4, 9.0 Hz, 1H), 
7.467.43 (m, 1H), 7.427.37 (m, 1H), 7.357.29 (m, 2H), 7.267.20 (m, 3H), 4.09 (s, 2H, 
CH2), 3.98 (s, 3H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.8, 165.8, 142.1, 140.9, 140.4, 137.5, 134.7, 133.4, 
132.7, 129.0, 129.0, 128.6, 128.2, 126.3, 124.9, 122.1, 116.7, 114.9, 52.8 (CH3), 41.8 (CH2) 
ppm. 
LC/MS: m/z = 424 and 426 [M + H
+
]; tR = 16.82 min; 99.5 % pure (UV). 
 
  
2-(3-benzylbenzamido)-5-bromobenzoic acid (18)   was prepared according to method C. 
Sufficient purity was achieved without further purification; yield: 98 %. Mp: 225227 °C. 1H 
NMR (500 MHz, DMSO-d6)  = 12.06 (s, 1H), 8.62 (d, J = 9.1 Hz, 1H), 8.10 (d, J = 2.2 Hz, 
1H), 7.857.80 (m, 2H), 7.777.72 (m, 1H), 7.527.47 (m, 2H), 7.327.24 (m, 4H), 
7.227.16 (m, 1H), 4.04 (s, 2H, CH2) ppm. 
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13
C NMR (125 MHz, DMSO-d6)  = 168.8, 164.9, 142.4, 140.8, 140.3, 136.8, 134.5, 133.3, 
132.8, 129.2, 128.8, 128.7, 127.6, 126.3, 124.7, 122.1, 118.9, 114.4, 41.0 (CH2) ppm. 
LC/MS: m/z = 410 and 412 [M + H
+
]; tR = 14.62 min; 100.0 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-4,5-dimethoxybenzoate (19a) was prepared 
according to method BI. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 40 %. 
1
H NMR (500 MHz, CDCl3)  = 12.21 (br. s, 1 H, NH), 8.75 
(s, 1 H), 8.158.12 (m, 2 H), 7.787.75 (m, 2 H), 7.687.65 (m, 2 H), 7.52 (s, 1 H), 7.517.47 
(m, 2 H), 7.447.39 (m, 1 H), 4.05 (s, 3 H, OCH3), 3.97 (s, 3 H, OCH3), 3.93 (s, 3 H, OCH3) 
ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.8, 165.4, 154.1, 144.6, 144.0, 140.0, 138.1, 133.5, 
128.9, 128.0, 127.8, 127.5, 127.2, 112.1, 106.8, 103.4, 56.2 (OCH3), 56.1 (OCH3), 52.3 
(OCH3) ppm. 
LC/MS: m/z = 392 [M + H
+
]; tR = 14.81 min; 98.4 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-4,5-dimethoxybenzoic acid (19) was prepared 
according to method C. Sufficient purity was achieved without further purification; yield: 29 
%. Mp: 185 °C (decomposition). 
1
H NMR (500 MHz, DMSO-d6)  = 14.78 (br. s, 1 H, NH), 
8.54 (s, 1 H), 8.148.08 (m, 2 H), 7.787.73 (m, 2 H), 7.727.61 (m, 3 H), 7.567.33 (m, 3 
H), 3.81 (s, 3 H, OCH3), 3.74 (s, 3 H, OCH3) ppm. 
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13
C NMR (125 MHz, DMSO-d6)  = 163.4, 150.5, 143.2, 142.9, 139.0, 135.7, 134.1, 129.0, 
128.1, 127.8, 126.8, 126.8, 117.6, 117.4, 114.3, 102.6, 55.5 (OCH3), 55.4 (OCH3) ppm. 
LC/MS: m/z = 378 [M + H
+
]; tR = 12.37 min; 95.6 % pure (UV). 
 
 
methyl 4,5-dimethoxy-2-(3-phenoxybenzamido)benzoate (20a) was prepared according to 
method BI. For purification the solvent was evaporated and the remaining solid was 
suspended in MeOH. After filtration the precipitate was washed with MeOH to provide the 
pure compound; yield: 57 %. 
1
H NMR (500 MHz, CDCl3)  = 12.12 (br. s, 1 H, NH), 8.67 (s, 
1 H), 7.767.73 (m, 1 H), 7.69 (dd, J = 2.0, 2.0 Hz, 1 H), 7.517.47 (m, 2 H), 7.407.34 (m, 2 
H), 7.21 (ddd, J = 8.2, 2.5, 0.9 Hz, 1 H), 7.177.12 (m, 1 H), 7.127.06 (m, 2 H), 4.01 (s, 3 H, 
OCH3), 3.93 (s, 3 H, OCH3), 3.91 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.6, 165.0, 158.1, 156.5, 154.0, 144.0, 137.9, 136.8, 
130.1, 129.9, 123.8, 122.0, 121.3, 119.4, 117.4, 112.1, 106.8, 103.3, 56.1 (OCH3), 56.1 
(OCH3), 52.2 (OCH3) ppm. 
LC/MS: m/z = 408 [M + H
+
], 815 [2M + H
+
]; tR = 14.56 min; 95.5 % pure (UV). 
 
 
4,5-dimethoxy-2-(3-phenoxybenzamido)benzoic acid (20) was prepared according to 
method C. Sufficient purity was achieved without further purification; yield: 98 %. Mp: 
218219 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.29 (br. s, 1 H, NH), 8.45 (s, 1 H), 
7.707.66 (m, 1 H), 7.59 (dd, J = 7.9, 7.9 Hz, 1 H), 7.527.49 (m, 1 H), 7.497.41 (m, 3 H), 
7.27 (ddd, J = 8.2, 2.5, 0.9 Hz, 1 H), 7.21 (tt, J = 7.5, 1.0 Hz, 1 H), 7.147.06 (m, 2 H), 3.84 
(s, 3 H, OCH3), 3.78 (s, 3 H, OCH3) ppm. 
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13
C NMR (125 MHz, DMSO-d6)  = 169.8, 163.6, 157.4, 155.9, 153.3, 143.8, 136.7, 136.5, 
130.8, 130.3, 124.1, 121.9, 121.3, 119.2, 116.7, 112.8, 107.8, 103.1, 55.6 (OCH3), 55.6 
(OCH3) ppm. 
LC/MS: m/z = 394 [M + H
+
], 435 [M + H
+
 CH3CN]; tR = 12.32 min; 96.9 % pure (UV). 
 
 
methyl 2-amino-4-methoxybenzoate (21b) was prepared according to method A. The 
product was purified by CC (n-hexane/EtOAc 6:4); yield: 12 %. 
1
H NMR (500 MHz, CDCl3) 
 = 7.79 (d, J = 8.8 Hz, 1 H), 6.24 (dd, J = 8.8, 2.2 Hz, 1 H), 6.11 (d, J = 2.2 Hz, 1 H), 5.80 
(br. s, 2 H, NH2), 3.84 (s, 3 H, OCH3), 3.79 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.3, 164.2, 152.4, 133.0, 104.5, 104.4, 99.4, 55.1 (OCH3), 
51.2 (OCH3) ppm. 
LC/MS: m/z = 182 [M + H
+
]; tR = 8.73 min; 100.0 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-4-methoxybenzoate (21a) was prepared 
according to method BI. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 26 %. 
1
H NMR (500 MHz, CDCl3)  = 12.32 (br. s, 1 H, NH), 8.66 
(d, J = 2.5 Hz, 1 H), 8.178.13 (m, 2 H), 8.02 (d, J = 8.8 Hz, 1 H), 7.787.75 (m, 2 H), 
7.687.64 (m, 2 H), 7.517.47 (m, 2 H), 7.447.39 (m, 1 H), 6.67 (dd, J = 8.8, 2.5 Hz, 1 H), 
3.96 (s, 3 H, OCH3), 3.95 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 169.0, 165.7, 164.7, 144.7, 144.1, 140.0, 133.5, 132.5, 
128.9, 128.0, 127.9, 127.5, 127.2, 110.2, 107.7, 103.9, 55.6 (OCH3), 52.2 (OCH3) ppm. 
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LC/MS: m/z = 362 [M + H
+
], 403 [M + H
+
 CH3CN], 723 [2M + H
+
]; tR = 15.61 min; 99.6 % 
pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-4-methoxybenzoic acid (21) was prepared according 
to method C. Sufficient purity was achieved without further purification; yield: 98 %. Mp: 
248249 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.51 (br. s, 1 H, NH), 8.44 (d, J = 2.5 Hz, 
1 H), 8.067.99 (m, 3 H), 7.927.85 (m, 2 H), 7.787.73 (m, 2 H), 7.557.48 (m, 2 H), 
7.477.39 (m, 1 H), 6.77 (dd, J = 8.8, 2.5 Hz, 1 H), 3.86 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 170.1, 164.5, 163.8, 143.8, 143.3, 138.9, 133.2, 133.2, 
129.1, 128.3, 127.7, 127.2, 127.0, 108.8, 108.5, 104.5, 55.6 (OCH3) ppm. 
LC/MS: m/z = 348 [M + H
+
], 389 [M + H
+
 CH3CN], 695 [2M + H
+
]; tR = 13.50 min; 100.0 % 
pure (UV). 
 
 
methyl 2-amino-5-methoxybenzoate (22b) was prepared according to method A. Sufficient 
purity was achieved without further purification; yield: 62 %. 
1
H NMR (500 MHz, CDCl3)  
= 7.36 (d, J = 3.2 Hz, 1 H), 6.96 (dd, J = 8.8, 3.2 Hz, 1 H), 6.64 (d, J = 8.8 Hz, 1 H), 5.43 (br. 
s, 2 H, NH2), 3.88 (s, 3 H, OCH3), 3.77 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.3, 150.5, 145.1, 123.3, 118.2, 113.1, 110.7, 55.8 
(OCH3), 51.6 (OCH3) ppm. 
LC/MS: m/z = 182 [M + H
+
], 223 [M + H
+
 CH3CN]; tR = 5.88 min; 95.2 % pure (UV). 
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methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-methoxybenzoate (22a) was prepared 
according to method BII. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 82 %. 
1
H NMR (500 MHz, CDCl3)  = 11.85 (br. s, 1 H, NH), 8.91 
(d, J = 9.1 Hz, 1 H), 8.138.11 (m, 2 H), 7.777.74 (m, 2 H), 7.677.64 (m, 2 H), 7.59 (d, J = 
3.2 Hz, 1 H), 7.507.47 (m, 2 H), 7.447.38 (m, 1 H), 7.21 (dd, J = 9.1, 3.2 Hz, 1 H), 3.99 (s, 
3 H, OCH3), 3.86 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.8, 165.0, 154.5, 144.5, 140.1, 135.6, 133.7, 128.9, 
128.0, 127.8, 127.4, 127.2, 122.0, 121.2, 116.1, 114.7, 55.6 (OCH3), 52.6 (OCH3) ppm. 
LC/MS: m/z = 362 [M + H
+
], 403 [M + H
+
 CH3CN], 723 [2M + H
+
]; tR = 15.45 min; 98.1 % 
pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-5-methoxybenzoic acid (22) was prepared according 
to method C. For purification the remaining solid was washed with MeOH and CH2Cl2 to 
provide the pure compound; yield: 92 %. Mp: 236239 °C. 1H NMR (500 MHz, DMSO-d6)  
= 11.90 (br. s, 1 H, NH), 8.61 (d, J = 9.1 Hz, 1 H), 8.048.00 (m, 2 H), 7.897.86 (m, 2 H), 
7.777.73 (m, 2 H), 7.54 (d, J = 2.8 Hz, 1 H), 7.537.48 (m, 2 H), 7.457.39 (m, 1 H), 7.28 
(dd, J = 9.1, 2.8 Hz, 1 H), 3.80 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.6, 163.9, 154.4, 143.5, 138.9, 134.5, 133.4, 129.1, 
128.2, 127.6, 127.1, 126.9, 121.9, 120.3, 118.2, 115.0, 55.4 (OCH3) ppm. 
LC/MS: m/z = 348 [M + H
+
], 695 [2M + H
+
]; tR = 13.07 min; 96.8 % pure (UV). 
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methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-6-methoxybenzoate (23a) was prepared 
according to method BIII. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 46 %. 
1
H NMR (500 MHz, CDCl3)  = 10.78 (br. s, 1 H, NH), 8.31 
(dd, J = 8.5, 0.9 Hz, 1 H), 8.078.04 (m, 2 H), 7.767.73 (m, 2 H), 7.677.64 (m, 2 H), 
7.517.47 (m, 3 H), 7.447.39 (m, 1 H), 6.76 (dd, J = 8.5, 0.9 Hz, 1 H), 3.99 (s, 3 H, OCH3), 
3.90 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 169.2, 165.1, 159.4, 144.7, 140.2, 140.0, 133.4, 133.4, 
128.9, 128.0, 127.8, 127.4, 127.2, 113.8, 109.4, 107.2, 56.3 (OCH3), 52.6 (OCH3) ppm. 
LC/MS: m/z = 362 [M + H
+
], 723 [2M + H
+
]; tR = 13.57 min; 96.5 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-6-methoxybenzoic acid (23) was prepared according 
to method C. Sufficient purity was achieved without further purification; yield: 90 %. Mp: 
158162 °C. 1H NMR (500 MHz, DMSO-d6)  = 10.44 (br. s, 1 H, NH), 8.027.99 (m, 2 H), 
7.867.83 (m, 2 H), 7.777.75 (m, 2 H), 7.537.46 (m, 4 H), 7.457.41 (m, 1 H), 6.98 (dd, J 
= 7.9, 1.6 Hz, 1 H), 3.83 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 167.7, 164.7, 157.5, 143.4, 139.0, 137.2, 133.1, 131.3, 
129.1, 128.2, 128.1, 126.9, 126.8, 116.8, 116.6, 108.6, 56.1 (OCH3) ppm. 
LC/MS: m/z = 348 [M + H
+
], 695 [2M + H
+
]; tR = 13.30 min; 99.2 % pure (UV). 
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2-([1,1'-biphenyl]-4-ylcarboxamido)-5-hydroxybenzoic acid (24) was prepared according 
to method E. The product was purified by CC (starting with n-hexane/EtOAc 1:1 to EtOAc + 
3 ‰ formic acid) followed by preparative TLC (CH2Cl2 + 7 drops formic acid per 10 mL 
solvent); yield: 34 %. Mp: 193196 °C. 1H NMR (500 MHz, DMSO-d6)  = 11.88 (br. s, 1 H, 
NH), 9.64 (br. s, 1 H, ArOH), 8.51 (d, J = 8.8 Hz, 1 H), 8.038.00 (m, 2 H), 7.897.85 (m, 2 
H), 7.787.74 (m, 2 H), 7.537.49 (m, 2 H), 7.46 (d, J = 2.8 Hz, 1 H), 7.457.38 (m, 1 H), 
7.08 (dd, J = 8.8, 2.8 Hz, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.8, 163.7, 152.7, 143.3, 139.0, 133.6, 133.1, 129.1, 
128.2, 127.6, 127.1, 126.9, 121.9, 121.1, 118.4, 116.8 ppm. 
LC/MS: m/z = 334 [M + H
+
], 667 [2M + H
+
]; tR = 11.31 min; 96.6 % pure (UV). 
 
 
methyl 2-amino-4-nitrobenzoate (25b) was prepared according to method A. The product 
was purified by CC (n-hexane/EtOAc 6:4); yield: 37 %. 
1
H NMR (500 MHz, CDCl3)  = 8.01 
(d, J = 8.8 Hz, 1 H), 7.51 (d, J = 2.2 Hz, 1 H), 7.41 (dd, J = 8.8, 2.2 Hz, 1 H), 6.06 (br. s, 2 H, 
NH2), 3.93 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.3, 151.3, 150.7, 132.8, 114.9, 111.1, 110.1, 52.2 
(OCH3) ppm. 
LC/MS: m/z = no ionization; tR = 10.08 min; 100.0 % pure (UV). 
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methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-4-nitrobenzoate (25a) was prepared according 
to method BI. For purification the solvent was evaporated and the remaining solid was 
suspended in MeOH. After filtration the precipitate was exhaustively washed with MeOH and 
CH2Cl2 to provide the pure compound; yield: 15 %. 
1
H NMR (500 MHz, CDCl3)  = 12.17 
(br. s, 1 H, NH), 9.89 (d, J = 2.2 Hz, 1 H), 8.28 (d, J = 8.8 Hz, 1 H), 8.218.10 (m, 2 H), 7.94 
(dd, J = 8.8, 2.2 Hz, 1 H), 7.847.73 (m, 2 H), 7.727.61 (m, 2 H), 7.547.47 (m, 2 H), 
7.477.39 (m, 1 H), 4.07 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.8, 165.6, 151.4, 145.3, 142.9, 139.8, 132.5, 132.1, 
129.0, 128.2, 128.0, 127.6, 127.3, 119.3, 116.6, 115.5, 53.3 (OCH3) ppm. 
LC/MS: m/z = 377 [M + H
+
], 418 [M + H
+
 CH3CN]; tR = 15.03 min; 97.6 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-4-nitrobenzoic acid (25) was prepared according to 
method C. For purification the remaining solid was washed with MeOH and CH2Cl2 to 
provide the pure compound; yield: 94 %. Mp: 280283 °C. 1H NMR (500 MHz, DMSO-d6)  
= 12.48 (br. s, 1 H, NH), 9.55 (d, J = 2.2 Hz, 1 H), 8.28 (d, J = 8.8 Hz, 1 H), 8.098.04 (m, 2 
H), 8.01 (dd, J = 8.8, 2.2 Hz, 1 H), 7.957.90 (m, 2 H), 7.817.74 (m, 2 H), 7.567.49 (m, 2 
H), 7.477.41 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.6, 164.9, 150.2, 144.1, 141.5, 138.8, 132.8, 132.6, 
129.1, 128.4, 127.9, 127.3, 127.0, 122.6, 117.2, 114.3 ppm. 
LC/MS: m/z = 363 [M + H
+
], 404 [M + H
+
 CH3CN], 725 [2M + H
+
]; tR = 13.25 min; 100.0 % 
pure (UV). 
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methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-cyanobenzoate (26a) was prepared 
according to method BII. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 43 %. 
1
H NMR (500 MHz, CDCl3)  = 12.29 (br. s, 1 H, NH), 9.13 
(d, J = 8.8 Hz, 1 H), 8.42 (d, J = 2.0 Hz, 1 H), 8.138.11 (m, 2 H), 7.84 (dd, J = 8.8, 2.0 Hz, 1 
H), 7.797.76 (m, 2 H), 7.677.64 (m, 2 H), 7.517.48 (m, 2 H), 7.457.40 (m, 1 H), 4.04 (s, 
3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.6, 165.6, 145.4, 145.3, 139.7, 137.6, 135.4, 132.5, 
129.0, 128.2, 128.0, 127.6, 127.2, 120.9, 118.0, 115.3, 105.9, 53.1 (OCH3) ppm. 
LC/MS: m/z = 357 [M + H
+
], 713 [2M + H
+
]; tR = 15.32 min; 97.2 % pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-5-cyanobenzoic acid
5
 (26) was prepared according to 
method C. Sufficient purity was achieved without further purification; yield: 80 %. Mp: 
246247 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.46 (br. s, 1 H, NH), 8.87 (d, J = 8.8 Hz, 
1 H), 8.38 (d, J = 2.0 Hz, 1 H), 8.07 (dd, J = 8.8, 2.0 Hz, 1 H), 8.048.01 (m, 2 H), 7.907.87 
(m, 2 H), 7.777.73 (m, 2 H), 7.537.48 (m, 2 H), 7.467.41 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.6, 164.7, 144.6, 144.1, 138.7, 137.5, 135.4, 132.5, 
129.1, 128.4, 127.9, 127.2, 127.0, 120.2, 118.1, 117.2, 105.0 ppm. 
LC/MS: m/z = 343 [M + H
+
], 685 [2M + H
+
]; tR = 13.30 min; 97.5 % pure (UV). 
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methyl 2-amino-4-(trifluoromethyl)benzoate (27b) was prepared according to method A. 
The product was purified by CC (n-hexane/EtOAc 1:1); yield: 61 %. 
1
H NMR (500 MHz, 
CDCl3)  = 7.96 (d, J = 8.2 Hz, 1 H), 6.936.89 (m, 1 H), 6.886.82 (m, 1 H), 5.92 (br. s, 2 
H, NH2), 3.91 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.7, 150.2, 135.7 (q, JCF = 32.1 Hz), 132.2, 120.3 (q, JCF 
= 272.0 Hz), 113.4 (q, JCF = 3.7 Hz), 113.0 (q, JCF = 1.8 Hz), 112.3 (q, JCF = 3.7 Hz), 51.9 
(OCH3) ppm. 
LC/MS: m/z = 261 [M + H
+
 CH3CN]; tR = 12.01 min; 85.2 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-4-(trifluoromethyl)benzoate (27a) was 
prepared according to method BII. For purification the solvent was evaporated and the 
remaining solid was suspended in MeOH. After filtration the precipitate was washed with 
MeOH to provide the pure compound; yield: 22 %. 
1
H NMR (500 MHz, CDCl3)  = 12.16 
(br. s, 1 H, NH), 9.36 (dd, J = 1.3, 0.6 Hz, 1 H), 8.22 (d, J = 8.2 Hz, 1 H), 8.158.12 (m, 2 H), 
7.797.76 (m, 2 H), 7.687.64 (m, 2 H), 7.517.47 (m, 2 H), 7.467.40 (m, 1 H), 7.38 (ddd, J 
= 8.2, 1.3, 0.6 Hz, 1 H), 4.04 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.2, 165.6, 145.1, 142.3, 139.9, 136.1 (q, JCF = 32.0 Hz), 
132.9, 131.6, 129.0, 128.2, 127.9, 127.6, 127.2, 123.4 (q, JCF = 273.1 Hz), 118.9 (q, JCF = 3.7 
Hz), 117.5 (q, JCF = 4.2 Hz), 53.0 (OCH3) ppm. 
LC/MS: m/z = 400 [M + H
+
], 441 [M + H
+
 CH3CN], 799 [2M + H
+
]; tR = 16.51 min; 100.0 % 
pure (UV). 
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2-([1,1'-biphenyl]-4-ylcarboxamido)-4-(trifluoromethyl)benzoic acid (27) was prepared 
according to method C. Sufficient purity was achieved without further purification; yield: 84 
%. Mp: 245246 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.35 (br. s, 1 H, NH), 9.10 (d, J = 
1.6 Hz, 1 H), 8.26 (d, J = 8.2 Hz, 1 H), 8.088.04 (m, 2 H), 7.957.89 (m, 2 H), 7.817.75 
(m, 2 H), 7.57 (dd, J = 8.2, 1.6 Hz, 1 H), 7.557.49 (m, 2 H), 7.477.41 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.0, 164.8, 144.0, 141.4, 138.8, 133.4 (q, JCF = 32.0 
Hz), 132.7, 132.5, 129.1, 128.4, 127.8, 127.2, 127.0, 122.9 (q, JCF = 273.1 Hz), 119.2 (q, JCF 
= 3.7 Hz), 116.3 (q, JCF = 3.7 Hz) ppm. 
LC/MS: m/z = 386 [M + H
+
], 427 [M + H
+
 CH3CN], 771 [2M + H
+
]; tR = 14.11 min; 100.0 % 
pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-(trifluoromethyl)benzoate (28a) was 
prepared according to method BII. For purification the solvent was evaporated and the 
remaining solid was suspended in MeOH. After filtration the precipitate was washed with 
MeOH followed by CC (n-hexane/EtOAc 9:1) to provide the pure compound; yield: 42 %. 
1
H 
NMR (500 MHz, CDCl3)  = 12.24 (br. s, 1 H, NH), 9.13 (d, J = 8.8 Hz, 1 H), 8.38 (d, J = 2.0 
Hz, 1 H), 8.158.12 (m, 2 H), 7.85 (dd, J = 8.8, 2.0 Hz, 1 H), 7.797.76 (m, 2 H), 7.687.65 
(m, 2 H), 7.527.48 (m, 2 H), 7.457.40 (m, 1 H), 4.04 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.2, 165.6, 145.2, 144.6, 139.8, 132.9, 131.4 (q, JCF = 3.6 
Hz), 129.0, 128.3 (q, JCF = 3.6 Hz), 128.2, 128.0, 127.6, 127.2, 124.5 (q, JCF = 33.9 Hz), 
120.6, 122.6 (q, JCF = 271.3 Hz), 114.9, 52.9 (OCH3) ppm. 
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LC/MS: m/z = 400 [M + H
+
], 441 [M + H
+
 CH3CN], 799 [2M + H
+
]; tR = 16.70 min; 95.1 % 
pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-5-(trifluoromethyl)benzoic acid (28) was prepared 
according to method C. For purification the remaining solid was washed with MeOH and 
CH2Cl2 to provide the pure compound; yield: 49 %. Mp: 265266 °C. 
1
H NMR (500 MHz, 
DMSO-d6)  = 12.41 (br. s, 1 H, NH), 8.93 (d, J = 8.8 Hz, 1 H), 8.28 (d, J = 2.0 Hz, 1 H), 
8.068.03 (m, 2 H), 8.01 (dd, J = 8.8, 2.0 Hz, 1 H), 7.927.87 (m, 2 H), 7.787.73 (m, 2 H), 
7.547.47 (m, 2 H), 7.467.40 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.9, 164.7, 144.3, 144.0, 138.8, 132.7, 130.9 (q, JCF = 
3.7 Hz) 129.1, 128.4, 127.9 (q, JCF = 3.7 Hz), 127.8, 127.2, 127.0, 123.8 (q, JCF = 271.3 Hz), 
122.8 (q, JCF = 33.0 Hz) 120.4, 116.8 ppm. 
LC/MS: m/z = 386 [M + H
+
], 771 [2M + H
+
]; tR = 14.60 min; 99.8 % pure (UV). 
 
 
methyl 2-amino-5-(trifluoromethoxy)benzoate (29b) was prepared according to method A. 
The product was purified by CC (n-hexane/EtOAc 1:1); yield: 26 %. 
1
H NMR (500 MHz, 
CDCl3)  = 7.777.68 (m, 1 H), 7.207.11 (m, 1 H), 6.65 (d, J = 9.5 Hz, 1 H), 5.80 (br. s, 2 
H, NH2), 3.89 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 167.6, 149.2, 138.8 (q, JCF = 1.8 Hz), 127.9, 123.8, 120.7 
(q, JCF = 256.0 Hz), 117.5, 110.5, 51.8 (OCH3) ppm. 
LC/MS: m/z = 236 [M + H
+
], 277 [M + H
+
 CH3CN]; tR = 12.13 min; 96.0 % pure (UV). 
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methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-(trifluoromethoxy)benzoate (29a) was 
prepared according to method BIII. For purification the solvent was evaporated and the 
remaining solid was suspended in MeOH. After filtration the precipitate was washed with 
MeOH to provide the pure compound; yield: 86 %. 
1
H NMR (500 MHz, CDCl3)  = 12.06 
(br. s, 1 H, NH), 9.05 (d, J = 9.1 Hz, 1 H), 8.168.09 (m, 2 H), 7.96 (d, J = 2.5 Hz, 1 H), 
7.817.74 (m, 2 H), 7.687.64 (m, 2 H), 7.517.48 (m, 3 H), 7.447.40 (m, 1 H), 4.02 (s, 3 
H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.0, 165.5, 145.0, 143.4 (q, JCF = 1.8 Hz), 140.7, 139.9, 
133.1, 130.7, 129.0, 128.1, 127.9, 127.5, 127.2, 123.4, 122.0, 120.5 (q, JCF = 257.5 Hz), 
116.1, 52.9 (OCH3) ppm. 
LC/MS: m/z = 416 [M + H
+
], 457 [M + H
+
 CH3CN], 831 [2M + H
+
]; tR = 16.64 min; 100.0 % 
pure (UV). 
 
 
2-([1,1'-biphenyl]-4-ylcarboxamido)-5-(trifluoromethoxy)benzoic acid (29) was prepared 
according to method C. Sufficient purity was achieved without further purification; yield: 98 
%. Mp: 245246 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.17 (br. s, 1 H, NH), 8.81 (d, J = 
9.1 Hz, 1 H), 8.068.03 (m, 2 H), 7.92 (dd, J = 3.0, 0.8 Hz, 1 H), 7.917.88 (m, 2 H), 
7.787.74 (m, 2 H), 7.747.68 (m, 1 H), 7.537.49 (m, 2 H), 7.467.41 (m, 1 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 168.6, 164.5, 143.9, 142.7 (q, JCF = 1.8 Hz), 140.1, 
138.8, 132.9, 129.1, 128.3, 127.8, 127.2, 127.0, 127.0, 123.3, 121.9, 118.6, 120.0 (q, JCF = 
256.0 Hz) ppm. 
LC/MS: m/z = 402 [M + H
+
], 803 [2M + H
+
]; tR = 14.58 min; 100.0 % pure (UV). 
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methyl 2-amino-5-methylbenzoate (30b) was prepared according to method A. Sufficient 
purity was achieved without further purification; yield: 82 %. 
1
H NMR (500 MHz, CDCl3)  
= 7.67 (d, J = 2.2 Hz, 1 H), 7.10 (dd, J = 8.2, 2.2 Hz, 1 H), 6.60 (d, J = 8.2 Hz, 1 H), 5.55 (br. 
s, 2 H, NH2), 3.88 (s, 3 H, OCH3), 2.24 (s, 3 H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.6, 148.3, 135.2, 130.8, 125.4, 116.8, 110.7, 51.4 
(OCH3), 20.2 (CH3) ppm. 
LC/MS: m/z = no ionization; tR = 8.48 min; 98.0 % pure (UV). 
 
 
methyl 2-([1,1'-biphenyl]-4-ylcarboxamido)-5-methylbenzoate (30a) was prepared 
according to method BII. For purification the solvent was evaporated and the remaining solid 
was suspended in MeOH. After filtration the precipitate was washed with MeOH to provide 
the pure compound; yield: 85 %. 
1
H NMR (500 MHz, CDCl3)  = 12.00 (br. s, 1 H, NH), 8.86 
(d, J = 8.8 Hz, 1 H), 8.158.12 (m, 2 H), 7.91 (d, J = 2.2 Hz, 1 H), 7.777.75 (m, 2 H), 
7.687.65 (m, 2 H), 7.517.47 (m, 2 H), 7.44 (dd, J = 8.8, 2.2 Hz, 1 H), 7.437.39 (m, 1 H), 
3.98 (s, 3 H, OCH3), 2.38 (s, 3 H, CH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 169.1, 165.2, 144.5, 140.1, 139.5, 135.6, 133.7, 132.1, 
131.0, 128.9, 128.0, 127.9, 127.4, 127.2, 120.4, 115.0, 52.4 (OCH3), 20.7 (CH3) ppm. 
LC/MS: m/z = 346 [M + H
+
], 691 [2M + H
+
]; tR = 16.44 min; 99.1 % pure (UV). 
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2-([1,1'-biphenyl]-4-ylcarboxamido)-5-methylbenzoic acid (30) was prepared according to 
method C. Sufficient purity was achieved without further purification; yield: 95 %. Mp: 
246248 °C. 1H NMR (500 MHz, DMSO-d6)  = 12.13 (br. s, 1 H, NH), 8.63 (d, J = 8.8 Hz, 
1 H), 8.058.01 (m, 2 H), 7.907.86 (m, 3 H), 7.797.74 (m, 2 H), 7.537.47 (m, 3 H), 
7.467.40 (m, 1 H), 2.33 (s, 3 H, CH3) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 170.1, 164.1, 143.6, 138.9, 138.8, 134.8, 133.3, 132.1, 
131.3, 129.1, 128.3, 127.6, 127.1, 126.9, 119.9, 116.4, 20.2 (CH3) ppm. 
LC/MS: m/z = 332 [M + H
+
], 663 [2M + H
+
]; tR = 13.78 min; 100.0 % pure (UV). 
 
 
3-(3-phenoxybenzamido)-[1,1'-biphenyl]-4-carboxylic acid (31) was prepared according to 
method D. The product was purified by CC (n-hexane/EtOAc 8:2); yield: 91 %. Mp: 189190 
°C. 
1
H NMR (500 MHz, DMSO-d6)  = 12.26 (br. s, 1 H, NH), 9.02 (d, J = 1.9 Hz, 1 H), 8.12 
(d, J = 8.2 Hz, 1 H), 7.747.71 (m, 3 H), 7.62 (d, J = 7.9, 7.9 Hz, 1 H), 7.557.50 (m, 4 H), 
7.477.42 (m, 3 H), 7.29 (ddd, J = 8.2, 2.5, 0.9 Hz, 1 H), 7.21 (tt, J = 7.4, 1.1 Hz, 1 H), 
7.147.08 (m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.9, 164.1, 157.4, 155.9, 145.7, 141.4, 138.9, 136.4, 
131.9, 130.8, 130.3, 129.2, 128.6, 126.9, 124.1, 122.1, 121.5, 121.3, 119.2, 117.9, 116.8, 
115.4 ppm. 
LC/MS: m/z = 410 [M + H
+
], 819 [2M + H
+
]; tR = 15.23 min; 99.1 % pure (UV). 
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4-(3-phenoxybenzamido)-[1,1'-biphenyl]-3-carboxylic acid (32) was prepared according to 
method D. The product was purified by preparative TLC (n-hexane/EtOAc 1:1 + 7 drops 
formic acid per 10 mL solvent) and washed with CH2Cl2; yield: 42 %. Mp: 207208 °C. 
1
H 
NMR (500 MHz, DMSO-d6)  = 12.20 (br. s, 1 H, NH), 8.75 (d, J = 8.8 Hz, 1 H), 8.29 (d, J = 
2.5 Hz, 1 H), 7.98 (dd, J = 8.8, 2.5 Hz, 1 H), 7.787.72 (m, 1 H), 7.717.66 (m, 2 H), 7.61 
(dd, J = 7.9, 7.9 Hz, 1 H), 7.577.53 (m, 1 H), 7.537.42 (m, 4 H), 7.417.34 (m, 1 H), 
7.327.25 (m, 1 H), 7.247.17 (m, 1 H), 7.167.04 (m, 2 H) ppm. 
13
C NMR (125 MHz, CDCl3)  = 169.9, 163.9, 157.3, 156.0, 140.1, 138.7, 136.4, 134.7, 
132.3, 130.8, 130.3, 129.1, 128.9, 127.6, 126.4, 124.1, 122.1, 121.6, 120.6, 119.1, 117.3, 
116.9 ppm. 
LC/MS: m/z = 410 [M + H
+
], 451 [M + H
+
 CH3CN], 819 [2M + H
+
]; tR = 14.61 min; 100.0 % 
pure (UV). 
 
 
methyl 4-bromo-3-hydroxybenzoate (33f). To 3-hydroxybenzoate (1 equiv) in acetic acid 
was added bromine (1 equiv) dropwise. The reaction mixture was stirred at room temperature 
for 18 h, water was added and the mixture was extracted with EtOAc. The combined organic 
layers were washed with brine and dried over MgSO4. The product was purified by CC (n-
hexane/EtOAc 92.5:7.5) followed by crystallization from EtOAc/n-hexane (in fridge 
overnight); yield: 48 %. 
1
H NMR (500 MHz, METHANOL-d4)  = 11.51 (br. s, 1 H, OH), 
8.43 (d, J = 8.2 Hz, 1 H), 8.33 (d, J = 2.0 Hz, 1 H), 8.11 (dd, J = 8.2, 2.0 Hz, 1 H), 4.64 (s, 3 
H, OCH3) ppm. 
13
C NMR (125 MHz, METHANOL-d4)  = 175.3, 163.9, 142.9, 139.7, 130.5, 126.0, 124.7, 
61.9 (OCH3) ppm. 
LC/MS: m/z = no ionization; tR = 9.28 min; 97.8 % pure (UV). 
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methyl 4-bromo-3-phenoxybenzoate (33e). A mixture of methyl 4-bromo-3-
hydroxybenzoate (33f, 1 equiv), phenylboronic acid (2 equiv), copper acetate (1 equiv), 
triethylamine (5 equiv) and 3 Å molecular sieves in CH2Cl2 was stirred at room temperature 
for 72 h under a N2 atmosphere. After filtration over celite the solvent was evaporated. 
Purification by CC (n-hexane/EtOAc 8:2) provided the pure compound; yield: 37 %. 
1
H NMR 
(500 MHz, CDCl3)  = 7.72 (d, J = 8.2 Hz, 1 H), 7.68 (dd, J = 8.2, 1.9 Hz, 1 H), 7.59 (d, J = 
1.9 Hz, 1 H), 7.397.36 (m, 2 H), 7.16 (tt, J = 7.4, 1.1 Hz, 1 H), 7.026.97 (m, 2 H), 3.87 (s, 3 
H, OCH3) ppm. 
13
C NMR (125 MHz, Acetone-d6)  = 148.0, 138.6, 136.5, 116.2, 113.2, 112.1, 107.5, 106.2, 
102.2, 102.0, 100.5, 33.8 (OCH3) ppm. 
LC/MS: m/z = no ionization; tR = 13.54 min; 97.5 % pure (UV). 
 
 
2-phenoxy-[1,1'-biphenyl]-4-carboxylic acid (33d) was prepared according to method D. 
The product was purified by CC (n-hexane/EtOAc 7:3); yield: 66 %. 
1
H NMR (500 MHz, 
CDCl3)  = 7.94 (dd, J = 7.9, 1.6 Hz, 1 H), 7.72 (d, J = 1.6 Hz, 1 H), 7.637.56 (m, 3 H), 
7.437.39 (m, 2 H), 7.387.35 (m, 1 H), 7.347.29 (m, 2 H), 7.09 (tt, J = 7.4, 1.1 Hz, 1 H), 
7.006.94 (m, 2 H) ppm. 
13
C NMR (125 MHz, CDCl3)  = 171.1, 157.1, 153.9, 139.0, 136.7, 131.4, 129.8, 129.6, 
129.2, 128.3, 128.0, 125.5, 123.3, 121.2, 118.5 ppm. 
LC/MS: m/z = no ionization; tR = 12.33 min; 97.6 % pure (UV). 
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methyl 4-fluoro-2-(2-phenoxy-[1,1'-biphenyl]-4-ylcarboxamido)benzoate (33a) was 
prepared according to method BIII. The product was purified by CC (n-hexane/EtOAc 9:1); 
yield: 65 %. 
1
H NMR (500 MHz, CDCl3)  = 12.19 (br. s, 1 H, NH), 8.72 (dd, J = 12.1, 2.6 
Hz, 1 H), 8.09 (dd, J = 9.0, 6.5 Hz, 1 H), 7.84 (dd, J = 8.0, 1.9 Hz, 1 H), 7.70 (d, J = 1.9 Hz, 1 
H), 7.677.60 (m, 3 H), 7.447.32 (m, 5 H), 7.117.08 (m, 1 H), 7.067.01 (m, 2 H), 6.81 
(ddd, J = 9.0, 7.5, 2.6 Hz, 1 H), 3.94 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.3, 166.4 (d, JCF = 253.0 Hz), 164.9, 156.9, 154.5, 143.9 
(d, JCF = 13.7 Hz), 137.0, 136.8, 134.9, 133.2 (d, JCF = 10.1 Hz), 131.7, 129.8, 129.2, 128.3, 
127.9, 123.4, 122.0, 118.8, 118.8, 111.3 (d, JCF = 2.7 Hz), 110.0 (d, JCF = 22.0 Hz), 107.5 (d, 
JCF = 28.4 Hz), 52.5 (OCH3) ppm. 
LC/MS: m/z = 442 [M + H
+
], 483 [M + H
+
 CH3CN], 883 [2M + H
+
]; tR = 17.02 min; 89.0 % 
pure (UV). 
 
 
4-fluoro-2-(2-phenoxy-[1,1'-biphenyl]-4-ylcarboxamido)benzoic acid (33) was prepared 
according to method C. For purification the remaining solid was washed with MeOH to 
provide the pure compound; yield: 77 %. Mp: 223227 °C. 1H NMR (500 MHz, DMSO-d6)  
= 12.45 (br. s, 1 H, NH), 8.50 (dd, J = 12.1, 2.6 Hz, 1 H), 8.148.09 (m, 1 H), 7.847.80 (m, 
1 H), 7.73 (d, J = 8.2 Hz, 1 H), 7.627.59 (m, 2 H), 7.52 (d, J = 1.9 Hz, 1 H), 7.467.42 (m, 2 
H), 7.417.34 (m, 3 H), 7.12 (tt, J = 7.3, 1.2 Hz, 1 H), 7.077.03 (m, 1 H), 7.036.99 (m, 2 
H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.4, 165.0 (d, J = 249.0 Hz), 163.9, 156.5, 153.5, 
143.1 (d, J = 12.8 Hz), 136.7, 136.1, 134.7, 134.0 (d, JCF = 11.0 Hz), 131.9, 130.2, 129.0, 
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128.4, 128.0, 123.5, 122.3, 118.5, 118.2, 113.0 (d, JCF = 2.8 Hz), 110.1 (d, JCF = 22.0 Hz), 
106.4 (d, JCF = 27.0 Hz) ppm. 
LC/MS: m/z = 428 [M + H
+
], 469 [M + H
+
 CH3CN], 855 [2M + H
+
]; tR = 15.13 min; 97.2 % 
pure (UV). 
 
 
methyl 4-chloro-2-(2-phenoxy-[1,1'-biphenyl]-4-ylcarboxamido)benzoate (34a)   was 
prepared according to method BIII. The product was purified by CC (n-hexane/EtOAc 9:1); 
yield: 22 %. 
1
H NMR (500 MHz, CDCl3)  = 12.08 (br. s, 1 H, NH), 9.01 (d, J = 2.2 Hz, 1 H), 
8.00 (d, J = 8.5 Hz, 1 H), 7.83 (dd, J = 7.9, 1.9 Hz, 1 H), 7.68 (d, J = 1.9 Hz, 1 H), 7.647.60 
(m, 3 H), 7.447.40 (m, 2 H), 7.387.31 (m, 3 H), 7.117.07 (m, 2 H), 7.057.01 (m, 2 H), 
3.95 (s, 3 H, OCH3) ppm. 
13
C NMR (125 MHz, CDCl3)  = 168.4, 164.9, 156.9, 154.6, 142.6, 141.2, 137.0, 136.8, 
134.9, 132.0, 131.7, 129.9, 129.2, 128.3, 127.9, 123.4, 123.0, 121.9, 120.3, 118.9, 118.7, 
113.3, 52.6 (OCH3) ppm. 
LC/MS: m/z = 458 and 460 [M + H
+
], 915 and 917 [2M + H
+
]; tR = 17.56 min; 97.5 % pure 
(UV). 
 
 
4-chloro-2-(2-phenoxy-[1,1'-biphenyl]-4-ylcarboxamido)benzoic acid (34) was prepared 
according to method C. For purification the remaining solid was washed with MeOH to 
provide the pure compound; yield: 92 %. Mp: 230234 °C. 1H NMR (500 MHz, DMSO-d6)  
= 12.31 (br. s, 1 H, OCH3), 8.75 (d, J = 2.2 Hz, 1 H), 8.04 (d, J = 8.5 Hz, 1 H), 7.82 (dd, J = 
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7.9, 1.9 Hz, 1 H), 7.73 (d, J = 7.9 Hz, 1 H), 7.637.59 (m, 2 H), 7.52 (d, J = 1.9 Hz, 1 H), 
7.467.42 (m, 2 H), 7.407.34 (m, 3 H), 7.27 (dd, J = 8.5, 2.2 Hz, 1 H), 7.167.09 (m, 1 H), 
7.036.99 (m, 2 H) ppm. 
13
C NMR (125 MHz, DMSO-d6)  = 169.3, 163.8, 156.5, 153.5, 141.9, 138.6, 136.7, 136.1, 
134.7, 132.9, 131.9, 130.2, 129.0, 128.4, 128.0, 123.5, 123.0, 122.4, 119.3, 118.5, 118.2, 
115.4 ppm. 
LC/MS: m/z = 444 [M + H
+
], 485 [M + H
+
 CH3CN], 887 [2M + H
+
]; tR = 15.37 min; 97.3 % 
pure (UV). 
 
Computational chemistry 
Pharmacophore modelling and virtual screening. The following compounds I─VII were 
retrieved from literature
1,6─9
: 
 
Figure S1. Compounds used for the flexible alignment. 
 
I: Published by Arhin et al.
6
 (“compound 1”) as inhibitor of S. aureus RNAP. It was shown 
that these compounds do not bind to the Rifamycin binding site, but the exact mode of action 
is not known. 
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II and III: Published by Artsimovitch et al.
7
 (“CBR703 and CBR9379”) as inhibitors of E. 
coli RNAP. They bind to a surface exposed groove at the junction of the ’-bridge helix and 
the -subunit. 
IV, V and VI: Published by André et al.
8
 (“SB8 and SB2”) and Villain-Guillot9 (“compound 
11b”) as inhibitors of E. coli RNAP. The mode of action of these compounds is the prevention 
of the protein-protein interaction between 70 and the RNAP core enzyme. 
VII: Published by Larsen et al.
1
 (“compound 1”) as inhibitor of transcription/ translation in S. 
aureus. Resynthesis and testing in our E. coli RNAP in vitro inhibition assay revealed VII as 
a potent inhibitor of E. coli RNAP (IC50 42 µM). 
 
Compounds I─VII (Fig. S1) were aligned using the flexible alignment module of MOE 
(Molecular Operating Environment)
10
 with the stochastic search option turned on. We 
modified the default flexible alignment settings; the Aromaticity and CO2-type centroid 
weights were set at 2 – strikingly these two chemical moieties are present in most of the initial 
seven template compounds. Weights on volume and acceptor/donor projection features were 
switched on. Further, we set the configuration limit to 100 and conjugate gradient 
minimization steps to 1000. The alignment with the best similarity score was retained and 
refined within MOE. 
 
 
Figure S2. Final pharmacophore model used for virtual screening. 
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This alignment was used to identify common features within the seven superimposed ligands 
via the Pharmacophore Consensus utility (tolerance of 1.2 and threshold value of 50% 
(ligands that match one feature)). The resulting pharmacophore model (consisting of 9 
features) was manually refined and reduced to 7 features with 6 needed partial matches. The 
final pharmacophore model (Fig. S2) consisted of following features (F1-F4 - feature radius 
of 1.5 Å, F5-F7 - feature radius of 1 Å): 
Feature F1 (rose): O2|Ani|N[O,o]|(O(C=O)C (this includes CO2-like centroids (both acids and 
ester), anionic atoms as well as N.sp
2
-O moieties (i.e. oximes, nitro) 
Feature F2 (orange): Aro (all aromatic systems) 
Feature F3 (violet): HBD/HBA/Aro (this feature can be matched by either a hydrogen-bond 
donor or acceptor or by an aromatic system) 
Feature F4: Aro/Hyd/pi (in this position aromatic, hydrophobic or planar-conjugated pi 
systems are requested) 
Feature F5 (green): Hydrophobic 
Features F6+F7 (hatched orange): Aromatic ring projections 
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Figure S3. Overlay of the resulting pharmacophore model with inhibitors I─VII and 3. 
 
A virtual library was built including approximately 2000 synthetic in-house compounds that 
had been developed as aromatase, CYP17, CYP11B1, CYP11B2, thromboxane A2, 5 
reductase, 17 HSD1, 17 HSD2, FabH and PqsD inhibitors. For each compound a 
conformational search was performed using the default parameters of the conformational 
search module of MOE2010. Conformers were energy minimized using MMFF94xs 
forcefield and the Generalized Born implicit solvent model. The obtained multiple-conformer 
database was now used in the pharmacophore search. 
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Figure S4. Experimentally validated virtual hit compounds. 
 
In total 64 hits were found matching at least the four core features and the two aromatic 
projections, while the presence of the accessory feature was not mandatory. All hit 
compounds were tested on inhibitory potency, for eleven of them (comprising five different 
structural classes) an inhibition >20% was measured at 200 µM (Fig. S4). 
Based on the activities of 1‒4, the seven-feature pharmacophore model (Fig. S2) was 
extended by two additional features (F8 and F9): 
Features F8+F9 (hatched yellow): Aro/Hyd (feature radius of 1.5 Å) 
Using this model (Fig. S5) in further screenings, a compound will be defined as a hit if, beside 
the 4 core features, at least one of the new accessory features is present. 
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Figure S5. Extended pharmacophore model. 
 
 
Figure S6. Overlay of the extended pharmacophore model with A) most potent hit compound 
3 B) described inhibitor V 
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6.4  Supporting information to Publication IV 
Materials and methods 
Transcription assay. Core and holo enzyme of RNA polymerase (E. coli origin) were 
purchased from Epicentre Biotechnologies (Madison, WI). E. coli σ70 factor was cloned and 
purified as described below. Final concentrations in a total volume of 30 μl were one unit of 
RNA polymerase (0.7 μg core or 0.5 μg holo enzyme) which were used along with 0.53 μM 
of [5,6-
3
H]-UTP, 400 μM of ATP, CTP and GTP as well as 100 μM of UTP, 20 units of 
RNAse inhibitor (RiboLock, Fermentas), 10 mM DTT, 40 mM Tris-HCl (pH 7.5), 150 mM 
KCl, 10 mM MgCl2 and 0.01 % Triton-X-100. Ten different DNA templates (properties and 
concentrations described below) were used. Prior to starting the experiment, the compounds 
were dissolved in DMSO (final concentration during experiments: 2 %). Dilution series of 
compounds were prepared using a liquid handling system (Janus, Perkin Elmer, Waltham, 
MA). The components described above (including the inhibitors) were preincubated in 
absence of NTPs and DNA for 10 min at 25 °C. Transcription reactions were started by the 
addition of a mixture containing DNA template and NTPs. When core enzyme was used (with 
or without σ70) the incubation was performed for 20 min at 37 °C, in case of holo enzyme the 
inc ubation time was only 10 min. For experiments with separate addition of σ70, core enzyme 
was preincubated with σ70 or DMSO for 10 min at 25 °C to allow formation of the holo 
enzyme. The following steps were carried out as described above for the holo enzyme. The 
reaction was stopped by the addition of 10 % TCA, followed by a transfer of this mixture to a 
96 well Multiscreen GFB plate (Millipore, Billerica, MA) and incubation for 45 min at 4 °C. 
The plate underwent several centrifugation and washing steps with 10 % TCA and 95 % 
ethanol to remove residual unincorporated 
3
H-UTP. After that the plate was dried (30 min, 50 
°C) and 30 μl of scintillation fluid (Optiphase Supermix, 1 Perkin Elmer) was added to each 
well. After 10 min the wells were assayed for presence of 
3
H-RNA by counting using a 
Wallac MicroBeta TriLux system (Perkin Elmer). To obtain inhibition values for each 
sample, their counts were related to DMSO controls. 
DNA templates. Kool NC-45 template was purchased from Epicentre Biotechnologies. 
According to the supplier the sequence of this circular and single-stranded DNA is 
ctggaggagattttgtggtatcgattcgtctcttagaggaagcta which does not contain a hammerhead. 
Unsheared genomic calf thymus DNA and T-phage DNA were purchased from Sigma-
Aldrich (St. Louis, MO). Poly(dA:dT) template was purchased from Invivogen (San Diego, 
CA). pcDNA3.1/V5-His-TOPO (pcDNA3.1) plasmid was used in religated form (purchased 
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from Invitrogen, Carlsbad, CA). pGEM beta-gal Control (pGEM) was purchased from 
Promega (Madison, WI). Both plasmids were amplified and purified using MaxiPrep kits 
according to the guidelines of the manufacturer (Sigma-Aldrich). To obtain genomic DNA 
from E.coli, DH5α cells were incubated in TE buffer substituted with SDS and proteinase K 
followed by subsequent phenol and chloroform treatment (twice each). Nucleic acids obtained 
after ethanol precipitation were treated with RNAse A and precipitated again with ammonium 
acetate and isopropanol resulting in pure genomic DNA. To obtain T7A1 PCR fragments, a 
two-step PCR was performed using Taq DNA polymerase (NEB, Ipswich, MA). Firstly, parts 
of the neomycin gene of pcDNA3.1 were amplified. The different 3’ primers defined the 
length of the PCR product (oligo 3pp-1 for fragment “T7A1_149”: acccaagcggccggagaacctg; 
oligo 3pp-2 for fragment “T7A1_437”: ttctcggcaggagcaaggtgag; oligo 3pp-3 for fragment 
“T7A1_763”: tgtcctgatagcggtccg). The universal 5’ oligo was flanked by the T7A1 promoter 
containing the -10 and -35 consensus sequences (oligo T7A1-5pr: 
gactcagtgatatcaaaaagagtattgacttaaagtctaacctataggatacttacagccatcgagaggctgatcaagagacaggatga
gg) resulting in PCR products all containing a 59 bp T7A1 promoter on their 5’ ends. The 
exact sizes of the PCR products were 149 bp (MW: 97 kDa) for “T7A1_149”, 437 bp (MW: 
284 kDa) for “T7A1_437” and 763 bp (MW: 496 kDa) for “T7A1_763”. To obtain the 
„T7_promoter template“ the same procedure as with “T7A1_437” was followed with the 
difference that the T7A1 promoter sequence was substituted by the T7 promoter sequence. 
The PCR products were gel purified (kit from PEQLAB, Erlangen, Germany) and elongated 
in a second PCR using the same 3’ oligos and a 5’ oligo increasing the size by 13 bp (oligo 
T7A1-elong: cagaccatgatcagactcagtgatatc). These PCR products were directly purified (kit 
from Fermentas) and served as templates in transcription assays. 
RNA polymerase inhibitors. Lipiarmycin was a generous gift from Novartis (Basel, 
Switzerland). Corallopyronin, Myxopyronin and Sorangicin were donated by Klaus Gerth 
(HZI, Braunschweig, Germany). The Rifamycins were purchased from Sigma-Aldrich. SB2 
(Benzoic acid, 3-[5-[[4-oxo-3-(2-propen-1-yl)-2-thioxo-5-thiazolidinylidene]methyl]-2-
furanyl]) was purchased from ChemDiv (San Diego, CA) and synthesized as described in 
literature (57). CBR703 (Benzenecarboximidamide, N-hydroxy-N'-phenyl-3-
(trifluoromethyl)) was synthesized according to a published procedure (WO 01/51456A2). 
Determination of IC50 values. Three different concentrations of a compound were chosen for 
the determination of an IC50 value (two samples for each concentration). The calculation of 
the IC50 value was performed by plotting the percent inhibition vs. the concentration of 
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inhibitor on a semi-log plot. From this the molar concentration causing 50 % inhibition was 
calculated. At least three independent determinations were performed for each compound. 
Cloning and purification of Ec σ70. For cloning of E.coli σ70 factor into an expression 
vector, genomic DNA from DH5α cells was used (purified as described above). To amplify 
σ70 sequence primers were used being flanked by the restriction site KpnI and a thrombin 
cutting site (oligo Ec-5-sigma: gagacggtaccctggtgccgcgcggcagcatggagcaaaacccgcagtcacag) or 
SacI (oligo Ec-3-sigma: gagaggagctcttaatcgtccaggaagctacgcag). Amplification was performed 
using Phusion HF DNA polymerase (NEB, Ipswich, MA). The PCR product was cloned into 
pCR Blunt II TOPO vector by TOPO reaction (Invitrogen) followed by restriction digestion 
with KpnI and SacI to obtain σ70 sequence. In a next step the fragment was gel purified and 
ligated into the KpnI/SacI linearized final expression vector pET45b(+) (purchased from 
Merck, Darmstadt, Germany). The sequence of the final expression vector was verified by 
sequencing (performed by Seqlab, Goettingen, Germany). Recombinant E. coli σ70 factor was 
overexpressed in E. coli BL21 (DE3) in presence of 0.5 mM IPTG (Acros Organics, Geel, 
Belgium) for 16 h at 16 °C. After several sonication cycles the cell lysate was treated with 
DNAse I (Roche, Basel, Switzerland). Inclusion bodies were collected by centrifugation and 
washed twice with lysis buffer (40 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 % Glycerol, 1 
mM BME, 0.1 mM PMSF, 0.35 mg/ml lysozyme). Finally, the pellet was solubilized in 
denaturation buffer (40 mM Tris HCl, pH 7.9, 6 M guanidinium HCl, 10 % glycerol, 1 mM 
EDTA, 10 mM DTT) for 1 h under vigorous stirring. After centrifugation the supernatant was 
dialysed over night at 4°C against renaturation buffer (20 mM Tris HCl, pH 7.9 at 4 °C, 300 
mM NaCl, 20 % glycerol, 1 mM BME). In a next step the fusion protein was purified by 
IMAC on an ÄKTA purifier (GE Healthcare) with a HisTrap FF column (GE Healthcare). 
Peak fractions were concentrated with VIVASPIN (MWCO 10 kDa, Sartorius Group, 
Goettingen, Germany) followed by a buffer exchange into storage buffer using PD-10 
columns (GE Healthcare). 
Formaldehyde agarose gel electrophoresis. To separate RNA transcripts a formaldehyde 
agarose (1 %) gel was prepared (containing MOPS buffer (40 mM MOPS, pH 7.0; 10 mM 
sodium acetate; 1 mM EDTA, pH 8.0) and 3.7 % formaldehyde). The RNA was dissolved in 
loading buffer (Roti-Load RNA) (Carl Roth, Karlsruhe, Germany) containing ethidium 
bromide for staining. On each of four sample lanes phenol-chloroform extracted and purified 
RNA from 8 transcription reactions was loaded next to a ssRNA ladder (New England 
Biolabs, Ipswich, MA). 
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Supplemental figures 
 
Supplementary Figure 1. Optimization of DNA template concentration. Different 
concentrations of the ten different DNA templates were used in transcription assays 
(performed with RNAP holo enzyme) to determine the concentration leading to the best 
transcription rate. Arbitrary units are shown. Arrows indicate the optimal concentration of 
templates (see also Table 2). Standard deviations are indicated by error bars. 
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Supplementary Figure 2. RNAP holo enzyme leads to a more efficient transcription of Kool 
and poly(dA:dT) templates compared to core enzyme. Formaldehyde agarose gel 
electrophoresis was performed to visualize transcripts formed after using RNAP holo and core 
enzyme along with Kool and poly(dA:dT) templates. M, RNA ladder. 
 
 
 
Supplementary Figure 3. Inhibition values of Rifapentin, Rifabutin and Sorangicin after 
usage of ten different DNA templates. IC50 values are displayed. The template that has been 
used is shown under each bar of the Rifapentin figure along with corresponding numbers (1-
10) which are also used in the figures of the other compounds. Standard deviations are 
indicated by error bars. sd, standard deviation. 
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Supplementary Figure 4. Superimposition of the open holoenzyme (PDB-id 3dxj; blue; in 
complex with Myxopyronin) and the closed elongation complex core (2ppb; pale yellow) of 
T. thermophilus RNAP. The opening of the main channel is summarized by the distances 
between Fix and Flex AA (dFix-Flex) as well as by the differences between open and closed 
state (Δopen-closed = dFix-Flex open - dFix-Flex closed). The distances between Z 
(Leu1086), placed centrally on the bridge helix, and the “switch-2“ residues i-k decrease 
comparing an active and an inhibited holoenzyme RNAP complex (e.g. dZ-k = dL1086-R615 
= 22.4 - 16.1 Å). Non template (brown) and template strand (white; deeply buried in the 
catalytic center) of the dsDNA are rendered as cartoons and transparent surfaces. (A) 
Enlargement of the main channel of RNAP is shown by the outward shifted coiled-coil, lid 
and rudder loop regions of the opened holoenzyme. The cyan (open) and yellow (closed) dots 
and spheres indicate the Cα atoms of four “fixed” (Fix AA; W-Z; Cα RMSD <1.0 Å) and 
eleven ”flexible“ residues (Flex AA; a-k). The green arrows (length proportional to distance) 
schematize the atomic shift of Flex AA between the open and the closed RNAP. (B) Zoomed 
view of the “switch-2“ region (orange circle). The Flex AA Arg613 (i), Phe614 (j), and 
Arg615 (k) are pushed centrally into the main channel in presence of Myxopyronin (purple 
dots). The magenta arrows (inverted compared to the green ones) highlight the narrowing of 
the access to the catalytic center. (C) Table illustrating the distances between Fix and Flex AA 
(dFix-Flex) in the open and closed RNAP states. AA, amino acids. 
 
 
 
Supplementary Table 1. Comparison of RNAP holo and core enzyme inhibition by selected 
compounds. IC50 values were determined for four compounds using either the RNAP core 
enzyme along with 350 ng of T7_promoter template or the RNAP holo enzyme along with 
350 ng of T7A1_437 template. The core to holo IC50 ratios are given to highlight the 
differences between the single compounds. 
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